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Abstract 
Pancreatic cancer is a solid tumour with poor prognosis and ineffective 
therapeutic approaches. Pancreatic tumour progression is 
characterised by a strong desmoplastic reaction and the role of the 
tumour microenvironment in supporting tumour growth and metastasis 
has been demonstrated. In particular, a new concept of the stem cell 
niche as a mixed population of mesenchymal stem cells and niche cells 
(myofibroblast cells) involved in promoting these processes is emerging. 
Paracrine transmission of the Hedgehog (Hh) pathway in the tumour 
microenvironment of pancreatic cancer has previously been reported.  
Based on these studies, this project aimed to identify and characterise 
the stromal pancreatic cancer cells able to respond to Hh pathway 
exogenous stimuli and to investigate their relationship to tumour 
progression, in order to define new targets for pancreatic cancer 
therapies.  
Screening of pancreatic primary tumours by gene and protein 
expression analysis demonstrated overexpression of Shh ligand not 
only at the epithelial but also at the stromal level in advanced stages of 
pancreatic cancer. In vitro modelling of the mesenchymal stem cell 
niche (mSCN) using human bone marrow-derived mesenchymal stem 
cells (MSCs) co-cultured with cancer-associated fibroblasts (CAFs) or 
myofibroblast-like cells (MF-like, REWDLQHGE\ WUHDWLQJ06&ZLWK7*)ȕ 
showed up-regulation of Shh gene and protein expression in 
comparison to single stromal cell populations (MSCs; CAFs and MF-like 
cells). The investigation of Hh paracrine signalling in pancreatic tumour 
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microenvironment using different 2D in vitro assays (transwell and 
direct co-cultures, NShh treatments and tumour condition media 
cultures) demonstrated the inability of cancer associated fibroblasts 
(CAFs) and mesenchymal stem cells (MSCs), when grown in culture 
conditions WKDWSUHYHQW WKHLUDFWLYDWLRQ LQFUHDVHRIĮ60$, to respond 
to Hh exogenous stimuli and suggested the mSCN as the stromal 
context in which paracrine induction of the Hh pathway takes place.  
Taken together, these results suggest a new concept, that Shh 
expression is an indicator of the mSCN in the pancreatic cancer 
microenvironment and that its role as a possible target for 
chemotherapy should be explored. 
  
 4 
 
Acknowledgements 
  
I would like to thank my supervisors: Professor Sue Watson who has 
been and will be an example to follow, Dr Anna Grabowska for her 
constant availability humanity and professionalism which impassioned 
me and made me fond of my project and of my work and Dr Argent 
Richard for his advice in many aspects of this PhD. I would also like to 
thank Andrea Greener for her administrative support. 
I would really like to thank everyone in the Division of Pre-Clinical 
Oncology who helped me every day with their encouragements and 
their precious advice. In particular, I would like to thank Dr David Onion, 
Dr Nektaria Papadopoulou and Dr Madeleine Craze who with their 
knowledge, passion and availability strongly supported and excited me. 
I would like to extent my gratitude to Dr Phil Clarke, for his guidance 
and patience in teaching me immunohistochemistry and data analysis, 
Narinder Mann for her friendship and support in tissue culture and Tara 
Claringburn, Cannon Donna and Bramley Beverly for their 
administrative support. Great thanks to Luana Sasso, Musah-Eroje 
Ahmed, Pamela Collier, Maria Estévez Cebrero, Niovi Nicolaou Dr 
Alexander Reece Smith, Suzy Underwood, Dr Simon Jiang, Dr Eve Lee 
and Dr Cerys Mayne for making my time in the department a pleasure 
and encourage me in my work.  
Finally, I would like to thank my parents, my grandmother my brother, 
my sister for being always supportive, helpful and for loving me in the 
way they do. Thanks to my second family in particular to Ezia who 
really helped me in any possible way. A huge thank to Marco, who 
 5 
 
became my husband during this PhD, for his incredible patience and 
support, which pulled me through the hardest moments.  
Finally, I would like to dedicate my thesis and these years of work to 
my JUDQGIDWKHU³QRQQR6DQGUR´who is always in my thoughts and my 
baby Dario who I can consider, with no doubt, P\EHVW³UHVXOW´  
  
 6 
 
 
Table of Contents 
Chapter 1 - Introduction .................................................................... 18 
1.1 Cancer underlying causes ....................................................................19 
1.1.1 Cancer and prevention...................................................................19 
1.1.2 Pancreatic cancer ..........................................................................22 
1.1.2.1 The Stroma component of pancreatic cancer ..........................25 
1.1.2.2 In vivo models of pancreatic cancer.........................................26 
1.2 The role of stroma in tumour development ...........................................29 
1.2.1 Interplay between epithelial and stromal cells ................................30 
1.2.2 Tumour microenvironment, cancer stem cells and resistance to 
chemotherapeutic treatment. .........................................................33 
1.3 Hedgehog signalling in development and homeostasis ........................38 
1.3.1 The Hedgehog Pathway ................................................................38 
1.3.2 Hh ligand expression regulation .....................................................42 
1.3.3 The Gli Transcription Factors. ........................................................44 
1.4 Hedgehog Signalling and Cancer .........................................................51 
1.4.1 Paracrine transmission of Hedgehog signalling .............................54 
1.4.1.1 In vivo and in vitro evidence supporting Hh paracrine signalling 
in tumour microenvironment ....................................................55 
1.4.2 Paracrine signalling vs autocrine signalling ....................................60 
1.4.3 Hh signalling in pancreatic cancer .................................................61 
1.4.4 Antagonists of Hh signalling and effect of Hh pathway inhibition on 
cancer ...........................................................................................65 
1.5 The stem cell niche ..............................................................................73 
1.5.1 Mesenchymal stem cell niche and its role in cancer .......................76 
1.5.2 Stem cell niche markers .................................................................78 
1.5.3 Hedgehog pathway and the stem cell niche ...................................79 
1.6 Hypothesis and aims ............................................................................85 
1.6.1 Summary of the main concepts ......................................................85 
1.6.2 Hypothesis .....................................................................................86 
1.6.3 Aims ..............................................................................................87 
Chapter 2 - Materials and Methods .................................................. 88 
2.1 Human Primary tissues ........................................................................89 
2.2 Cell culture ...........................................................................................94 
2.2.1 Cell culture conditions ....................................................................94 
2.2.1.1 Epithelial cancer cell line culture conditions .............................94 
 7 
 
2.2.1.2 Primary cell and MSC cell culture ............................................95 
2.2.2 Sub-culturing of cells .....................................................................96 
2.2.2.1 Cell counting ...........................................................................97 
2.2.2.2 Freezing cells ..........................................................................97 
2.2.2.3 Cell recovery ...........................................................................98 
2.2.3 In vitro cell treatments ....................................................................98 
2.2.3.1 NShh treatment .......................................................................98 
2.2.3.7*)ȕWUHDWPHQW .......................................................................99 
2.2.3.3 Cell harvesting from in vitro cell treatment assays for RNA 
extraction and immunofluorescence (IF) ................................ 100 
2.2.4 Transwell co-culture ..................................................................... 100 
2.2.5 Direct co-culture........................................................................... 102 
2.2.5.1 Cell harvesting from direct co-culture for RNA extraction ....... 103 
2.2.6 Optimisation of in vitro mesenchymal stem cell niche models ...... 103 
2.2.6.1 Transwell co-culture between in vitro mSCN models and 
epithelial cancer cells ............................................................ 105 
2.2.7 Tumour conditioned media (TCM) assay ..................................... 107 
2.3 Molecular Techniques ........................................................................ 109 
2.3.1 RNA extraction from cells ............................................................ 109 
2.3.2 RNA extraction from tissues......................................................... 109 
2.3.3 cDNA synthesis. .......................................................................... 111 
2.3.4 Quantitative Real-time Polymerase chain reaction (qPCR). ......... 111 
2.3.4.1 RT-PCR data analysis. .......................................................... 118 
2.4 Protein expression analysis ................................................................ 119 
2.4.1 Immunohistochemistry ................................................................. 119 
2.4.1.1 IHC staining of Shh and Ptch1 Hh proteins in pancreatic tumour 
and normal tissues ................................................................ 120 
2.4.1.2 IHC staining of Vimentin in pancreatic tumour and normal 
tissues ................................................................................... 122 
2.4.1.3 Data analysis of IHC .............................................................. 124 
2.4.2 Immunofluorescence (IF) ............................................................. 125 
2.4.2.1 Data Analysis of IF staining ................................................... 129 
2.5 Statistics ............................................................................................. 131 
Chapter 3 - Results: Analysis of Hh signalling in primary tissues132 
3.1 Introduction ........................................................................................ 133 
3.2 Screening of Hh pathway gene expression in pancreatic and lung 
tumour tissues ................................................................................... 134 
3.2.1 Investigation of Hh pathway signalling in pancreatic samples ...... 134 
3.2.2 Hh pathway expression in normal and NSCLC tumour lung primary 
tissues ......................................................................................... 141 
3.2.3 Protein expression analysis of Hh pathway in primary pancreatic 
tumour tissues. ............................................................................ 144 
 8 
 
3.2.4 Hh ligand protein expression analysis in pancreatic tissues ......... 144 
3.2.5 Investigation of the activity of the Hh pathway in pancreatic tissues
 .................................................................................................... 153 
3.4 Summary of results ............................................................................ 161 
Chapter 4 - Results: Characterisation of Hh pathway in epithelial 
and stromal cells .......................................................... 163 
4.1 Introduction ........................................................................................ 164 
4.2 Screening of pancreatic epithelial and fibroblast cells ......................... 165 
4.2.1 Hh pathway expression in pancreatic cancer epithelial and primary-
derived fibroblasts cells ............................................................... 165 
4.2.2 Protein expression analysis of Hh ligand expression in cancer 
epithelial cells .............................................................................. 170 
4.3 Investigation of pancreatic CAF responsiveness to exogenous Hh stimuli
 .......................................................................................................... 174 
4.3.1 Investigation of the mesenchymal-like phenotype in CAFs stroma 
cells ............................................................................................. 174 
4.3.2 Investigation of responsiveness of CAFs to NShh treatment ........ 176 
4.4 Investigation of the CAF responsiveness to paracrine signals in 2D co-
culture and using tumour-conditioned medium (TCM) ........................ 179 
4.4.1 TCM effect of Hh signalling pathway paracrine induction in CAFs179 
4.4.2 Investigation of Hh pathway paracrine induction in stromal-like cells 
by 2D in vitro co-culture assays ................................................... 182 
4.4.2.1 The pancreatic CAFs responsiveness in a trans-well system.182 
4.4.2.2 The responsiveness of pancreatic CAFs in a direct co-culture 
system. .................................................................................. 188 
4.5 Summary of chapter ........................................................................... 190 
Chapter 5 - Results: The Stem Cell Niche ..................................... 191 
5.1 Introduction ........................................................................................ 192 
5.2 Investigation of the responsiveness of MSCs to Hh paracrine stimuli . 193 
5.2.1 NShh treatment of MSCs. ............................................................ 193 
5.2.2 Effect of TCM on Hh paracrine activation in MSCs ...................... 195 
5.2.3 Effect of 2D transwell co-culture on Hh paracrine activation in MSCs
 .................................................................................................... 200 
5.3 Investigation of the effect of different media on MSC activation and Hh 
pathway activation ............................................................................. 203 
5.3.1 In vitro LQYHVWLJDWLRQ RI +K SDWKZD\ LQ 06&V FXOWXUHG LQ µ¶IUHH
GLIIHUHQWLDWLRQ¶¶PHGLXP ................................................................ 208 
5.4 Investigation of the effect of TGF-ȕRQWKHGLIIHUHQWLDWLRQRI06&VDQG
Hh pathway expression ...................................................................... 213 
5.4.1 TGF-ȕHIIHFWRQ06&DFWLYDWLRQ ................................................... 213 
5.4.2 TGF-ȕ(IIHFWRQWKH+KSDWKZD\ .................................................. 217 
 9 
 
5.5 The mesenchymal stem cell niche and the establishment of an in vitro 
model ................................................................................................. 223 
5.5.1 Investigation of Shh as marker of the stem cell niche .................. 224 
5.5.2 Investigation of Shh expression in the mesenchymal stem cell niche
 .................................................................................................... 244 
5.6 Investigation of paracrine responsiveness to Hh pathway stimuli in the 
stem cell niche model ........................................................................ 250 
5.6.1 Investigation of the effect of pancreatic TCM and NShh on Hh 
pathway activation in the mSCN in vitro model ............................ 250 
5.6.2 Comparison between the responsiveness of MSC single population 
and mSCN model to Hh paracrine stimuli .................................... 254 
5.6.3 Comparison between responsiveness of different mSCN models to 
Hh paracrine stimuli ..................................................................... 257 
5.7 Summary of results ............................................................................ 262 
Chapter 6 - Discussion .................................................................... 264 
6.1 Results overview ................................................................................ 265 
6.2 Shh is over-expressed in primary tumour pancreatic tissues at the 
epithelial and stromal level ................................................................. 267 
6.2.1 SHH ligand is over express in pancreatic primary tissue in 
comparison to lung tissues .......................................................... 267 
6.2.2 Shh is over-expressed in pancreatic cancer not only at the epithelial 
level but also at the stromal level. ................................................ 269 
6.2.3 Hh downstream pathway expression suggests the existence of both 
paracrine and stromal autocrine signal in PDAC. ......................... 275 
6.3 Hh pathway expression in epithelial and stromal pancreatic tumour cells
 .......................................................................................................... 278 
6.3.1 Pancreatic CAF or MSCs alone are not able to respond to Hh 
paracrine stimuli in 2D in vitro assays. ......................................... 280 
6.4 A myofibroblast-like cell population originates from MSCs and expresses 
Shh ligand. ......................................................................................... 288 
6.4.1 TGF-ȕWUHDWPHQWRI06&VWULJJHUVDQLQFUHDVHLQĮ60$H[SUHVVLRQ
and is likely to be responsible for GLI1 gene expression regulation
 .................................................................................................... 292 
6.5 The mesenchymal stem cell niche ...................................................... 296 
6.5.1 A mesenchymal stem cell niche (mSCN) model can be reproduced 
in vitro and results in up regulation of the Shh ligand ................... 297 
6.5.2 The mSCN is the best tumour stromal context able to respond to Hh 
paracrine stimuli .......................................................................... 309 
6.5.2.1 Shh paracrine responsiveness comparison between different 
mesenchymal mSCN in vitro models ..................................... 312 
6.5.2.2 Next step in the paracrine induction of Hh signalling in a in vitro 
mSCN model ......................................................................... 313 
6.6 Applicability of the data presented in this thesis for development of novel 
therapeutic approaches ..................................................................... 315 
 10 
 
6.7 Conclusions ....................................................................................... 319 
6.8 Future work ........................................................................................ 321 
6.9 Final Conclusions ............................................................................... 328 
Chapter 7 - References ................................................................... 329 
Appendix: Software Programmes .................................................. 350 
 
 
  
 11 
 
Table of figure 
Figure 1.1 Therapeutic Targeting of the Hallmarks of Cancer. ...... 21 
Figure 1.2 Origin of stroma cells in tumour microenvironment. ... 30 
Figure 1.3 Tumour microenvironment regulates drug sensitivity. 34 
Figure 1.4 Tumour microenvironment regulates drug sensitivity. 35 
Figure 1.5 Activation of Hh signaling. ............................................. 39 
Figure 1.6 Gli2 and Gli3 proteins can act both as repressor and 
activators. ...................................................................... 46 
Figure 1.7 Hh pathway expression during development. .............. 48 
Figure 1.8 Example of Hh paracrine signaling. ............................... 59 
Figure 1.9 Distribution of stem cell niches in a  adult human body
 ........................................................................................ 74 
Figure 1.10 Intestinal stem cell niche regulation. ........................... 80 
Figure 1.11 Mesenchymal Stem Cell Niche formation and 
recruitment in pancreatic tumour microenvironment. 84 
Figure 3.1 Screening of the gene expression Hh ligands in normal 
and tumour pancreatic tissues. ................................. 136 
Figure 3.2 Hh ligand expressions in different tumour stage of 
primary pancreatic tissues. ........................................ 138 
Figure 3.3 Hh pathway activity in primary pancreatic tissues. .... 140 
Figure 3.4 Screening of SHH gene expression in normal and 
tumour lung tissues. ................................................... 142 
Figure 3.5 Screening of GLI1 gene expression in normal and 
tumour lung tissues. ................................................... 143 
Figure 3.6 Shh protein expression in primary pancreatic normal 
and tumour tissues. .................................................... 146 
Figure 3.7 Quantification of Shh protein expression in primary 
pancreatic normal and tumour tissues. .................... 147 
Figure 3.8 Vimentin expression in normal and pancreatic tumour 
tissues .......................................................................... 149 
Figure 3.9 Shh epithelial and stromal expression correlates with % 
stromal component. .................................................... 150 
Figure 3.10 Shh expression in the stromal component increases in 
proportion to the level of staining in the epithelial 
component. .................................................................. 151 
Figure 3.11 Shh was expressed at the stroma level and increased 
with tumour aggressiveness. ..................................... 152 
 12 
 
Figure 3.12 Ptch1 protein expression analyses in normal and 
tumour pancreatic tissues. ......................................... 154 
Figure 3.13 Ptch1 expression at the stromal level does not 
correlate with its expression in the epithelial 
component. .................................................................. 156 
Figure 3.14 Expression of Ptch1 within the epithelial and stroma 
compartments do not correlate.................................. 157 
Figure 3.15 Ptch1 is highly expressed in the epithelial component 
of normal and tumour pancreatic tissues ................. 158 
Figure 3.16 Correlation analysis between Shh and Ptch1 protein 
expressions in pancreatic normal and tumour tissues.
 ...................................................................................... 160 
Figure 4.1 Screening of epithelial cells, CAFs and MSCs for the 
main genes associated with the Hh pathway and 
epithelial/ myofibroblast markers .............................. 167 
Figure 4.2 Shh and Dhh protein expression analyses by IF in 
epithelial pancreatic cancer cells .............................. 171 
Figure 4.3 Gli1 expression in pancreatic epithelial cancer cells . 172 
Figure 4.4 &$)FHOOVH[SUHVVĮ60$FHOODFWLYDWLRQPDUNHU ........ 175 
Figure 4.5 Investigation of the responsiveness of CAFs to NShh.
 ...................................................................................... 177 
Figure 4.6 GLI1 and ACTA2 gene expression induction in 
pancreatic CAFs treated with NShh. .......................... 178 
Figure 4.7 Pancreatic TCM effect on Hh pathway expression in 
CAFs. ............................................................................ 181 
Figure 4.8 Investigation of paracrine interaction between P5T 
pancreatic fibroblast and P308T primary epithelial 
cancer cells. ................................................................. 183 
Figure 4.9 Time-course of Hh pathway paracrine induction in 
pancreatic CAFs. ......................................................... 185 
Figure 4.10 Investigation of pancreatic CAFs dose-dependent 
responsiveness to Hh ligands paracrine induction. 187 
Figure 4.11 Epithelial pancreatic primary fibroblast direct co-
cultures.. ...................................................................... 189 
Figure 5.1 MSC responsiveness to NShh treatment. .................... 194 
Figure 5.2 GLI1 expression correlated with ACTA2 gene 
expression. .................................................................. 195 
Figure 5.3 Effect of pancreatic tumour conditioned medium (CM) 
on Hh pathway expression in MSCs. ......................... 197 
 13 
 
Figure 5.4 MSCs passage effects on Hh pathway paracrine 
responsiveness to TCM stimuli.................................. 199 
Figure 5.5 MSCs passage effects on paracrine responsiveness to 
Hh pathway stimuli in 2D co-culture. ......................... 201 
Figure 5.6 *HQHDQGSURWHLQH[SUHVVLRQDQDO\VLVRIĮ60$LQ06&V
cultured in free differentiation medium. .................... 204 
Figure 5.7 MSCM prevented the activation of MSCs over time. .. 207 
Figure 5.8 Hh pathway expression in MSCs cultured in free 
differentiation medium ................................................ 210 
Figure 5.9 Media effect on Shh signalling pathway expression in 
MSCs. ........................................................................... 212 
Figure 5.10 Effect of TGF-ȕ RQ 06&V DFWLYDWLRQ LQ 3&$ IUHH
differentiation media. .................................................. 214 
Figure 5.11 Different media effect on TGF-ȕWUHDWPHQWRI06&V 216 
Figure 5.12 Effect of TGF-ȕWUHDWPHQWRQ+KSDWKZD\H[SUHVVLRQLQ
MSCs cultured in PCA free differentiation media. .... 218 
Figure 5.13 TGF-ȕWUHDWPHQWHIIHFWRQ+KSDWKZD\JHQHH[SUHVVLRQ
in MSCs grown in different media. ............................. 219 
Figure 5.14 Effect of TGF-ȕWUHDWPHQWRQ+KSDWKZD\H[SUHVVLRQLQ
MSCs grown in different media. ................................. 221 
Figure 5.15 Correlation analyses between GLI1 and ACTA2 gene 
expression after TGF-ȕWUHDWPHQW ............................. 222 
Figure 5.16 Investigation of SHH gene expression in a stem cell 
niche in vitro model. ................................................... 226 
Figure 5.17 Investigation of stem cell niche marker gene 
expression in a stem cell niche in vitro model. ........ 229 
Figure 5.18 ,QYHVWLJDWLRQRIĮ60$SURWHLQH[SUHVVLRQLQDVWHPFHOO
niche in vitro model. ................................................... 231 
Figure 5.19 Investigation of SHH gene expression in different 
ratios of MSCs and MF-like cells in the mSCN in vitro 
model. ........................................................................... 234 
Figure 5.20 Investigation of mSCN marker gene expression in 
different mSCN model co-culture ratios. ................... 236 
Figure 5.21 Investigation of the effect of CAFs on mSCN in vitro 
model and SHH gene and protein expression .......... 238 
Figure 5.22 Investigation of the effect of CAFs on mSCN marker 
expression in an in vitro model.................................. 240 
Figure 5.23 Investigation of the effect of CAFs on Postn protein 
expression in a mSCN in vitro model ........................ 241 
 14 
 
Figure 5.24 ,QYHVWLJDWLRQRIWKHHIIHFWRI&$)VRQWKHĮ60$SURWHLQ
expression in a mSCN in vitro model ........................ 242 
Figure 5.25 Investigation of Shh as marker of stem cell niche.... 246 
Figure 5.26 Comparison between Postn marker in the mSCN model 
and single populations ............................................... 248 
Figure 5.27 &RPSDULVRQEHWZHHQĮ60$PDUNHULQWKHP6&1PRGHO
and single populations ............................................... 249 
Figure 5.28 TCM effect on mSCN in vitro model. .......................... 251 
Figure 5.29 Effect of NShh and FBS concentration on the paracrine 
responsiveness of the Hh pathway in a mSCN in vitro 
model. ........................................................................... 253 
Figure 5.30 Comparison between MSC single population and 
mSCN model responsiveness to Hh paracrine stimuli 
in a transwell (TW ) system ........................................ 255 
Figure 5.31 Comparison between MSC single population and 
mSCN model responsiveness to NShh stimuli ......... 256 
Figure 5.32 Comparison between different mSCN models in their 
responsiveness to Hh paracrine signalling: ............. 260 
Figure 5.33 Ptch1 protein expression induction by Hh paracrine 
signalling in different mSCN models: ........................ 261 
Figure 6.1 MSCs in culture are able to differentiate into MF-like 
cells .............................................................................. 302 
Figure 6.2 Schematic diagram that depicts the conclusions, 
hypothesis and future aims (red writing) defined in this 
project. ......................................................................... 320 
 
 
 
 
  
 15 
 
List of Tables 
Table 1.1 Hh pathway inhibitors and their phase I clinical trial. .... 69 
Table 1.2  Hh inhibitors under preclinical research investigation . 71 
Table 2.1 Clinical Data of Lung Primary Tissues. SCC: Squamous 
Cell Carcinoma of Lung; NSCLC: Non Small cells Lung 
Carcinoma ...................................................................... 90 
Table 2.2 Clinical Data of Pancreatic Primary Tissues. .................. 91 
Table 2.3 Type of cells, origin and culture media included in this 
study. .............................................................................. 96 
Table 2.4 Primers utilised for qPCR ............................................... 117 
Table 2.5 Material chosen in the IF staining .................................. 128 
 
 
  
 16 
 
List of Abbreviations: 
 
 
BCC: Basal Cell Carcinoma 
BSA: Bovine Serum Albumin 
CAFs: Cancer Associated Fibroblasts 
CML: Chronic Myeloid Leukaemia 
DAB:   3,3'-Diaminobenzidine 
DHH: Desert Hedgehog 
DMEM: 'XOEHFFR¶V0RGLILHG(DJOH0HGLXP 
EACC: European Collection of Cell Cultures 
ECM: Extracellular Matrix 
EDTA: ethylenediaminetetraacetic acid 
EMT: Epithelial Mesenchymal Transition 
FBS: Fetal Bovine Serum 
FDM: Free Differentiation Media 
GFP: Green Fluorescence Protein 
GLI1: Glioma-associated oncogene 1 
GLI2: Glioma-associated oncogene 2 
GLI3: Glioma-associated oncogene 3 
HPI : Hedgehog Pathway Inhibitor 
HPRT: Hypoxanthine±Guanine Phosphoribosyltransferase gene 
HRP:  Horse Radish Peroxidase 
HGF/SF: /hepatocyte growth factor/ scatter factor 
IF: Immunofluorescence 
IHC: Immunohistochemistry 
 17 
 
IHH: Indian Hedgehog 
IPMN: Intraductal Pancreatic Mucinous Neoplasm 
MCN: Mucinous Cystic Neoplasm 
MDT: Moderate Differentiate Tumour 
MF: Myofibroblast 
MSCs: Mesenchymal Stem cells 
MSCM: Mesenchymal Stem Cell Media 
MSCGS: Mesenchymal Stem Cell Growth Supplement 
NSCLC: Non Small Cell Lung Carcinoma  
NT: Normal tissue 
PanIN: Intraepithelial Pancreatic Lesion 
PBS: Phosphate Buffered Saline 
PDAC: Pancreatic Ductal Adenocarcinoma 
PDT: Poorly Differentiated Tumour 
PSC: Pancreatic Stellate Cells 
PTCH1: patched homolog1 
PTCH2: patched homolog2 
RFP: Red Fluorescence Protein 
SCLC: Small Cell Lung Carcinoma 
SCN: Stem Cell Niche 
SHH: Sonic Hedgehog 
SMO: Smoothened 
7*)ȕ7XPRXU*URZWK)DFWRUȕ 
TME: Tumour Condition Media 
  
18 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Chapter 1 - Introduction 
Chapter 1 - Introduction 
 
19 
 
1.1  Cancer underlying causes 
1.1.1  Cancer and prevention 
Cancer is a consequence of the alteration of normal cell proliferation 
and can start from one or few cells of a tissue and then spread in all 
directions via the circulation. It can be considered a genetic disease as 
it arises from modifications in the normal expression of genes 
implicated in important processes during the lifetime of a cell, such as 
division, differentiation, apoptosis and DNA repair. The contribution of 
inherited factors to cancer development has been estimated around 5-
10% of cases, highlighting the high impact of environmental factors that 
play a role in 90-95% of tumours [Anand et al. 2008]. Environmental 
and inherited factors should not, however, be considered as 
independent factors that play an autonomous role in cancer formation 
but as interdependent causes of it [Mucci et al. 2001]. The development 
of cancer can be in fact considered a multistep process characterised 
by progressive evolution from a normal cell phenotype to a cell with 
aggressive and invasive behaviour. Cancer cells acquire six biological 
characteristics that accumulate in a multistep process: uncontrolled cell 
proliferation, reduced ability to undergo apoptosis, evasion of growth 
suppression, support of angiogenesis, self sufficiency in growth signals, 
and capacity for invasiveness and metastasis [Hanahan and Weinberg 
2011]. The proliferative phenotype can be triggered by mutations 
affecting functionality in genes classified in two main groups: 
oncogenes and tumour suppressor genes. These two kinds of genes 
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encode proteins that maintain and regulate the balance of cell 
proliferation by respectively triggering and inhibiting it in normal tissue. 
Modification in genes implicated in the regulation of cell apoptosis and 
DNA repair are also a major cause of cancer development [Hanahan 
and Weinberg 2011]. 
 An important influence on cancer development is also exerted by the 
tumour micro-environment. The interplay between cancer cells and cells 
constituting the microenvironment (stromal cells) seems to strongly 
affect the survival of both cell types and contribute to the progression of 
the tumour [Tysnes and Bjerkvig, 2007]. 
There are more than 200 types of cancer, each with different causes, 
symptoms and treatments.  Each year in the UK there are 289,000 new 
cases diagnosed, and the latest statistics show that 324,579 people 
were diagnosed with cancer in 2010 (www.cancerresearchuk.org). 
These data suggest that prevention would be the most appropriate 
approach. Prevention is based mainly on the avoidance of cancer-
producing agents that range from the well characterised ones, such as 
smoking tobacco, to environmental hazards and the effect of diet. 
Moreover, screening programmes to identify tumours before they 
produce symptoms have been carried out for several types of cancer. 
However, identification of cancer in the first stages of its development is 
still a major challenge. For this reason it is important to define the right 
therapeutic approach, in order to treat cancer once it is already at an 
advanced stage. Cancer can be treated by using different therapies like 
chemotherapy (the use of drugs to kill cancer cells) radiotherapy (use of 
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X-ray to kill cancer cells); hormone therapy (stops hormones from 
reaching hormone-sensitive cancer cells) and biological therapy (that 
include immunotherapy, cancer vaccination and gene therapy).  
Chemotherapy is the therapy most commonly used and investigated. 
One of the basic concepts of therapy is to inhibit cancer hallmarks in 
order to inhibit their acquired capability of uncontrolled proliferation, 
growth and invasiveness (Figure 1). Cancer cells are, however, often 
able to become resistant to treatment by compensating via signalling 
through alternative pathways. For this reason, combined drugs with 
different hallmarks target could be more effective and reduce the 
probability of developing resistance. 
  
Figure 1.1 Therapeutic Targeting of the Hallmarks of Cancer. Picture taken 
from Hanahan and Weinberg 2011 article in Cell, Volume 144, Issue 5, Pages 
646-674 [Hanahan and Weinberg 2011] Copyright licence obtained from Elsevier. 
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1.1.2  Pancreatic cancer 
Pancreatic cancer is one of the most dangerous solid tumours with a 5 
year survival rate around 6 %. In the United States, in 2012, it was 
estimated there would be 43,920 new cases, of which 37,390 were 
predicted to die within 5 years [Siegel 2012]. 
Therapeutic approaches in pancreatic cancer are still not good enough 
to overcome it, especially if discovered at a late stage. The most used 
chemotherapeutic agents at the moment to fight the progression of 
pancreatic cancer are fluorouracil (5FU) (an anti-metabolite that affects 
the DNA-repair process resulting in cell death) and gemcitabine (a 
nucleoside analogue that blocks DNA replication after its incorporation) 
[Barone et al 2003; Oliani et al 2004; Hidalgo et al. 2010]. Of these two 
drugs gemcitabine seems to have fewer side effects and so it is more 
widely used (www.cancerresearchuk.org). Different combinations of 
gemcitabine with drugs targeting other pathways involved in cancer 
progression are also under trial but still not really applied in patients 
[Oliani et al 2004; Hidalgo et al. 2010]. In advanced tumours 
chemotherapy is just a palliative to increase survival by only a few 
weeks, or months, but is not very effective [Oliani et al 2004; Hidalgo et 
al. 2010]. Moreover 5% of the epithelial pancreatic cancer cells seems 
to be formed from cancer stem cells (identified for their expression of 
CD44, CD24, and epithelial specific antigen ESA stem cell markers) 
known to be able to exert an important role on chemotherapy resistance 
[Ischenko et al. 2010] clearly suggesting the need for new drugs able to 
Chapter 1 - Introduction 
 
23 
 
overcome this resistance and to be more effective than those currently 
used. 
Pancreatic cancer often starts with pre-malignant lesions that then 
progress to malignant tumour by accumulating mutations in key genes 
involved in cell proliferation control, like K-ras, p16/CDKN2A, TP53 and 
SMAD4 [Feldmann et al 2007].  
There are three types of pancreatic precursor lesions: intraepithelial 
pancreatic lesion (Pan IN), intraductal mucinous neoplasm (IPMNs) and 
mucinous cystic neoplasm (MCN). The precursor lesions that normally 
develop into invasive pancreatic ductal adenocarcinoma (PDAC), the 
most common form of pancreatic tumours, are the PanIN. These 
lesions are divided in three groups (PanIN1; PanIN2, PanIN3) based on 
a gradual acquisition of a papillary architecture and cytological 
degenerative criteria [Hruban et al. 2001]. PanIN1 lesion presents with 
K-ras mutation, whereas PanIN2 and PanIN3 acquire also respectively 
p16/CDKN2A and TP53, SMAD4 tumour suppressor gene mutations 
that drive the degenerative progression towards PDAC. In fact, PDACs 
show the expression of more than one of these mutations and their 
effect synergise in a final uncontrolled cell proliferation and invasive 
phenotype [Feldmann 2007].  
K-ras protein is a proto-oncogene involved in cell growth and 
differentiation. Its mutated form in codon 12 is very common in 
pancreatic cancer (95% of pancreatic cancers) [Almouguera et al. 1988] 
and is able to trigger uncontrolled proliferation of pancreatic epithelial 
cells in engineered mice conditionally expressing it (K-rasG12D). 
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However to fully develop PDAC, synergistic effects of the other 
suppressor gene mutations are needed [Tuveson et al. 2004]. 
It was also observed that 48 of 50 samples (98%) of pancreatic cancer 
analysed presented an alteration in the Rb/P16 (also called INK4a) 
pathway. This signalling is implicated in the regulation of cell cycle 
phase G1, and the alteration of the P16 tumour suppressor activity 
triggers an uncontrolled cell proliferation and then neoplasia [Schutte et 
al. 1997].  
Finally the role of SMAD4 was demonstrated to have differential tumour 
stage-dependent roles in pancreatic tumours. SMAD4 is a transcription 
factor triggered during the activation of the WXPRXU JURZWK IDFWRU ȕ
(7*)ȕ) pathway. A study in a genetically engineered mouse model 
showed a double effect of this pathway in PDAC. Deletion of SMAD4 in 
mouse with KrasG12D mutation and inhibition of INK4a resulted in an 
increase in PDAC formation into a moderately or well differentiated 
tumour stage, indicating its role as a tumour suppressor protein. 
However, expression of wild-type SMAD4 can increase, in the same 
engineered mouse (KrasG12D-INK4a null), the progression to poorly 
differentiated tumour by promoting epithelial mesenchymal transition 
(EMT), a mechanism that induces the trans-differentiation of epithelial 
cell into mesenchymal cells increasing their motility and the property of 
tumour cells invasiveness. This process shows its double role in the 
determination of tumour grade, differentiation and aggressiveness in 
PDAC [Bardeesy et al. 2006].  
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Pancreatic cancer is also characterised by the alteration of pathways 
normally involved in development like Hedgehog, Wnt and Notch 
pathways. All these signalling pathway play a role in regulation of cell 
proliferation, survival and differentiation and their alteration seems to 
synergise with Kras mutation in PDAC [Maitra et al. 2008; Morris et al. 
2010].  
1.1.2.1  The Stroma component of pancreatic cancer 
A very important role in pancreatic tumour progression is exerted by the 
stromal component. PDAC is characterised by a strong desmoplastic 
reaction associated with tumour progression. The origin of this stromal 
component is a consequence of proliferation of in situ fibroblasts, 
pericytes and pancreatic stellate cells (PSCs) [Feig et al. 2012].  
PSCs are cells normally inactivated that, under stimuli from epithelial 
cells, express Į-VPRRWKPXVFOHSURWHLQĮ60$FROODJHQW\SH I and III, 
laminin, fibronectin and extracellular matrix (ECM) protein. All these 
proteins contribute to increased stromal volume, cell contractility and 
invasion [Omary et al. 2007]. Study of the origin of fibrosis showed a 
clear role for activated PSC in the increase in connective tissue in the 
pancreas [Haber et al. 1999].  
Another important stromal cell observed in pancreatic cancer is 
myofibroblast cells recruited from bone marrow that constitutes 
approximately 25% of cancer-associated fibroblast (CAFs) [Chu et al. 
2007]. Other components of tumour stroma are endothelial cell 
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precursors and cells of the inflammatory/ immune system [Scarlett et al. 
2011]. 
1.1.2.2  In vivo models of pancreatic cancer 
Xenograft models have been performed for pancreatic cancer in order 
to investigate the main pathways involved in this type of tumour and to 
identify targets for new therapies. These models successfully showed 
the reconstitution of PDAC and its desmoplastic effect (Feldmann et al 
2008; Bailey et al 2008; Berman et al 2003). However, the growth of 
tumour cells in vitro before mouse implantation has been demonstrated 
to alter the molecular characteristics of the cells (Daniel et al 2009) and, 
moreover, these models seem unable to represent the tumour stroma in 
all its complexity. Studies focused on patient-derived xenografts (PDX), 
models obtained by tumour fragment engraftment into 
immunocompromised mice, support the idea that in vitro growth 
reduces, by clonal selection, the variety of cellular type and subtype 
normally present in the pancreatic tumour (Kopetz et al 2012), including 
cancer stem cells (CSC) responsible for resistance to chemotherapy (Li 
et al 2007; Jimeno et al 2009). PDX have been used in the investigation 
of new therapeutic drugs directed against the main pathways involved 
in the development of pancreatic cancer (e.g. K-RAS, HER2 and Hh) 
with the aim of reducing the pancreatic tumour mass and blocking 
metastasis [Mattie et al 2013; Siolas et al 2013; Walters et al 2013]. The 
molecular characterisation (gene expression and microRNA 
microarrays, mutation analysis, short tandem repeat (STR) profiling, 
Chapter 1 - Introduction 
 
27 
 
and immunohistochemistry) of 8 human patient tumours was compared 
to the corresponding xenograft models and showed a high correlation 
[Mattie et al 2013]. PDX models for pancreatic tumour showed the 
ability to metastasise and develop the desmoplastic reaction typical of 
this type of cancer [Fu et al 1992; Suetsugu et al 2012]. These models 
have been largely used for the investigation of the stromal reaction in 
this tumour. Considering the tendency of the mouse stromal cells to 
substitute the original human stroma, the implantation of primary tumour 
in transgenic mice expressing fluorescent protein like GFP (green 
fluorescent protein) allowed the investigation and characterisation of the 
stromal cells involved in the pancreatic cancer [Suetsugu et al 2012]. 
Moreover an interesting method to image the progression of tumour 
stroma has also been used: the human tumour was initially established 
as a xenograft in a mouse and then orthotopically transplanted into a 
sequence of transgenic mice expressing different fluorescent markers 
(e.g. RFP, GFP). In this way, progression in the tumour stroma was 
observed [Suetsuguarticle 2 et al 2012]. Nevertheless, the PDX models 
have shown some limitations: the necessity to implant the human 
tumour in immunodeficient mice completely eliminates the possibility of 
testing immunotherapies. Moreover, problems associated with storage 
of tumour specimens and the need to re-establish after freezing can 
alter the tumour. Furthermore, in PDX as well as in xenograft models, 
the human stroma is still being replaced by mouse stroma. Finally, 
primary tumour resected and transplanted before the therapeutic 
treatment exclude the investigation of refractory cancers. 
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Other important models for the investigation of pancreatic cancer and 
chemotherapeutic approaches able to maintain an intact immune-
system are the engineered mice, such as that described in the literature 
[Bardeesy et al. 2006]. A very interesting and representative engineered 
model was obtained by constitutively expressing the Kras-P53 mutation 
in the, so called, KPC mice. This model was successfully used to 
investigate the role of gemcitabine and Hh pathway inhibitors on drug 
delivery and pancreatic volume mass reduction, highlighting the 
importance of the Hh pathway in this tumour [Olive et al. 2009]. 
However, in a recent study focused on the investigation of the genomic 
alterations in pancreatic cancer, 12 pathways were showed to be 
involved in this tumour and all these pathways were showed to be 
important for its development. In view of this study transgenic mice 
expressing only 2 or 3 mutation could fail to reproduce the human 
PDAC [Jones et al 2008]. 
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1.2  The role of stroma in tumour development  
The microenvironment of a tumour plays a fundamental role in the 
process of development, growth and metastasis. This microenvironment 
comprises tumour epithelial cells and the surrounding stroma which is 
made up of fibroblasts, vascular and lymph endothelial cells, 
extracellular matrix, and a range of immune and inflammatory cells [De 
Wever et al. 2008]. Stromal cells can be classified into a number of 
subtypes including myofibroblasts, CAFs, fibrocytes, and pericytes. An 
important role for myofibroblasts in the modulation of the stroma 
physiology and pathology in the cancer setting has been demonstrated 
[Spaeth et al. 2009]. The myofibroblasts are the main components of 
the stroma and in normal tissue act in the process of wound healing, but 
also in tissue morphogenesis at an embryonic level. In the tumour 
setting, through the secretion of chemokines, cytokines, matrix 
metalloproteinases (MMPs) and extracellular matrix (ECM) components, 
they are able to modify the structure of stroma and to induce the 
invasion and migration of tumour cells to other tissues (metastasis). A 
number of positive and negative markers have been used to identify 
myofibroblasts. All m\RILEUREODVWV H[SUHVV Į-VPRRWK PXVFOH DFWLQ Į-
SMA), as well as vimentin, desmin, cadherin11 and Collagen Type 1. 
However, it is impossible to find a profile of markers to define perfectly a 
sub-population due to the diversity of the origins of CAFs present in a 
tumour [De Wever et al. 2008 ; Anderberg C, Pietras K 2009 ]. In fact, 
as shown in Figure 2, the source of myofibroblasts and CAFs can be a 
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consequence of trans-differentiation of several kinds of cells resident in 
the tumour (adipocyte, epithelial and endothelial cells) or differentiation 
of circulating mesenchymal stem cells (MSCs) [ De Wever et al. 2008].   
 
 
Figure 1.2 Origin of stroma cells in tumour microenvironment.  Stroma 
cells can derive from transdifferentiation of different types of cell lines resident 
in the tumour microenvironment or from circulating and recruited MSC from 
bone marrow. Image taken from De Wever et al. International Journal of 
Cancer Volume 123, Issue 10, pages 2229-2238, 5 SEP 2008  
Copyright licence obtained from John Wiley and Sons. 
1.2.1  Interplay between epithelial and stromal cells 
A role for these fibroblasts in the signalling network between stroma 
and tumour-derived epithelial cells and in overall growth, vascularisation 
and invasion of the tumour, has been confirmed in vivo and in vitro 
studies. 
Co-culture in vitro shows the reciprocal paracrine communication 
between CAFs and epithelial tumour cells. A mixed population of cancer 
cells and CAFs showed a synergistic effect on the expression of 
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cytokines and growth factors that sustain tumour growth, like VEGF 
(vascular endothelial growth factor) and G-CSF (granulocyte colony 
formation factor) [Kurcenova et al 2010]. Furthermore, co-cultures 
between CAFs and human melanoma cells showed a supportive role of 
CAFs in the cancer cell proliferation process. It seems, in fact, that 
CAFs release paracrine factors that protect tumour cells from serum 
deprivation-induced apoptosis and cytotoxicity and stimulate their 
colony formation ability [Kucerova et al. 2010]. The effect of stroma on 
tumour invasiveness has been demonstrated in vitro with co-cultures of 
myofibroblast and cancer cells isolated from colon cancer. After 48h it 
was possible to see migration of cancer cells on a collagen gel only 
when myofibroblasts were present. Cancer cell pro-invasive activity was 
stimulated by two factors secreted from myofibroblasts: the scatter 
factor/hepatocyte growth factor (SF/HGF) and TGF-ȕ XS-regulated 
extracellular matrix tenascin C (TNC) [De Wever et al. 2004]. Finally 
normal fibroblasts co-cultured with pancreatic tumour cells expressing 
K-ras, express Palladin protein which in turn stimulates their activation 
GHWHFWHG DV LQFUHDVH RI Į60$ DQG YLPHQWLQ H[SUHVVLRQ Activated 
fibroblasts are then able to increase tumour cell invasion and create a 
tunnel structure that allows the migration of cancer cells [Brentnall et al. 
2012]. 
As well as in vitro experiments the interplay between stroma and 
epithelial cancer cells has been thoroughly demonstrated by in vivo 
experiments. Pancreatic stellate cells when co-transplanted with 
pancreatic cancer cells in orthotopic mice were able to induce tumour 
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growth, angiogenesis and cancer cell metastasis. Tracking of the 
movement of cancer cells through use of mixed female pancreatic 
cancer cells transplanted with or without male PSC, which could be 
monitored using a Cy3-labeled fluorescent probe able to detect the Y 
chromosome, showed how human PSC migrate with cancer cells to the 
secondary site of the tumour, directly participating in the metastatic 
process [Xu et al. 2010]. 
In the tumour microenvironment, 20% of cancer-associated fibroblasts 
originate from MSCs [Spaeth et al. 2009]. This differentiation is induced 
by paracrine factors released from epithelial cancer cells [Mishra et al 
2008]. A recent study identified GRP78 factor the responsible to induce 
WKH Į60$ H[SUHVVLRQ D PDUNHU RI &$)V LQ 06&V YLD 7*)ȕ6PDG
pathway activation [Peng et al 2013]. In vivo experiments have 
confirmed the effect of MSCs on the growth and proliferation of a 
tumour. For example xenograft tumour formed from a 1:1 mix of the 
ovarian tumour cell line Skov3 and MSCs grew significantly more than 
the Skov3 cells implanted alone. Moreover, in the mixed tumour the 
secretion of growth factors by both kinds of cells was observed: 
epithelial cancer cells grown in MSC-conditioned media secreted an 
increased amount of IL-6, HGF, TGF-ȕ 9(*) DQG WKH VDPH HIIHFW
could be obtained stimulating the MSC cells with Skov3-conditioned 
media [Spaeth et al. 2009].  
Moreover, MSCs have been observed to have an angiogenic effect 
through the release of VEGF and desmin in xenografts formed from 
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Skov3 cells and MSCs compared to a xenograft tumour alone [Spaeth 
et al. 2009]. 
 Finally, subcutaneous injection of MSCs and breast cancer cells into 
mice, in order to form xenografts, triggers the expression of the 
chemokine CCL5 in mesenchymal stem cells which in turn enhances 
the motility and metastasis of breast cancer cells (by paracrine 
activation) [Karnoub et al. 2007].  
1.2.2  Tumour microenvironment, cancer stem cells and resistance 
to chemotherapeutic treatment 
Recent evidence showed a very important role of the tumour 
microenvironment in promoting chemotherapeutic drug resistance 
observed in cancer cells of different tumours. 
The basic mechanism consists of mutational changes due to DNA 
damage caused from drug treatment on mesenchymal stroma cells. 
Chemotherapeutic activation of transcription factor NF-kȕ in 
mesenchymal stroma cells was demonstrated [Sun et al 2012], which in 
turn is able to stimulate the transcription of the Wnt family member 
WNT16B. This factor was then demonstrated by in vitro and in vivo 
experiments to trigger the Wnt pathway in prostate, breast and ovarian 
cancer cells and increase their resistance to drug treatment via 
paracrine mechanism (Figure 1.3) [Sun et al. 2012]. 
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Figure 1.3 Tumour microenvironment regulates drug sensitivity. Drug 
responses of cancer epithelial cells are not exclusively determined by their 
intrinsic characteristics, but are also controlled by signals derived from the 
TME. (Figure taken from Arne Östman volume 18 | number 9 | September 
2012 nature medicine). Copyright licence obtained from Nature Publishing 
Group. 
 
 
 
Stromal cell response to chemotherapy and radiation treatment also 
result in the up-regulation of HGF which enhances paracrine activation 
of the c-Met receptor in breast cancer cells leading to resistance to RAS 
inhibitors (often used in the chemotherapeutic treatment of breast 
cancer). Chemotherapeutic resistance is also increased via the same 
mechanism in colorectal cancers with BRAF mutations and HER2 
positive breast cancer (two markers of drug sensitivity already known 
and used to identify the molecular mechanism of treatment resistance) 
(Figure 1.4) [Wilson et al. 2012; Straussman et al. 2012]. 
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Figure 1.4 Tumour microenvironment regulates drug sensitivity.  Figure 
taken from  Arne Östman volume 18 | number 9 | September 2012 nature 
medicine . Copyright licence obtained from Nature Publishing Group. 
 
Stromal cells exert chemotherapeutic resistance also in a more indirect 
way, by supporting the survival of cancer stem cells (CSC). These cells 
constitute a small percentage of the entire tumour but are able to trigger 
tumour formation and growth when implanted in mice [Al-Hajj et al. 
2003]. CSC have been in fact observed to be involved in the origin of 
leukemia [Lapidot et al. 1994], breast [Alhajj et al. 2003], and pancreas 
tumour [Li et al. 2007]. Although CSC are a minority of the cells in the 
context of pancreatic cancer, when transplanted in NOD/SCID mice 
they are able to trigger significant tumour growth [Li et al. 2007]. CSC 
are defined based on three main biological properties: capacity of self-
renew, ability to differentiate into different cell types and, as said, ability 
to induce in vivo formation of a new tumour after implantation in a 
mouse model. Currently, these are many controversial theories about 
their origin including that they derive from:  
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x Stem cells resident in the tissue where the tumour is formed  
x Mutated mesenchymal stem cells recruited following inflammation and 
wound healing   
x Fusion of bone marrow stem cells with resident cells resulting 
transformed cancer stem cells  
x Progenitor cells that acquire a capacity for self-renewal through 
deregulation of self-renewal pathways like Hedgehog, Wnt, Notch 
[Tysnes and Bjerkvig 2007]. 
CSC are demonstrated to be resistant to chemotherapy and to be 
capable of causing tumour relapse in different type of tumour 
highlighting the importance of their role in the tumour microenvironment 
(TME) [Rajan et al. 2008]. 
Recent studies showed the important role of myofibroblast cells within 
the TME in cancer stem cell survival, introducing the concept of a 
cancer stem cell niche and its role in promoting tumour progression and 
metastasis [Malanchi et al. 2012, Lonardo et al. 2012]. It has been 
shown that myofibroblast cells secreting factors like Periostin protein 
(POSTN), a component of extracellular matrix, help the survival of 
cancer stem cells by recruiting Wnt pathway that is able to maintain the 
cancer stem cell survival and self-renew. The re-programming of cancer 
stem cell niche in the metastatic secondary site seems to be 
fundamental in triggering the tumour to begin metastasis [Malanchi et al. 
2012]. 
Thus, this study highlights the importance of a deeper understanding of 
the mechanisms that regulate the interplay between tumour and stroma 
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that can give important information for future combinatorial clinical 
treatments designed to block this interaction which is a fundamental 
step in cancer progression. 
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1.3  Hedgehog signalling in development and 
homeostasis 
1.3.1  The Hedgehog Pathway 
Hedgehog (Hh) signalling was identified for the first time in the fruit fly 
Drosophila melanogaster as one of the signalling molecules implicated 
in development. Subsequently Hh proteins have been characterised in 
a multitude of species, including humans. The Hh pathway is now 
implicated in many important processes such as development, adult 
tissue homeostasis, tissue repair in chronic inflammation, 
carcinogenesis and stem cell maintenance [Ingham PW 2008; Katoh y 
Katoh 2006]. 
Three homologous Hh ligands are secreted from different tissues at 
various stages of development: Shh (Sonic Hedgehog); Ihh (Indian 
Hedgehog) and Dhh (desert Hedgehog) [Ingham and Mc Mahon 2001]. 
The Hh ligands bind to a 12-pass transmembrane protein, Patched-1 
(Ptch-1), relieving the repression exerted on a seven-pass 
transmembrane GPCR-like (G protein coupled receptor) protein, 
Smoothened (SMO), and triggers the Hh signalling cascade. SMO de-
repression activates the serine/threonine kinase STK36 which in turn 
phosphorylates the negative regulator of the Hh pathway SUFU that 
becomes inactivated and subsequently promotes the nuclear 
accumulation of full-length GLI  transcription factors (Gli1, Gli2 and Gli3) 
(Figure 1.5) [Ingham PW 2008; Katoh y Katoh 2006]. 
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Figure 1.5 Activation of Hh signaling.  A) Inactivated Hedgehog signaling. 
B) The Hh ligand, binding to transmembrane protein receptor Patch, relieves 
from repression the transmembrane protein SMO that becomes activate. Once 
activated SMO trigger a signal cascade during which the inhibition of the Hh 
pathway inhibitor Supressor of Fused (SuFu) allows the activation of Gli 
transcription factors and the Hh gene target transcription [Image taken from 
Atwood et al. 2012, original published in JCell Biol.; 199:193-197 doi: 
10.1083].No Copyright permission license was requested for non commercial 
reuse. 
 
The regulation of Hh pathway expression is quite complex and can 
occur at many different levels. For instance, Gli1 and Ptch1 are also 
target genes of the Hh pathway and they are normally used as 
indicators of Hh pathway activity [Lee et al 1997; Hidalgo and Ingham 
1990]. Gli1 and Ptch1 respectively exert a positive and negative 
feedback on the Hh pathway in order to balance the expression of the 
pathway gene targets. Ptch1 negative feedback prevents its own 
overexpression which would otherwise result in inhibition of the Hh 
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pathway with severe consequences during development [Goodrich et al. 
1999]. Moreover, both isoforms of Ptch, Ptch1 and Ptch2, can be 
activated by Shh but a stronger correlation was seen between Ptch2 
and Dhh. The Dhh-Ptch2 complex has been observed  mainly to act in 
specific organs and tissues like prostate, ovary, testis, skin and 
cerebellum suggesting a different localisation of action of these two 
receptor forms [Carpenter et al. 1998; Rahnama et al. 2004; Bajestan et 
al. 2006]. Due to the Ptch1 negative feedback induction, analysis of Hh 
pathway activity by detection of Ptch1 expression, even if recognised 
and used in many papers, could be more difficult.  
Gli1 expression regulation is also intricate, with recent evidence from 
literature showing that Ptch1 is able to inhibit Gli1 expression, not just 
through SMO inhibition relief, but also via an alternative non-canonical 
(independent from Smo and SuFu) mechanism. Two distinct domains in 
Ptch1 were identified as responsible for this new mechanism of Gli1 
inhibition and they are distinct and independent from the C-terminal 
region responsible for the canonical Hh pathway inhibition thorough 
Smo [Rahnama et al. 2006]. Moreover, other studies have shown 
activation of Gli1 via different non-canonical pathways including KRas 
DQG7*)ȕ[Nolan-Stevaux at al 2009] making the picture more complex 
and complicating the analysis of this pathway. 
Hh signalling transduction also depends on its localisation on the 
primary cilium of cells. There is still little known about regulation of this 
process but SMO localisation and activation in the cilium as a 
fundamental requirement for triggering of Hh signalling have been 
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suggested [Corbit et al. 2005; Rohatgi et al. 2009]. Moreover, mutation 
in the intraflagellar transport (IFT) proteins inhibited Hh signalling in the 
development of the murine limb bud [Haycraft et al. 2005]. It seems, in 
fact, that a very important role in the localisation of an Hh pathway 
complex of activators and repressors that acts downstream of SMO but 
before the GLI transcription factor is exerted by the IFT122 protein [Qin 
et al. 2011]. Further investigations on the relationship between cilium 
localisation and Hh pathway activity showed that Shh ligand or 
mutations that constitutively activates SMO are both able to induce 
SMO localisation to the cilium [Corbit et al 2005] confirming a role of 
cilium in Hh pathway signalling regulation. However, constitutive 
localisation of SMO in the cilium, by overexpression of SMO in the cell, 
is not enough to reach the maximum Hh pathway activation, suggesting 
that localisation in the cilium and SMO activation are two independent 
steps both necessary to signal transduction [Rohatgi et al. 2009].  
Further regulation of the pathway involves the localisation of GLI2 /GLI3 
transcription factors and the inhibitor SuFu in the apical part of the 
cilium where, in the absence of Hh signalling they are in a repressive 
form that does not translate the signal [Haycraft et al. 2005]. Recent 
evidence seems to implicate PKA (a protein involved in the machinery 
of Hh signalling transduction) in this localisation. PKA is a protein 
kinase, which in the context of cilium localisation, does not act by 
phosphorylation of Gli2 and Gli3 but in a more indirect way [Zeng et al. 
2010]. 
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In conclusion the Hh pathway is characterised by different levels of 
regulation showing the complexity of this signalling. 
1.3.2  Hh ligand expression regulation 
The Hh ligands, responsible for triggering the pathway, are found in 
mammals as three different genes SHH, DHH and IHH which probably 
originated via a duplication event. Dhh is the most similar ligand to the 
single homologous ligand in Drosophila, whereas Shh and Ihh 
developed later on in vertebrates [Ingham and McMahon 2001]. 
SHH/Shh act during vertebrate development at many different levels 
and in almost all organ and tissue formation (neural tube, limb, heart, 
gut, eye, bone and cartilage, muscle and others) by regulating cell fate 
differentiation, proliferation and survival. In this entire development 
process, Shh mainly acts in a paracrine manner inducing the 
downstream Hh pathway via short range action or in more distant cells 
(long range action) [Ingham and McMahon 2001].  
The secretion of Shh requires modification and organisation of the 
ligand. Full length Shh has a lipid modification that results in cholesterol 
and palmitic acid moieties at the C-terminus and N-terminus of the 
protein respectively [Porter et al. 1996; Pepinsky et al. 1998]. 
Cholesterol modification is very important for the anchorage to the 
cellular membrane and both lipid modifications regulate the ligand 
concentration and the potency of long range signalling [Grover et al. 
2011]. 
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To be secreted Shh needs to be organised in oligomers. Interestingly 
the structural organisation of these oligomers can influence the Shh 
mechanism of action. Small oligomers formed by electrostatic 
interaction and multimeric structures (consequence of a covalent 
binding with heparan sulphate proteoglycans (HSPG)) are in fact able to 
respectively trigger short and long range pathway activation [Vyas et al. 
2008] . Another regulator of Hh pathway long and short range activity is 
the intracellular localisation and secretion of the ligand. Hh ligand is 
distributed both basically and apically in the epithelial cells. Association 
between long range activity mediated by extracellular matrix proteins 
(ECM) (Dally and Dally-like glypicans) and apical secretion has been 
demonstrated [Ayers et al. 2010]. Consistently short range action 
correlated with basal secretion and did not seem to be affected by 
alteration of apical secretion [Ayers et al. 2010]. 
The secretion of Shh from the cells is mediated by a protein called 
Dispatched (Disp). As proof of the role of Dispatched in Shh secretion, 
Disp-null mice showed a very similar phenotype to Smoothened-null 
mice, with no Hh signalling. Moreover, the loss of Hh signalling in these 
null-mice was not a consequence of unsynthesised Hh molecules but of 
the inability to transport the Hh ligand across long distances to allow the 
long range paracrine activation, typical of developmental processes 
[Kawakami et al. 2002]. 
Other different methods of Shh transportation have also been 
suggested (e.g. extracellular vesicular particles, exosomes or for short 
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range communication cellular protrusion or nanotubes) [Therond et al. 
2012].  
The complexity of Hh ligand organisation and the regulation of its 
secretion is an important aspect of the Hh signalling since it is probably 
responsible for its ability to exert so many functions not just in 
development but also, as explained later on, in cancer development and 
formation. 
1.3.3  The Gli Transcription Factors. 
The net effect of Hh stimuli in vertebrates is the activation of three zinc-
finger transcription factors: Gli1, Gli2 and Gli3. [Ruiz I Altaba et al. 
2007]. These proteins encode both activator and repressor functions 
and act in a combinatorial and cooperative fashion [Aza-Blanc 2000; 
Park et al. 2000; Buttitta et al. 2003, Bai et al. 2004]. In Drosophila this 
transcriptional role is carried out by the homologous transcription factor 
Cubitus interruptus (Ci). Much of the information that we have so far, 
comes from studies on Drosophila which have revealed an intricate 
network of several factors during Hh signal transduction. 
Gli1, Gli2 and Gli3 proteins all have a C-terminal transactivation domain 
but only Gli2 and Gli3 have an N-terminal repressor domain [Sasaki et 
al. 1999]. When the Hh signal is absent, Gli2 and Gli3 in vertebrates, 
and Ci in Drosophila, are present in a latent transcriptional repressor 
form, binding to a multiple protein complex in the cytoplasm. This 
complex contains the kinesin-related protein Costal-2 (Cos2), the Fused 
kinase (Fu) and Suppressor of Fused (SuFu) [Ingham and McMahon 
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2001; Kasper et al. 2006 ]. The Gli2/3 proteins, as shown by studies in 
Drosophila focused on the homologous Ci, blocked in the cytoplasm by 
WKH &RV FRPSOH[ DUH SKRVSKRU\ODWHG E\ 3.$ *6.ȕ DQG &.
proteins and cleaved by the proteasome Slimb (supernumerary limb) 
within the C-terminal transactivation domain conferring on them 
repressor activity [Wang et al. 1999; Price and Kalderon 2002]. After 
cleavage the proteins retain the N-terminal repressor domain, allowing 
them to bind to promoters and inhibit transcription of Hh target genes 
(Figure 1.6). 
When the Hh signalling is activated the Gli2/3 proteins are not bound 
but are released as full-length transcription factors. During this process, 
the Cos2 complex undergoes several changes including the recruitment 
of Cos2 protein by the cytoplasmic tail of Smo, the activation of Fu and 
the phosphorylation of SuFu. All these modifications lead to the release 
and stabilisation of Gli proteins as transcriptional factors that activate 
the gene target of Hh signalling (Figure 1.6 ) [Ingham and Mc Mahon 
2001; Kasper et al. 2006]. 
The regulation of Gli1 activity differs from that of Gli2 and Gli3 because 
this takes place at the transcriptional level and the mRNA expression of 
Gli1 can be considered a direct indicator of Hh signalling activity [Lee et 
al. 1997]. Evidence shows that the regulation of Gli1 activity is 
dependent on the presence of functional Gli2 and Gli3. In fact Gli2 and 
Gli3 can directly activate Gli1 at the DNA level by binding to its 
promoter [Ding et al. 1998; Dai et al. 1999; Buttitta et al. 2003, Bai et al. 
2004].  
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The activation or inhibition of a target gene by Gli proteins can be 
enhanced by others factors that act during Hh signalling. For example 
SuFu, through the activation of histone deacetylase (Sap18 and Sin3), 
can enhance the inhibition of gene targets when the Hh signal is absent. 
On the other hand, proteins like Missing in Metastasis (MiM) and Yak1 
related kinase (Dyrk) can enhance the transcriptional activity of Gli1 and 
Gli2 (Figure 1.6)[ Kasper et al. 2006 ]. 
   
             
 
Figure 1.6 Gli2 and Gli3 proteins can act both as repressor and 
activators. When there is no signaling the multi-protein complex Cos2 blocks 
the Gli2/3 proteins in the cytoplasm. Here Gli2/3 proteins are phosphorylated 
E\ 3.$ *6.ȕ DQG &. SURWHLQV DQG FOHDYHG E\ WKH SURWHDVRPH 6OLPE
within the C-terminal transactivation domain conferring on them repressor 
activity. When the Hh signaling is activated the Gli2/3 proteins are not tied but 
are released as full-length transcription factors. The activation or inhibition of a 
target gene by Gli proteins can be enhanced by others factors that act during 
Hh signalling such as SUFU (inhibitor of the pathway), MIM and Dyrk 
(activators of the pathway). Images taken from Kasper et al. 2006. Copyright 
licence obtained from Elsevier. 
  
 
The ability of Hh signalling to regulate so many different processes 
including development, proliferation and homeostasis is a consequence 
Chapter 1 - Introduction 
 
47 
 
of an interplay between the Gli proteins that act in an age-context and 
species-specific way, and the ability of each Gli protein to activate a 
distinct set of gene targets preferentially [Ruiz I Altaba et al. 2007; 
Buttitta et al. 2003; Ding et al. 1998]. 
Several studies show how Gli proteins act in a species-specific way 
having different effects depending on their context. For example in the 
mouse, loss of the function of any single or all Gli proteins does not 
completely abolish neural tube neurogenesis [Bai et al. 2004], in 
contrast with the results obtained in frog where there is a critical 
involvement of Gli function in the patterning of the neural plate and a 
important requirement for each Gli protein in the induction of all primary 
neurons [Nguyen et al. 2005]. The ability of these proteins to act in a 
context±dependent manner could be explained by their combinatorial 
activity [Bai et al. 2004, Buttitta et al. 2003, Park et al. 2000], their 
capability, in the case of Gli2 and Gli3, to act both as repressor and 
activator [Aza-Blanc 2000; Park et al. 2000; Buttitta et al. 2003, Bai et al. 
2004] and by the interaction of the Gli proteins with the other, above-
mentioned, proteins involved in the Gli network.  
A good example of the interplay between the Gli proteins is the 
GHYHORSPHQW RI YHUWHEUDWHV¶ QHXUDO SODWH DQG QHXUDO WXEH DQG
sclerotome induction. In the ventral neural plate a double Gli gradient 
with an opposite distribution of repressor and activator is responsible for 
tissue patterning (Figure 1.7). These double gradients regulate the 
differentiation of stem cells during development, and it is possible to 
observe an increase in Gli1 and Gli2 activator expression during the 
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undifferentiated and proliferating phases which gradually decreases 
during the differentiated stages, giving rise to high expression of the 
repressor forms of Gli3 and Gli2 (Figure 1.7) [Ruiz I Altaba et al. 2007]. 
 
 
Figure 1.7 Hh pathway expression during development.  a) Gli repressors 
and activators are differentially distributed in vertrebal neural plate leading to a 
differential expression of Hh gene target in time and space determining in this 
way the fate and the proliferation/survival rate of cells. b) Hh pathway in stem 
cell differentiation. Gli activators are highly expressed in undifferentiated and 
proliferating phases, and low expressed in differentiated cells, giving rise to 
increased expression of the repressor forms of Gli3 and Gli2 [Image taken 
from Altaba et al. 2007]. Copyright licence obtained from Elsevier. 
  
 
 
A study of the role of Shh in sclerotome induction confirmed the 
importance of Gli2 and Gli3 in development but it also showed how they 
can act both as repressors then as activators. In sclerotome induction, 
in fact, it is possible to observe repressor activity of Gli2 and activator 
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activity of Gli3 that are normally difficult to detect. Indeed regulation of 
Gli1 and Ptch1 in cultured cells by Gli3 activity has been observed. 
Moreover Gli2-/-Gli3+/- transgenic mice express the Shh target genes in 
contrast with Gli2-/-Gli3-/-. In the same study a role for Gli2 in the 
inhibition of Shh gene targets was confirmed by the observation that a 
Gli2-/+Gli3-/- mouse does not exhibit the same level of Shh target 
derepression as a Gli2-/-Gli3-/- mouse. An explanation for the difficulty in 
detecting Gli3 activator and Gli2 repressor activity could be that in 
normal conditions Gli2 is a stronger activator than Gli3 and Gli3 is a 
stronger repressor than Gli2. Therefore when Gli2 is expressed this 
would usually mask the activator activity of Gli3 and vice-versa [Buttitta 
et al. 2003]. 
The complexity of Gli regulation and function and their capacity to 
LQIOXHQFHHDFKRWKHU¶VDFWLYLW\DVREVHUYHGLQQHXUDOSODWHGHYHORSPHQW
and sclerotome induction, can be explained by the existence of protein 
complexes. The zinc finger structure of the Gli proteins supports this 
hypothesis, which may provide a possible binding site for other Gli 
proteins leading to the formation of homo- and/or heterodimers. Other 
observations support this hypothesis. For example in amphibians, when 
all but one Gli is removed it is possible to observe a loss of the 
neurogenic activity of Gli1 [Nguyen et al. 2005]. In mouse mesoderm 
the induction of Hh gene targets by Gli1 depends on the presence of 
Gli2 and Gli3 [Buttitta et al. 2003], and co-immunoprecipitation assays 
showed physical interaction of Gli proteins [Nguyen et al. 2005]. 
Chapter 1 - Introduction 
 
50 
 
However, there is currently too little data available to confirm this 
hypothesis with any certainty. 
In conclusion, this complex interplay of Gli proteins, even if still not well 
understood, may explain the numerous functions of the Hedgehog 
pathway and, as will be explained in the next paragraphs, their 
functional alterations are tightly  involved in the development of cancer. 
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1.4  Hedgehog Signalling and Cancer  
The target genes of the individual GLI transcription factors are 
numerous and have a variety of roles. Genes include cell-specific 
targets and their up-regulation can induce premalignant events 
including inhibition of apoptosis (via BCL2) [Bigelow et al. 2004], 
enhanced proliferation (via CCND2) [Duman-Scheel et al. 2002], 
angiogenesis (via VEGF) [Coultas et al. 2010], epithelial-mesenchymal 
transition (via SNAIL) [Li et al. 2006], and stem cell clonogenicity 
[Peacock et al. 2007]. For these reasons, deregulation of Hh signalling 
has been associated with several different cancers.  
Different types of tumours such as oesophageal [Berman et al. 2003], 
gastric [El Zaatary 2007; Yan et al 2013], pancreatic [Feldmann et al. 
2008; Xu et al. 2009], multiple myeloma [Peacock et al. 2007] and 
ovarian [Bhattacharya et al. 2008; Liao et al. 2008] show reactivation 
and overexpression of the Hh pathway. Recently deregulation of Hh 
pathway was seen also in breast [Tao et al. 2011], colon 
adenocarcinoma [Bian et al. 2007]; prostate [Chen et al. 2009] and lung 
[Yuan et al. 2007]. Moreover, the role of Hh pathway in these cancers 
seems to be involved in different stages of the carcinogenesis process. 
For example, an effect of Hh pathway in tumour development and in 
metastasis has been observed in pancreatic and gastric cancer [Thayer 
et al. 2003; Bailey et al. 2009; Yoo et al. 2011; Yan et al 2013], while in 
other tumours like prostate [Show et al. 2009], breast [Tao et al. 2011], 
and ovarian [Liao et al. 2009] it has been shown that there is an 
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important role for the Hh pathway in progression, tumour growth and 
proliferation [Yang et al. 2010] 
Other tumours associated with the Gorlin syndrome like basal cell 
carcinoma (BCC), medulloblastoma and rhabdomyosarcoma have been 
found to be associated with a loss of function of PTCH1 or SuFu genes 
[Unden et al. 1996; Lee et al. 2007; Goddrich et al. 1997; Tostar et al. 
2006]. The treatment of these tumours with Hh pathway inhibitors 
blocks tumour progression indicating a role for this pathway in these 
kinds of tumour. 
Screening of BCC samples and medulloblastoma has also shown an 
important association with two mutations ( SMOM1 and SMOM2) 
consequence of two nucleobase transitions in two different exons of  
the SMO protein [Xie et al. 1998; Lam et al. 1999; Reifenberger et al. 
1998]. Transgenic mice with SMOM2 expression driven from a keratin 5 
promoter showed an overexpression of SMOM2 and a skin phenotype 
typical of BCC. The same transgenic mice with SMOWT expression did 
not show any particular skin phenotype [Xie et al. 1998]. Finally the 
SmoM2 mutation was found to be associated with 3 BCCs of 31 
analysed but also with 1 PNET (Primitive Neuroectodermal Tumours of 
the Central Nervous System) tumour. The level of SMO expression in 
these tumours was higher compared to the control and was associated 
with increased expression of Gli1 and Ptch1. These results demonstrate 
that SMO mutations results in ligand-independent activation of SMO 
and consequently activation of the Hh pathway [Reifenberger et al. 
1998] 
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Evidence from the literature suggests a link between the Hh pathway 
and cancer stem cell frequency in breast cancer [Liu et al. 2006], 
multiple myeloma [Peacock et al. 2007] and chronic myelogenous 
leukemia [Zhao et al. 2009]. In all these tumours Hh induced self-
renewal and expansion of cancer stem cells. Hh pathway expression 
was also identified in pancreatic cancer stem cells (recognized as 
CD44+CD24+ESA+ cells) and its role in self-renewal and formation of 
new tumours in immunodeficient mice was confirmed. Gene expression 
analysis of SHH was compared between CD44+CD24+ESA+, CD44-
CD24-ESA- (considered non stem cells), pancreatic tumour cells and 
normal pancreatic cells. The expression of Shh was up-regulated 
around 43 times in pancreatic cancer stem cells in comparison to 
normal cells and only 4 times in CD44-CD24-ESA-  and bulk pancreatic 
tumour cells [Li et al. 2007]. Consistent with Hh expression in cancer 
stem cells, stem cells cultured from glioblastoma multiforme (GBM) 
(gliomaspheres) when treated with cyclopamine, showed dose-
dependent decreased proliferation, suggesting the presence of the Hh 
pathway signalling in these cells. In support of this, shRNA targeting 
SMO affected cell survival and induced apoptosis of gliomaspheres, 
suggesting the decreasing stem cell proliferation observed after 
cyclopamine treatment occurs not as a consequence of toxicity but as a 
direct consequence of Hh pathway inhibition [Clement et al. 2007].  
Since stem cells are known to be resistant to chemotherapy and 
radiotherapy, a better understanding of the role of Hh in these cells 
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could be important for future clinical application of new anti-cancer 
drugs. 
1.4.1   Paracrine transmission of Hedgehog signalling 
The mechanisms of Hh pathways activation in different cancer types 
are currently a topic of great interest. Recent studies [Yauch et al. 2008; 
Tian et al. 2009; Nakamura et al 2010] suggest a paracrine model for 
Hh signalling in certain cancers in contrast with the previous finding of 
tumour epithelial cells responding to Hh ligand overexpression in an 
autocrine manner [Thayer et al. 2003; Berman et al. 2003; Stecca et al. 
2007]. So far in the literature, four different types of Hh signalling in 
cancer have been proposed [Scales-De Sauvage 2009]. Type I tumour 
involves ligand-independent, mutation-driven signalling, i.e. 
medulloblastoma, and basal cell carcinoma, that are often a 
conVHTXHQFH RI *RUOLQ¶V 6\QGURPH Ln which mutation of PTCH1 and 
SuFu lead to constitutive activation of Hh signalling [Xie et al. 1998, 
Lam et al. 1999]. Type II is a ligand-dependent cancer, in which tumour 
cells respond to Hh ligand overexpression, triggering signalling in an 
autocrine manner. The type III tumour is tumour ligand-dependent and 
involves paracrine interactions in which tumour cells secrete Hh-ligands 
which trigger the signalling cascade of Hh pathway in the stromal 
component of the tumour microenvironment. Finally the type IV tumour 
IROORZVD³UHYHUVHSDUDFULQHPRGHO´LQZKLFK+KOLJDQGVDUHVHFUHWHGE\
the supporting stromal cells which act on malignant cells. So far this last 
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kind of signalling has only been observed in a hematologic model and a 
more thorough analysis is needed [Scales-De Sauvage 2009]. 
More recent articles show some weaknesses in the proposed autocrine 
model and propose that a paracrine model is more relevant for all 
cancer [Yauch et al. 2008; Tian et al. 2009; Olive et al. 2¶7RROet 
al. 2011].  
1.4.1.1  In vivo and in vitro evidence supporting Hh paracrine signalling 
in tumour microenvironment 
The role of the stromal microenvironment in human tumour growth is 
supported by evidence that Hh ligands failed to activate signalling in 
tumour epithelial cells [Yauch et al. 2008]. 
To verify the existence of Hh signalling in tumour epithelial cells, the 
sensitivity of these cells (measured by cell viability) to a small molecule 
SMO-acting antagonist and cyclopamine (also a SMO antagonist) has 
been correlated with the expression of Hh pathway activity in these cells. 
As predicted, no correlation was found in epithelial cells, but the half 
maximal inhibitory concentration (IC50) of the SMO antagonist required 
to inhibit the cell growth in an Hh-responsive mesenchymal cell line 
(HEPM) was found to be 400 times lower than that necessary to obtain 
the same effect in cancer cell lines. Moreover, co-culture of an epithelial 
cancer cell line and 10T1/2 mouse embryo cell line transfected with a 
Gli reporter construct showed a correlation between the induction of Gli 
activity in fibroblasts and the levels of Hh ligands expressed  by tumour 
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cells, demonstrating the capacity of the epithelial cells to induce 
paracrine signalling in fibroblast cells [Yauch et al. 2008]. 
Furthermore, separation of epithelial cells and stromal cells by using 
FACS sorting for CD24 (a marker expression of epithelial cells) from 
human breast tumour, showed high immunofluorescence (IF) staining of 
Shh and hedgehog interacting protein Hhip (gene target of Hh pathway) 
respectively in epithelial and stroma like cells (co-stained with vimentin 
to confirm their fibroblasts nature).These results support the idea of the 
paracrine signalling between tumour cells and stromal fibroblast cells 
[2¶7RROHet al. 2011].  
Tests in vivo have been carried out using mouse xenograft models 
established with surgical biopsies from cancer patients. The mouse 
stroma substitutes for the human stroma, and then, by using species-
specific probes it is possible to distinguish the human tumour vs. mouse 
stroma. The expression of Hh ligands in the human tumour cells 
correlated with the expression of Gli1 in mouse stroma confirming a 
paracrine-type induction [Yauch et al. 2008]. Finally, in order to test the 
effect of Hh signalling on tumour growth, mouse embryonic fibroblasts 
(MEFs) engineered to have conditional removal of SMO were implanted 
with colon epithelial cell lines expressing luciferase and compared with 
a mouse control in which there was a normal expression of SMO. The 
mouse with the SMO knockout in MEF cells showed a reduction in 
tumour size as assessed by reduced luciferase activity [Yauch et al. 
2008]. 
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An additional recent publication from the same group also showed 
paracrine Hh signalling. The expression of an oncogenic allele of 
Smoothened (SmoM2) was induced in epithelial pancreatic cells in a 
mouse model. Surprisingly, no impact on pancreatic development and 
neoplasia was observed, showing the absence of Hh signalling in cells 
possessing the mutant SMO [Tian et al. 2009]. Mice obtained by 
crossing PdxCre/SmoM2 mice (in which SMOM2 is expressed only in 
epithelial pancreatic cells) with Ptch-/DF= PLFH GLG QRW VKRZ ȕ-
galactosidase expression (detected by Ptch-LacZ reporter 
immunostaining) in ductal epithelial cells but only in mesenchymal 
pancreatic cells, demonstrating that the pancreatic epithelium is not 
competent to transduce autocrine Hh signalling. Finally the 
PdxCre;Kras mice with Kras-driven pancreatic tumours after treatment 
of pancreatic ductal epithelial cell (PDEC) line with recombinant Shh  or 
molecule agonist of SMO, induced strong activation of the Hh pathway 
(determined by Gli1 mRNA expression) only in fibroblasts and not in 
epithelial cells [Tian et al. 2009]. 
A recent study of Nolan-6WHYDX[¶V group confirms the observation in 
pancreatic ductal adenocarcinoma (PDAC), demonstrating that genetic 
deletion of SMO in KrasG12D-driven PDAC has no effect on tumour 
progression and development and so indicating a possible absence of 
the pathway in these cells [Nolan-Stevaux et al. 2009]. 
Moreover, experiments on prostate cancer support the paracrine Hh 
signalling model, and the fundamental role of myofibroblasts in this 
process [Shaw et al. 2009]. It was observed that biclonal xenograft 
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tumours obtained from a 1:1 mix of prostatic cancer cells (LNCaP) and 
immortalized urogenital mesenchymal cells (UGSM-2), showed 
significantly lower tumour growth in comparison to a biclonal xenograft 
in which the prostatic cancer cells over-expressed Shh (LNShh+UGSM-
2) [Shaw et al. 2009].  There was also a strong association between 
increased tumour proliferation and the amount of myofibroblasts 
present in the stroma, confirming the fundamental role of the stroma in 
cancer progression [Shaw et al. 2009].  In order to better understand 
this role a microarray analysis of target genes expression in these 
myofibroblasts was performed. As result of this analysis a correlation 
between the expression of the main genes of the Hh pathway (Shh, Gli1, 
Gli2 and Patch) and nine gene targets that are normally expressed in 
the stroma of the prostate during embryonic development was observed. 
There is growing evidence for a stromal phenotype in prostate cancer 
that responds to Hh ligands by exerting growth-promoting activities that 
stimulate tumour cell proliferation [Shaw et al. 2009]. 
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Figure 1.8 Example of Hh paracrine signaling. Epithelial tumor cells 
produce Hh ligands which activate the Hh pathway in stroma cells of the 
surrounding tumour microenvironment (including fibroblast cells, epithelialcells  
endothelial cells, and immune cells). As reply to this induction the stroma cells 
produce growth factors and matrix proteins that promote tumor growth.  Image 
taken from Curran and Ng, volume 455 (7211) 2008 Nature. Copyright licence 
obtained from Nature Publishing Group. 
 
The paracrine transmission of Hh signalling is important for future 
clinical applications as demonstrated by a recent work that showed an 
effect of Hh pathway inhibition in stromal cells in enhancing the delivery 
of chemotherapeutic agents. Mouse models for pancreatic tumour 
obtained by conditional expression of mutant p53 and Kras proteins in 
cancer cells, showed a reduction of metastasis and increased tumour 
cell apoptosis when treated with the Hh pathway inhibitor IPI-926 and 
with the chemotherapeutic agent gemcitabine. IPI-926 is a drug which 
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targets SMO and blocks its activity. It was demonstrated that blocking 
SMO activity led to a depletion of the pancreatic stroma and increased 
vascularisation of the tumour allowing the delivery of gemcitabine and 
consequently a significant reduction of the tumour volume [Olive et al. 
2009]. 
1.4.2  Paracrine signalling vs autocrine signalling 
The results described so far seem to confirm paracrine transmission of 
the Hh pathway in cancer; however, other works continue to show 
contrasting results. In more than one study, epithelial cancer cells 
treated with cyclopamine in the absence of the stroma cells in vitro, 
induced apoptosis [Qualtrough et al. 2004; Sanchez et al. 2004; 
Mukherjee, et al. 2006]. Moreover, the same pancreatic cell lines as 
WKRVHXVHGLQ<DXFK¶V work, have, in other experiments, shown a dose-
dependent decrease in cell proliferation after cyclopamine treatment 
and Gli1 knock-down by Gli1 siRNA transfection [Xu et al. 2009]. These 
results could be explained by a non-specific effect of cyclopamine or 
drug toxicity; however, competition of cyclopamine binding using 
purmorphamine (an Hh agonist that bind to SMO) [Xu et al. 2009] or 
reproduction of its effect by using siRNA targeting Gli1 and SMO 
[Sanchez et al. 2004; Mukherjee, et al. 2006; Xu et al. 2009] seems to 
support its specific role in Hh pathway inhibition and so, autocrine Hh 
signalling in cancer epithelial cells. In addition, a number of studies 
have shown Hh pathway overexpression in epithelial cancer cells 
including pancreatic [Thayer et al. 2003; Xu et al. 2009], prostate 
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[Sanchez et al. 2004], ovarian [Liao et al. 2009], gastrointestinal 
[Berman et al. 2003]l, breast [Mukherjee, et al. 2006] and melanoma 
[Stecca et al. 2007]. 
Many of these discrepancies could be explained by different methods 
used to define Hh signalling.  Another possible explanation is that the 
involvement of Hh pathway could be cell type-dependent (i.e. stromal 
cells could have different response kinetics in comparison to epithelial 
cells) [Ruiz I Altaba et al. 2008]. Recently the existence of a non-
canonical pathway has been described, in which the Gli proteins are 
regulated from different pathways like p53 [Abe et al. 2008; Stecca and 
Ruiz I Altaba 2008]; TGF-B, Kras [Nolan-Stevaux et al. 2009] and Wnt 
[Yang et al. 2008] and could explain the expression of Gli1 mRNA in 
epithelial tumour cells. 
1.4.3  Hh signalling in pancreatic cancer 
Pancreatic cancer is characterised by a very high desmoplastic 
response during the tumour development. At the advanced tumour 
stage, the stromal component is very high and is able to increase 
tumour cell proliferation and metastasis [Merika et al. 2012].  
The Hh pathway has been investigated in this cancer for its role in 
promoting the increase of desmoplasia. It was shown how pancreatic 
cancer cells constitutively expressing or over-expressing Shh ligand 
and orthotopically implanted into mice were able to significantly 
augment the stromal mass and induce the activation of stromal cells 
into a more aggressive phenotype, marked by the increased expression 
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RI Į60$ Collagen I and fibronectin [Bailey et al.2008]. In the same 
work, in vitro assays showed how myofibroblast cells increase GLI1 
gene and protein expression after treatment with ectopic Shh, indicating 
an active Hh signalling in these cells. Moreover rhShh (10ȝg/ml) 
treatment increased the in vitro invasion capability of myofibroblasts 
cells. Finally, modulation of Shh expression affected the ĮSMA 
expression in murine stroma cells and induced the differentiation of 
pancreatic stellate cells into myofibroblast cells suggesting a role for 
Shh in driving stromal cell activation [Bailey et al. 2008]. 
Therefore, mainly paracrine induction of Hh pathway in this tumour 
seems to be likely. Other work strongly confirms and supports this 
observation. Hh-antagonist treatment does not affect GLI1 gene 
expression and cell growth in pancreatic tumour cells indicating no 
pathway activity in them [Yauch et al. 2008]. Moreover, co-culture of 
pancreatic cancer cells, expressing different level of Hh ligands, with 
fibroblast cells increased GLI1 gene expression in the fibroblast cells 
proportionally to the level of ligands detected. Finally implantation of 
pancreatic cancer cells with different levels of ligands in xenograft mice 
Ptch1-lacZ;Rag2-/- confirmed the same ligand-dependent paracrine 
activation in stromal cells observed in vitro [Yauch et al. 2008]. Ptc-
LacZ reporter mouse, as already discussed, were also used in the work 
of Tian et al. and confirmed the downstream activation of Hh pathway in 
the stromal microenvironment and its absence in cancer epithelial cells 
[Tian et al. 2009]. Finally comparison between fibroblasts from 
pancreatic ductal adenocarcinoma (PDAC) and normal pancreas 
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showed 100 times greater expression of SMO in CAFs. The modulation 
of SMO by siRNA in these cells also reduced GLI1 expression and 
blocked the ability of these cells to respond to ectopic NShh treatment, 
confirming the activity of Hh pathway in these stromal cells [Walter et al. 
2010]. 
The role of Hh pathway in development of pancreatic cancer was 
investigated in mice with overexpression of Shh at an early stage of 
pancreatic development, and showed abnormal pancreas with 
characteristics very similar to PanIN lesions; the mice were not able to 
survive [Thayer et al 2003]. Further studies on xenograft mice 
supported the formation of a histologically undifferentiated pancreatic 
tumour. However, this tumour developed without following the 
progression via PanIN lesions typical of the PDAC. It did not follow the 
pattern formation typical of PDAC in which a gradual progression of still 
differentiated epithelial tumour cytokeratine (CK19) positive cells is 
common. However, this does not exclude a role of the pathway in the 
early stage of the tumour [Pasca di Magliano et al. 2006]. In the same 
work, simultaneous activation of Shh and K-Ras synergistically increase 
the formation of human PDAC in comparison to K-Ras mutated mice 
[Pasca di Magliano et al. 2006]. Moreover the co-expression of Shh at 
epithelial level and K-Ras significantly increased the tumour growth and 
cancer cell proliferation and survival [Morton et al. 2007]. The 
relationship between K-Ras and the Hh pathway is, however, still 
unclear. A synergistic effect was observed in this study but the inhibition 
of Shh in K-Ras mutated mouse did not alter cell proliferation; however, 
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simultaneous inhibition of Shh and PI3 Kinase blocked cancer cell 
proliferation. These data indicate that K-Ras and the Hh pathway act 
independently but they are both very important for PDAC cancer 
development and progression [Morton et al. 2007]. It was also shown 
that autocrine Hh pathway transmission seems optional especially 
during the first stage of tumour development, suggesting that different 
kinds of signals may be involved at different steps of this tumour 
[Morton et al. 2007]. In contrast to this idea, in another study, 
p48-Cre;LSL-KrasG12D;Smoflox/flox mice with no expression of SMO 
in pancreatic cancer cells, and so unable to respond to Hh ligand 
autocrine stimuli, did not show any difference in the formation of PDAC 
and PanIN lesion in comparison to mice wild type for SMO expression, 
suggesting again a role for Hh in PDAC but the inability of cancer cells 
to trigger it via autocrine signals [Nolan-Stevaux et al. 2009].  
These evidences support the role of Hh pathway in pancreatic cancer 
development and progression and they highlight the importance of Hh 
inhibition in the treatment of this cancer. Paracrine activation of Hh 
pathway in this type of cancer seems very likely but it is not yet possible 
to exclude also the existence of an autocrine signal in cancer cells. This 
overview of Hh pathway in PDAC shows the difficulty in the fully 
understanding the behaviour of this pathway in cancer and the 
necessity of further studies.  
Inhibition of Hh pathway for PDAC treatment, as well as for other types 
of cancer, is already under investigation and important results have 
been observed as described in the next section.  
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1.4.4  Antagonists of Hh signalling and effect of Hh pathway 
inhibition on cancer 
The compounds screened for Hh pathway inhibition can be divided into 
three main groups based on the target protein: inhibitors that target the 
binding between Shh and Ptch1, such as the antibody 5E1 and 
robotnikinin; inhibitors of SMO protein (Cyclopamine, IPI-926 GDC-
0449, Cur6141, SANT-1, SANT-4) and Gli inhibitors (GANT-56, GANT-
61, HPI-1) [Yang et al. 2010].  
The first Hh pathway inhibitor (HPI) used for the treatment of cancer (i.e. 
basal cell carcinoma) was cyclopamine, a natural compound extracted 
from corn lilies that binds SMO protein, blocking its activity [Taipale et al. 
2000; Chen et al. 2002]. The treatment of orthotopic xenograft models 
for pancreatic cancer with cyclopamine showed reduced tumour 
development, and in vitro studies resulted in a reduced proliferation and 
invasiveness of cancer cells [Feldmann et al. 2008]. However, in some 
studies cyclopamine showed high toxic effects, teratogenic properties 
and poor bioavailability [Lipinsky et al. 2008, Yauch et al 2008]. This led 
to the testing of a similar natural compound, IPI-926, and to the 
synthesis of other novel inhibitors directed against the SMO protein, 
such as Hh-antag, SANT-1, SANT-4 [Chen et al. 2002] Cur-61414 
[Williams et al. 2003] and GDC-0449 [Lo Russo et al. 2011].  
GDC-0449 (Vismodegib) is one of the most efficient chemotherapeutic 
agents against the Hh pathway and has recently been tested on 
patients with locally advanced solid tumour (33 patients with BCC; 8 
patients with pancreatic cancer; 1 patient with medulloblastoma; and 17 
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patients with other types of tumours). Fifty-seven percent of the patients 
affected by BCC showed tumour regression and significant results have 
been obtained in the treatment of medulloblastoma. However, no 
tumour regression was observed in the 8 patients affected by 
pancreatic cancer [Lo Russo et al 2011]. Recently, the emergence of a 
SMO mutation that confers resistance to the treatment has been 
demonstrated [Yauch et al. 2009] in medulloblastoma cancer cells 
treated with GDC-0449. 
A number of research projects are currently focused on inhibition of the 
Hh pathway in the treatment of pancreatic cancer. Considering the 
strong desmoplastic effect characteristic of this cancer and its poor 
prognosis (Chu et al 2007), a treatment combining a drug targeting the 
stroma component and an agent able to block the epithelial tumour cell 
proliferation is now becoming the main approach used in new trials.  
Phase II clinical trial studies on pancreatic cancer have been performed 
for either IPI-969209 or GDC-0449 in combination with gemcitabine 
[Madden 2012; Catenacci et al 2013]. The patients treated with IPI-
969209 (also known as Sarigedib) or GDC-0449 and gemcitabine were 
compared with patients treated with a placebo combined with 
gemcitabine. None of the combined treatments (Hh antagonist and 
gemcitabine) show a regression of the tumour or an improvement in the 
survival rate, in comparison to gemcitabine alone [Madden 2012; 
Catenacci et al 2013].  
Variable and contrasting results have been obtained in the investigation 
in pancreatic cancer of co-treatment with IPI-969209 and gemcitabine. 
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The treatment of mice with an orthotopic tumour with IPI-969209 and 
gemcitabine resulted in inhibition of pancreatic cancer stem cell 
migration and a significant reduction of the metastasis [Feldmann et al. 
2008]. Consistent with these results, in transgenic mice with pancreatic 
tumours the same combined treatment resulted in a strong reduction in 
the desmoplastic reaction typical of this type of tumour [Olive et al. 
2009]. However, a more recent study from the same group showed that 
in an engineered mouse model capable of developing PDAC, 
histologically very similar to the human type, the prolonged (more than 
3 months) inhibition of Hh pathway (by treatment with IPI-969209 or by 
knocking down Shh in the cancer cells) reduced the survival rate of 
mice with tumour and was associated with an undifferentiated 
aggressive tumour phenotype. Although, consistent with the Olive et al 
work, the tumour mass was reduced in these mice and the stroma mass 
was comparable to that found in normal pancreas, the combination of 
IPI-969209 and gemcitabine failed to obtain tumour regression. The 
reason for these results seems to be increased formation of vasculature. 
The main hypothesis formulated in this work suggests that 
myofibroblast cells have the tendency to inhibit endothelial cell 
proliferation. This would explain the poor vasculature in the stroma of 
pancreatic cancer. In agreement with this hypothesis, the inhibition of 
the Hh pathway in the tumour microenvironment and, as consequence, 
the depletion of the stroma mass, led to an increase of the vasculature, 
which indirectly induced an undifferentiated phenotype by supporting 
cancer cell proliferation [Rhim et al 2014]; treatment with antiangiogenic 
Chapter 1 - Introduction 
 
68 
 
drugs (showed to be effective [Rhim et al 2014]) combined with 
inhibition of Hh pathway could be an interesting strategy to investigate. 
The IPI-969209 trial has been suspended; however, other five trials are 
ongoing for the use of GDC-0449 in pancreatic cancer [Kim and Rudin 
2014].  
A suggested explanation for the failures observed in phase II clinical 
trials, was that pancreatic stellate cells are able to support the survival 
of cancer stem cells in pancreatic tumour by constituting a cancer stem 
cell niche [Lonardo et al 2012.]. Additionally, targeting pancreatic 
stellate cells, with Hh inhibitor CUR199691, as well as a combination of 
gemcitabine and an inhibitor of cancer stem cells SB431542, did result 
in tumor growth. This could have a very important impact on tumour 
relapse in which cancer stem cells are known to have a major role 
[Lonardo et al. 2012]. 
 At present, other SMO inhibitors BMS-833923 (Bristol-Myers Squibb), 
PF04449913 (Pfizer) and LY2940680 (Eli Lilly), are under investigation 
in clinical trials of a range of advanced cancers 
(http://www.clinicaltrials.gov/). 
Moreover, other more recent drugs (MS-0022 and AZD8542) targeting 
SMO in the pancreatic tumour microenvironment showed interesting in 
vitro and in vivo effects on the reduction of tumour mass and 
progression [Strand et al 2011; Hwang et al 2012]. However, both of 
these new drugs are still in a preclinical phase. in their investigation as 
chemotherapeutic drugs.«««««««««««««««««««
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The table below shows the main Hh pathway inhibitors currently used in clinical phase trials:  
 
             Table 1.1 Hh pathway inhibitors and their phase I clinical trial.  
              Modified from Amakye et al  Nature Medicine 19(11): 1410-1422 (2013). Copryright obtained from Nature Publishing Group. 
Agent Mechanism of Action Phase(s) Cancer(s) 
GDC-0449 SMO Inhibitor 1, 2 
BCC, medulloblastoma, pancreatic, 
breast, SCLC, ovarian, gastric, 
glioblastoma, , multiple myeloma 
BMS-833923 (XL139) SMO Inhibitor 1, 2 CML, BCC, gastric, multiple myeloma 
LY2940680 
 
SMO Inhibitor 1 SCLC, advanced solid tumours 
IPI-926 SMO Inhibitor 1, 2 Pancreatic cancer 
LDE225 (Sonidegib) SMO Inhibitor 1, 2,3 
Pancreatic cancer, Breast cancer 
SCLC, BCC, medulloblastoma, CML, 
advanced solid tumours 
LEQ506 SMO Inhibitor 1 BCC, medulloblastoma 
PF-04449913 SMO Inhibitor 1 CML 
 
                BCC: basal cell carcinoma, CML: Chronic Myeloid Leukaemia; SCLC Small cell lung cancer.
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As illustrated so far, the main approach currently for targeting Hh 
pathway in cancer is by binding SMO and inhibiting its activation. 
However, as explained before, some types of cancer can be a 
consequence of overexpression of Gli proteins triggered by alternative 
pathways. In these cases, and also in cancer arising from a SMO 
mutation, which may compromise the binding of chemotherapeutic 
agents, it may be important to develop new drugs targeting Gli1 or Gli2 
proteins directly. So far, new therapeutic agents against Gli proteins, 
like GANT58 and GANT61 have been tested but they still need further 
investigation [Lauth et al. 2007]. Moreover, other key steps of the Hh 
signalling, like the binding of the Shh ligand to its receptor, the 
translocation of the transmembrane protein SMO in the cilium and the 
fosforilation of key intracellular proteins, are also under investigation but 
still at the preclinical phase. 
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The following table summarise the Hh antagonist currently under 
preclinical investigation [Amakye et al 2013]. 
 
Table 1.2  Hh inhibitors under preclinical research investigation 
Modified from Amakye et al  Nature Medicine 19(11): 1410-1422 (2013).  
Copyright obtained from Nature Publishing Group. 
Hh pathway inhibitor Mechanism of Action Phase of investigation 
Cyclopamine SMO Inhibitor Research 
SANT 1,2,3 SMO Inhibitor Research 
CA1 and CA2 Inhibit cilia biogenesis, do not bind SMO Research 
SMANT 
Inhibits cilia accumulation, 
distinct binding mode on 
SMO 
Research 
Glucocorticoids, class I 
(FA and TA) 
Induce SMO accumulation in 
cilia Research 
Glucocorticoids , class II 
(Bud and Cic) 
Inhibit cilia accumulation of 
SMO Research 
ALLO1 and ALLO2 Distinc binding mode to SMO Research 
Compound 5 Binds SMO and inhibits cilial translocation Research 
Robotnikinin Binds to SHH and blocks pathway activity Research 
RU-SKI Inhibits Hh acyltransferase Research 
Hh-specific monoclonal 
antibody 5E1 
Blocks binding of Hh ligands 
to PTCH1 Research 
GANT58 and GANT61 
Block GLI1- and GLI2-
mediated reporter activity; 
GANT61 interferes with DNA 
binding of GLI1 
Research 
HPI 1±4 
Act at or downstream of 
SUFU; modulate GLI1 
processing, activation and or 
trafficking 
Research 
Arsenics Act at level of GLIs Research 
Myristoylated aPKC 
peptide inhibitor (PSI) 
Inhibits the phosphorylation 
and activation of GLI1 by 
PKC 
Research 
Rapamycin 
Inhibits TNF-Į±induced and 
mTOR-S6K±mediated 
phosphorylation and 
activation of GLI1  
Research 
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Considering the new evidence reporting paracrine transmission of Hh 
signalling in cancer, further inhibitors need to be tested in order to 
check their efficiency in the types of tumour showing paracrine 
mechanisms of Hh signalling.  
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1.5  The stem cell niche 
The concept of the stem cell niche consists in the interaction between 
human stem cells and support cells (niche cells) which are responsible 
for maintaining, by direct cell contact or paracrine signalling, the 
proliferation, survival and self-renewal capacity of stem cells [Schofield 
et al. 1978]. The stem cell niche is not just present during embryonic 
development but also in adult tissues. In the human adult body there 
are different stem cell niches divided to low and high turnover niches 
based on the frequency of self-renewing and differentiating stem cells 
activity (Figure 1.9) [Hsu and Fuchs 2012].  
Niche cells can directly derive from stem cell differentiation, and their 
interplay with stem cells through regulatory positive and negative 
feedback is mediated by important pathways involved in development 
like Wnt, BMP (Bone morphogenetic protein), Notch and Hedgehog 
[Hsu and Fuchs 2012 ; Yeung et al. 2011].  For example in the intestinal 
stem cell niche, myofibroblast cells keep the stem cells undifferentiated 
and maintain their survival by secreting factors like Wnt gene targets 
and BMP antagonists that regulate the stem cell activity (Gremlin1) 
[Yeung et al. 2011]. 
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Figure 1.9 Distribution of stem cell niches in a  adult human body .Picture taken from Hsu and Fuchs 2012, Nat Rev 
Mol Cell Biol. 2012 January 23; 13(2): 103±114.Copyright licence obtained from Nature Publishing Group. 
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One of the most important adult niches is present in human bone 
marrow and is made up of mesenchymal stem cells (MSCs) and 
fibroblast cells (niche cells). MSCs are multipotent but not pluripotent 
cells characterised by their ability to self-renew and differentiate into 
different cell lineages such as condrocytes, adipocytes and osteocytes 
[Pittenger et al. 1999]. MSCs do not originate exclusively from 
mesoderm but also from the endodermic and ectodermic layer during 
development. In these locations, MSCs are in their quiescent state 
which can be reactivated under particular conditions, such as wound 
healing and inflammation but also cancer [Khun et al. 2010].  
There are three main criteria to identify MSCs: 1) the ability to adhere to 
plastic as a monolayer when in standard in vitro culture, 2) multipotency 
i.e. the ability to differentiate into the three cell lineages described 
above and 3) the expression of specific surface markers. So far there is 
no one marker that allows identification of MSCs but rather a 
combination of different expressed and unexpressed superficial 
markers. Expression of CD105, CD73 and CD90, and lack of 
expression of CD45, CD34, CD14 or CD11b, CD79alpha or CD19 and 
HLA-DR surface molecules appear to be the best criteria to distinguish 
these cells from other stem or non-stem cells [Dominici et al. 2006]. 
Interestingly, the bone marrow mesenchymal stem cell niche (mSCN) is 
often located very near to another niche, the haematopoietic one, and 
so near to blood vessels. However, even if these niches tend to strictly 
interact they are separate. This proximity of bone marrow to blood 
Chapter 1 -Introduction 
  
76 
 
vessels could however clarify how MSCs are easily able to migrate to 
different parts of the body [Mendez-Ferrer et al. 2010]. 
1.5.1  Mesenchymal stem cell niche and its role in cancer 
The mSCN has been investigated for its role in tumour 
microenvironment using Į60$-RFP+ transgenic mice (in which 
H[SUHVVLRQRI5)3ZDVUHJXODWHGE\Į60$promoter) to investigate the 
stromal changes that characterise tumour progression [Quante et al. 
2011]. Generation of chronic gastritis, metaplasia and dysplasia was 
induced by Helicobacter felis infection or constitutive expression of IL-
ȕLQWKHVWRPDFK. ,QFUHDVHRIĮ60$SRVLWLYHFHOOVP\RILEUREODVWFHOOV
was observed in both mouse models at the late stage of dysplasia in 
comparison to control samples. These cells were then investigated for 
their growing and survival property in culture and for their vimentin 
expression to confirm their myofibroblast (MF) nature. Interestingly, the 
myofibroblasts originated in the infected mice showed a natural 
tendency to survive in culture in comparison to myofibroblasts from 
healthy donors. Moreover, in culture, these cells were often surrounded 
by RFP-ve cells (undifferentiated MSCs) suggesting the existence of an 
in vitro niche. It was demonstrated that the 20 % of Į60$-positive 
CAFs in the tumour microenvironment were bone marrow-derived and 
that their source was MSCs. Furthermore bone marrow-derived CAFs 
were longer-lived and promoted tumour growth significantly more than 
other stromal cells. Finally, the mSCN (MSCs and MF cells) was 
observed to be recruited in a SDF-1/CXCR4 dependent manner into the 
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gastric cancer stroma [Quante et al. 2011]. In agreement with this work, 
the tail vein injection of bone marrow MSCs in mice with partial 
pancreatectomy, resulted in recruitment of these cells to the pancreas 
and their differentiation as PSC (that as explain have features of 
myofibroblast cells). Moreover, a significant reconstitution of pancreas 
in comparison to mice controls (mice not injected and mice with no 
pancreatectomy) was observed [Han et al. 2012].  
Finally a mutual role of MSCs and myofibroblast niche cells in 
maintaining their reciprocal survival was observed introducing the new 
concept that both cell types need each other to survive and that they 
secrete different factor, and behave differently in the niche context than 
alone [Quante et al. 2011].  
The origin of myofibroblast niche cells directly from MSC activation is 
probably a consequence of an asymmetrical division of stem cells. In 
agreement with this, quiescent intestinal stellate cells and MSC cells 
grown in vitro were able to arise and be activated into myofibroblast 
cells. This activation was measured as increased Į60$&ROODJHQ,DQG
mesenchymal associated transcription factor Lhx2 and Msx2 [Quante et 
al. 2011; Choi et al. 2009]. Moreover, in agreement with the niche 
concept, in the in vitro context, after long culturing far from the niche or 
after isolation by FACS sorting, MSCs become senescent and die 
[Quante et al. 2011; Pevsner-Fischer et al. 2011]. 
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1.5.2  Stem cell niche markers 
The presence of an in situ stem cell niche at the stromal level in primary 
tumour has been shown not just as a factor which promotes tumour 
progression but as a requisite to promote tumour metastasis [Malanchi 
et al. 2011]. However, this study was more focused on the investigation 
of a cancer stem cell niche in which cancer stem cells could derive from 
genetic changes of normal stem cells and on how a tumour in order to 
colonise a second tissue needs to recreate a cancer stem cell niche. 
The role of periostin (POSTN) was highlighted as a protein in the 
cancer stem cell niche context that seems very important for the 
survival and the maintenance of cancer stem cells. Periostin was in fact 
shown to be mainly expressed in fibroblasts within the cancer stem cell 
niche in comparison to fibroblasts alone. Periostin is a cell adhesion 
molecule for pre-osteoblasts and act in bone, teeth and limb 
development and in osteoblast recruitment and spreading [Erkan et al. 
2007; Malanchi et al. 2012]. In wound repair, it is able to induce 
myofibroblast differentiation and contraction [Elliott et al. 2012]. Its 
expression was observed in the stroma of pancreatic ductal 
DGHQRFDUFLQRPD 3'$& IURP Į60$ DQG YLPHQWLQ SRVLWLYH FHOOV
(myofibroblast like cells) in response to interaction with cancer cells. 
Moreover, once secreted, Postn seems to be able to induce a positive 
feed-back that maintains its expression in fibroblast cells and also 
induces WKH H[SUHVVLRQ RI Į60$ FROODJHQ-1, fibronectin, and 
transforming growth factor 1 in PSC [Malanchi et al. 2012; Erkan et al. 
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2007]. Speculation based on these results could suggest periostin as a 
good candidate for a marker of MF cells in the mSCN. 
A marker of MSCs in the niche context could instead be Nestin. Nestin 
expression was used and observed at the stromal level in gastric 
dysplasia together with myofibroblast-like cells [Quante et al. 2011]. 
Moreover, the investigation of the interaction between haematopoietic 
and bone marrow mSCN showed the expression of Nestin from a 
subpopulation of bone marrow mesenchymal stem cells [Mendez-Ferrer 
et al 2010]. Positive Nestin cells were shown to localise in the proximity 
of the hematopoietic stem cell niche. Moreover, Nestin positive cells 
were shown to respond in a paracrine manner to astrocyte cells by a 
process of self-renewal suggesting their stem cell nature [Becher et al. 
2008]. 
1.5.3  Hedgehog pathway and the stem cell niche 
Hh pathway is known to be one of the main pathways involved in the 
interplay between stem and niche cells. However, contrasting theories 
describe its role in the niche suggesting an effect on cell differentiation 
into myofibroblast cells [Yeung et al. 2011; Shaw et al. 2009; Bailey et 
al. 2008] or in contrast in the self-renewal and proliferation of  stem cell 
[Zhou et al. 2006; Becher et al. 2008; Zhao et al. 2009]. Mouse models 
with reduced expression of SMO showed a defect in long term function 
of hematopoietic stem cells (HSC) in comparison to mice with functional 
SMO suggesting a role in stem cell self renewal. This was also shown 
to be involved in BCR-ABL1-induced chronic myelogenous leukaemia 
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(CML). SMO-/- mice transplanted with BCR-ABL1 cells showed a 50% 
reduction in CML. Finally constitutive expression of SMO in transgenic 
mice induced an increase in stem cells and development of CML [Zhao 
et al. 2009].  
The same effect of Hh pathway on stem cell proliferation was observed 
in human fetal epidermis. Hh pathway main component (like Shh, Smo, 
GLI1 and Ptch1) were expressed in human putative epidermal stem 
cells (HPESCs) and modulation of the pathway with NShh (Hh pathway 
agonist) and Cyclopamine (Hh pathway antagonist) respectively 
increased and decreased the stem cell proliferation [Zhou et al. 2006]. 
In contrast with these observations, in the Yeung et al. review it was 
hypothesized that the Hh pathway is activated in myofibroblast cells of 
the intestinal stem cell niche. Accordingly to their theory, epithelial cells 
secrete Shh ligand that by paracrine induction induces myofibroblast 
cells to secrete BMP and Wnt pathway antagonist inducing in this way 
MSCs differentiation (Figure 1.10).  
 
Figure 1.10 Intestinal stem cell niche regulation. Image taken from Yeung 
TM, Chia LA, Kosinski CM, Kuo CJ. Cell Mol Life Sci. 2011 Aug;68(15):2513-
23. Epub 2011 Apr. Copyright licence obtained from Springer.  
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The effect of Shh ligand on myofibroblast DFWLYDWLRQGHWHFWHGDVĮ60$
expression increase) has also been demonstrated in other studies. Shh 
expression in epithelial cancer cells promoted desmoplasia and 
increase of myofibroblast-like cells [Bailey et al 2008], whereas in 
prostate tumours a correlation between Hh pathway expression and 
reactive stroma (classified by its abundance of myofibroblast cells) was 
observed following microarray analysis of normal and tumour prostate 
samples [Show et al. 2009].  
Other studies also REVHUYHG WKH UHODWLRQVKLS EHWZHHQ Į60$ DQG +K
pathway expression in non-tumorigenic tissue. For example, the effect 
of Hh modulation was investigated in the adult gut [Zacharias et al. 
2011]. Transgenic mice with under-regulation of Ihh and Shh presented 
mislocalization of intestinal sub epithelial myofibroblasts, loss of smooth 
muscle in villus cores and muscularis mucosa and crypt hyperplasia. 
Moreover, chronic over-expression of Ihh in the intestinal epithelium of 
transgenic mice led to progressive expansion of villus smooth muscle 
cells. These in vivo data support the promotion of Hh ligand-induced 
myofibroblast phenotype acquisition and are supported by in vitro 
assays in which treatment of mesenchymal cells extracted from mouse 
with ectopic Shh and Ihh showed an iQFUHDVHRIĮ60$SRVLWLYHFHOOV
The analysis of these mesenchymal cells for their expression of desmin 
XVHGDVPDUNHURIXQGLIIHUHQWLDWHGSUHFXUVRUFHOOVDQGĮ60$XVHGDV
marker of myofibroblast differentiated cells), revealed a mixed 
population consisting of progenitor cells (expressing desmin), 
GLIIHUHQWLDWHG FHOOV H[SUHVVLQJ RQO\ Į60$ DQG cells derived from 
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SURJHQLWRU FHOOV H[SUHVVLQJ GHVPLQ DQG Į60$ 6R speculating, the 
response observed could be interpreted as the effect of Hh ligands on a 
mixed population that mimics the concept of the stem cell niche. Finally, 
rat hepatic stellate cells (HSC) (the analogue of pancreatic stellate cells 
in liver) induced increased Shh expression and myofibroblast markers 
expression in CCL4-cirrhosis in vivo models and in in vitro cell culture 
with serum. Interestingly, when in a quiescent state these cells 
expressed Hh pathway inhibitor Hhip which then decreased during the 
activation process (SURYHGREVHUYLQJWKHLQFUHDVHRIĮ60$H[SUHVVLRQ
&ROODJHQȕ and mesenchymal-associated transcription factors Lhx2 
and Msx2) induced by serum-rich cultures or in presence of 
inflammation. Moreover, in this activated stage, expression of Shh 
ligand and Gli2 transcription factor was increased. Consistently, the 
mesenchymal phenotype acquisition was inhibited by treatment with 
cyclopamine [Choi et al 2009.] This strongly links the Hh pathway with 
the myofibroblast cell phenotype but moreover it makes the 
myofibroblast phenotype acquisition a reversible process, suggesting 
WKDW Į60$ DQG RWKHU PDUNHUV XVHG, are more an indicator of an 
activated state than an irreversible differentiated state. Finally, the 
expression of Shh in mesenchymal cells is an interesting observation   
that needs to be investigated. In agreement with the observation by 
Choi et al., SHH gene expression was increased during MSC 
differentiation into a myofibroblast-like cell GHWHFWHG DV Į60$ SURWHLQ
and gene expression increase) without the presence of epithelial cells 
Moreover, the expression was shown specifically in a mixed population 
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consisting of bone marrow MSCs and myofibroblast cells in comparison 
to single cell populations [Quante et al 2011]. These data locate the 
expression of Shh ligand not just at the epithelial level but at the stromal 
level too and suggest a new interpretation of Shh expression as a 
marker of the mSCN. In support of this observation, expression of Shh 
at stromal level was confirmed, and interestingly was observed to 
increase with tumour grade. Moreover, its localisation in the context of 
the hematopoietic stem cell niche and its role in promoting, by paracrine 
induction, stem cell self-renew has been shown [Becher et al. 2008].  
These data support the idea of a role for Hh in the mSCN but its role in 
promoting self-renewal or myofibroblast cell activation needs further 
investigation. Moreover, the investigation of Shh ligand expression and 
function in the stromal context is a new aspect that could have great 
impact in cancer treatment. 
Figure 1.11 shows the role of the Hh pathway in pancreatic cancer. The 
Hh pathway paracrine signalling activation in the main stroma cells that 
constitute the pancreatic cancer microenvironment and its expression in 
the mSCN were also shown. 
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Figure 1.11 Mesenchymal Stem Cell Niche formation and recruitment in 
pancreatic tumour microenvironment.Pancreatic epithelial cells secrete Hh 
ligands that are able to paracrinally activate the Hh pathway in myofibroblast 
(MF) cells in the paracrine stroma. The Hh pathway activation in these cells 
induce their activation (Increase of ĮSma) and  increase their proliferation. Hh 
ligands also induce the activation (Increase of ĮSma)  of pancreatic stellate 
cells (PSC), which, once activated, strongly contribute to the desmoplastic 
reaction observed in pancreatic tumour. Hh ligands finally are able to 
autocrinally activate the Hh pathway in cancer cells, to induce the EMT 
(Epithelial Mesenchymal Transition) process in them and to increase their 
proliferation. Recent evidence suggest the recruitment of a mesenchimal Stem 
Cell Niche (mSCN) in the tumour microenviromnment. The mSCN likely 
express Shh ligand. It is believed (still not proved) that PSCs and the mSCN 
constitute the microenvironment that support CSC (Cancer Stem Cell) survival 
and metastasis.   
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1.6  Hypothesis and aims 
1.6.1  Summary of the main concepts 
Pancreatic tumour is a cancer with poor prognosis: there are very few 
chemotherapeutic agents available to treat it and those available are 
not effective. It is characterised by a high stromal content and stromal 
components are thought to have an important role in tumour 
progression and induction of metastasis. Several studies have 
confirmed the importance of the Hh pathway in this cancer at different 
stages of the carcinogenesis process and the suitability of Hh inhibition 
as a chemotherapeutic approach. However, the mechanism of action of 
the Hh signalling in tumour progression is not clear yet, with many 
discrepancies emerging from the literature. 
Thus, there is a need for further investigation in order to better 
comprehend the role of Hh pathway in tumour development, 
progression and metastasis. Based on new evidence demonstrating 
paracrine signalling between epithelial cells and fibroblasts, a more 
accurate analysis of the stromal feedback to the tumour is required, and 
new Hh pathway targets in the stroma should be further investigated to 
enhance the efficiency and reduce the collateral effect of drugs used as 
chemotherapeutic agents.  
The recruitment of MSCs in tumour microenvironment and their 
GLIIHUHQWLDWLRQ LQWR DFWLYDWHG H[SUHVVLQJ Į60$ FDQFHU-associated 
fibroblasts is confirmed in numerous works as well as their role in 
tumour growth. Recently, the role of mesenchymal stem cell niche 
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(mSCN), constituted from mesenchymal stem cells and myofibroblast 
cells, has been investigated. The reciprocal dependence of both cell 
types to survive and form a niche is required to support activation and 
formation of the 20% of myofibroblasts in the tumour microenvironment.  
The investigation of the mSCN in tumour has shown the expression of 
Shh ligand when is present in a mixed population. However, no further 
studies have been performed on the role of Shh in the mSCN. Evidence 
from the literature described Hh both as promoter of stem cell activation 
into myofibroblast cells and in stem cell self-renewal.  
1.6.2  Hypothesis 
Considering the evidence from literature, in this project it was 
hypothesised that the expression of Shh ligand at the stromal level is a 
marker of a mesenchymal stem cell niche in the late stage of pancreatic 
tumour progression. Moreover, as Hh paracrine transmission has been 
shown to occur between cancer epithelial cells and the pancreatic 
tumour microenvironment [Yauch et al 2008], the mSCN, as part of the 
cancer stroma, was hypothesised to be able to respond to Shh 
paracrine stimuli during pancreatic cancer progression in a more 
efficient way than in cancer-associated fibroblasts or mesenchymal 
stem cells, also known to be part of the tumour stroma in different types 
of cancer [Spaeth et al 2009]. 
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1.6.3  Aims 
The aims of this project were as follows: 
1) Investigation of Shh ligand expression at the stromal level and its          
correlation with late stage of PDAC progression (Chapter 3) 
2) Confirmation, investigation and characterisation of stroma-like 
cells able to respond to Hh paracrine stimulation by pancreatic cancer 
cells (Chapter 4 and 5). 
3) Characterisation of an in vitro model of the mSCN and of the 
expression and role of Shh in its maintenance/formation (Chapter 5). 
4) Investigation of the mSCN as the best microenvironment context 
able to respond to Hh paracrine stimuli from epithelial pancreatic 
cancer cells (Chapter 5). 
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2.1  Human Primary tissues 
The primary pancreatic and lung tissues used in this project were 
collected from Queen's Medical Centre (Nottingham, UK) with informed 
patient consent and with full ethical approval (MREC reference 
H0403/37). Primary normal and tumour tissue samples were cut and 
collected by a consultant histopathologist from the same primary 
pancreatic or lung tissue of the same patient, in order to allow a direct 
comparison and nullify the inter-patient variability. Clinical information 
about the TNM tumour malignant classification [A staging system to 
classify tumours based on their size and /or extent (T) on their spread in 
lymph nodes (N) and whether they metastasised (M)], the level of 
tumour differentiation and the tumour histology were obtained from the 
KLVWRSDWRORJLVW¶V UHSRUW DQG DUH VXPPDULVHG LQ WKH IROORZLQJ WDEOHV 
(Table 2.1 and Table 2.2): 
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    Table 2.1 Clinical Data of Lung Primary Tissues. SCC: Squamous Cell Carcinoma of Lung; NSCLC: Non Small cells Lung Carcinoma 
Lung 
Samples Hystology 
Tumour 
Differentiation T N  M 
Lung 
Samples Hystology 
Tumour 
Differentiation T N  M 
LU22N           LU46T SCC Moderate 1B 0 X 
LU22T Adenocarcinoma   1B 0 X LU47T Adenocarcinoma   2 0 X 
LU23N           LU48T SCC   2B 1 X 
LU23T Adenocarcinoma Moderate 2 X X LU50T Adenocarcinoma Moderate 3 1 X 
LU27T Adenosquamous Poor 2 0 X LU51T Adenocarcinoma   2A 0 0 
LU28N           LU52T Adenosquamous Moderate 2A 0 X 
LU28T SCC Poor 2A 0 X LU53T Adenosquamous   2A 0 X 
LU29N           LU54T Adenocarcinoma   2 0 X 
LU29T Adenocarcinoma   1A 0 X LU55N           
LU30N           LU55T SCC Moderate 2B 1 0 
LU30T Adenocarcinoma   2A 0 X LU56T Adenocarcinoma   3 0 X 
LU31N           LU57T SCC   2B 0 X 
LU31T Pleomorphic Type    NSCLC   2A 0 0 LU58T 
Mucinous 
Adenocarcinoma   1B X X 
LU32N           LU59T Adenocarcinoma   2 2 X 
LU32T Mixed; SCC+ Neuroendocrine    1A 0 X LU60T Adenocarcinoma   2A 1 X 
LU33N           LU61T SCC   2B 2 X 
LU33T SCC   1B 0 X 
  
Large cCell 
Neuroendocrine   2A 0 X 
LU34N           LU63T Renal Metastasis         
LU34T SCC Poor 1B X X LU64T Mixed: SCC 
+Neuroendocrine   2A 1 0 
LU35N           LU66T SCC   2B 0 X 
LU35T Adenocarcinoma   2A 0 X LU67T Adenocarcinoma   1A 0 X 
LU42T SCC   3 1 0 LU68T SCC   2A 1 0 
LU44T Adenocarcinoma   3 0 X LU87N           
LU45T Adenocarcinoma   1A 0 X LU87T Large Cell Neuroendocrine   3 0 X 
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                                  Table 2.2 Clinical Data of Pancreatic Primary Tissues. 
Pancreatic 
Samples 
Histology of 
Tumour 
Level of 
differentiation 
Pancreatic 
Samples 
Histology of 
Tumour 
Level of 
differentiation 
P4N     P27N     
P4T 
 
Poorly P27T Adenocarcinoma Moderate 
P5N     P28N     
P5T Adenocarcinoma Moderate P28T Adenocarcinoma Poorly 
P6N     P30N     
P6T Adenocarcinoma moderate P30T Adenocarcinoma   
P9N     P31N Adenocarcinoma   
P9T Adenocarcinoma moderate P31T 
 
Moderate 
P10N     P32N     
P10T Adenocarcinoma Poorly P32T Adenocarcinoma Moderate 
P12N     P33N     
P12T Adenocarcinoma Moderate P33T Adenocarcinoma Moderate 
P18N     P35N     
P18T 
 
unknown P35T Adenocarcinoma Moderate 
P20N     P40N     
P20T Adenocarcinoma Moderate P40T Adenocarcinoma unknown 
P23N     P41N     
P23T Adenocarcinoma 
and Pancreatitis Poorly P41T Adenocarcinoma Poorly 
P26N     P42T Adenocarcinoma unknown 
P26T Adenocarcinoma moderate 
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The samples were cut and then immediately stored in RNAlater 
(Ambion) or fixed in at least 20 volumes of formal calcium (0.9% (w/v) 
calcium chloride in 3.7% (v/v) formaldehyde). Tissues in RNAlater were 
held at 4϶C overnight before long-term storage at -80϶C, and were used 
for extraction of genomic DNA and total RNA (see Section 2.3.2 below). 
Samples in formal calcium were processed as follows: 
 
x The pieces of tissues were left to fix for at least 24 h (penetrating 
the tissue at 1 mm per hour) before processing and paraffin 
embedding. 
x Tissue cassettes were labelled appropriately in pencil, including 
specimen details and block numbers. Fixed tissues were then 
placed in the corresponding cassette. Tissues too big to fit in the 
cassette were trimmed and divided into additional cassettes. 
Once closed into the cassettes, tissues were stored in 70% (v/v) 
methanol until processing. 
x Cassettes were loaded into a Leica TP1020 tissue processor and 
automatically dehydrated through one bath of 70% (v/v) 
methanol, one bath of 90% (v/v) methanol, five baths of 100% 
methanol, then cleared through three baths of xylene, for 1 h 
each, and then passed through two baths of molten paraffin wax 
at 65϶C. After the processing cycle, the cassettes were removed 
from the tissue processor and placed into the paraffin wax 
reservoir, pre-warmed to 65ºC, of a Leica E61160 embedding 
station. Tissues were removed from the cassettes and placed 
Chapter 2 -Materials and Methods 
  
93 
 
into moulds containing molten paraffin wax, and then the labelled 
portion of the cassettes placed on top. 
x The cassettes were placed on a cooling plate to solidify.  
x Once the paraffin had solidified the tissue blocks were removed 
from the moulds and excess paraffin was removed using a 
Thermo Scientific Shandon Para Trimmer. 
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2.2  Cell culture 
2.2.1  Cell culture conditions 
Different types of cell lines were included in this study: 3 human 
epithelial pancreatic cancer cell lines (PANC1; BXPC3; PAN1); a 
human primary pancreatic tumour-derived epithelial cell line (P308T); 
10 human primary-derived pancreatic cancer-associated fibroblasts 
(CAFs) (P1T, P3T P4T, P5T, P6T, P9T, P10T, P14T, P30T, P35T) and 
human bone marrow-derived mesenchymal stem cells (MSCs). Each 
type of cell line was cultured under specific growing conditions. 
2.2.1.1  Epithelial cancer cell line culture conditions 
PANC1 and BXPC3 pancreatic cancer epithelial cell lines were 
obtained from the European Collection of Cell Cultures (ECACC); the 
PAN1 cell line was previously derived in the Academic Unit of Cancer 
Studies (Division of Pre-Clinical Oncology), University of Nottingham. 
All these cell lines ZHUHFXOWXUHGLQ'XOEHFFR¶V0RGLILHG(DJOH0HGLXP 
(DMEM) (Sigma-Aldrich, Dorset, UK) containing 1% (w/v) glutamine 
(Sigma-Aldrich), 10% (v/v) FBS (Sigma-Aldrich) 100 U/ml penicillin, and 
100 U/ml streptomycin (Invitrogen, Paisley, UK) at 37϶C in a 5% CO2 
air-humidified atmosphere. 
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2.2.1.2  Primary cell and MSC cell culture 
The isolation of primary epithelial (P308T) and fibroblast cells from 
primary tissues was performed by post-doc researchers of the Pre-
clinical Oncology Division by using the following protocol: primary 
tissues were disaggregated with 2.4 U/ml dispase (Invitrogen) and 100 
U/ml collagenase type II (Invitrogen) at 37°C. The cells derived from 
tissue disaggregation were then cultured on collagen-coated plates and 
then expanded into T75 flasks in PCA medium (DMEM medium 
supplemented with 7.2 ȝJPO LQVXOLQ (Sigma-Aldrich), 1 ȝJPO
hydrocortisone (Sigma-Aldrich), 100 U/ml penicillin, 100 U/ml 
streptomycin, 0.25 ȝJPODPSKRWHULFLQ% mM L-glutamine, and 20% 
(v/v) FBS).  
Primary cells were frozen in labelled tumour bank tubes in liquid 
nitrogen (-150°C) in order to maintain a stock of cells to be use in the 
experiments. At this stage cells were available to be used in this project. 
Once defrosted different culture conditions, were used depending the 
experimental purpose CAFs were grown in mesenchymal stem cell 
media (MSCM) (Sciencell, Buckingham United Kingdom UK) with 
mesenchymal stem cell growth supplement (MSCGS) (Sciencell, 
Buckingham United Kingdom UK) and 5% (v/v) FBS (Sciencell, 
%XFNLQJKDP 8QLWHG .LQJGRP 8. DW Û& LQ D  &22 air-humidified 
atmosphere.  
The human MSCs were obtained from TCS Cellworks (Buckingham 
UK) and grown in the same culture condition as CAFs (MSCM plus 
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MSCGS added and 5% (v/v) FBS) DWÛ& LQD&22 air-humidified 
atmosphere.  
 
Table 2.3 Type of cells, origin and culture media included in this study. 
 
2.2.2  Sub-culturing of cells 
Cells were expanded in two or more flasks after reaching 80-90% 
confluence. 5ml Ethylenediaminetetraacetic acid (EDTA) (SIGMA-
Aldrich, Dorset, UK) was then added in a 75cm2 flask in order to detach 
the cell lines from the flask. For the same purpose, MSCs and 
pancreatic CAFs were instead treated with trypsin (SIGMA-Aldrich, 
Dorset, UK) (5ml/75cm2). EDTA and trypsin are a chelating agent and a 
serine protease, respectively, that are used in cell culture in order to 
disrupt cellular interactions, enabling the detachment from the flask. 
Both agents have maximal efficiency at 37°C. For this reason, cells 
treated with EDTA and trypsin were incubated for 5 min at 37°C and 
Cell lines Type of Cell line Tissue of Origin Growth of Media 
PANC1 Epithelial 
cancer cells Pancreas 
DMEM + 10% FBS 
(1% of Glutamine) 
PAN1 Epithelial 
cancer cells Pancreas 
DMEM + 10% FBS 
(1% of Glutamine) 
BXPC3 Epithelial 
cancer cells Pancreas 
DMEM + 10% FBS 
(1% of Glutamine) 
P308T 
Primary 
epithelial cancer 
cells 
Pancreas DMEM + 10% FBS (1% of Glutamine) 
CAFs 
Primary cancer 
associated 
Fibroblast  
Pancreas MSCM + 5% FBS+ MSCGS 
MSCs Mesenchymal Stem Cells Bone marrow 
MSCM + 5% FBS+ 
MSCGS 
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then transferred into a universal tube and centrifuged at 200g for 5 min. 
The EDTA/trypsin was then aspirated and the cell pellet was 
resuspended in an appropriate volume of medium depending on the 
size of the pellet. 
2.2.2.1  Cell counting 
In order to quantify the number of cells in a flask or a plate, the cell 
pellet was re-suspended in a small amount of media defined by the 
pellet volume (typically 1-2 ml). 50 µl of the cell suspension was mixed 
1:1 with 0.4% (w/v) trypan blue (SIGMA-Aldrich, Dorset, UK) in 
phosphate buffered saline (PBS) (Thermo scientific, Basingstoke 
Hampshire, UK) used to stain the dead cells. The cells that excluded 
trypan blue were then counted using a haemocytometer. 
2.2.2.2  Freezing cells 
In order to create a stock, cells were frozen at the lowest cell passage 
possible. Cells were harvested from the flasks at a confluence of 80% 
and the cell pellet was re-suspended in a freezing solution [10% (v/v) 
dimethylsulphoxide (DMSO) (Sigma-Aldrich) in the appropriate medium] 
at a concentration of 2x106 cells/ml. Cells were then transferred in 
labelled tumour bank tubes and rapidly frozen at -80°C over-night, 
before long-term storage in liquid nitrogen. 
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2.2.2.3  Cell recovery 
Frozen cells were resuscitated from frozen stocks when necessary. The 
bank tubes containing the cells were rapidly transferred from the 
storage bank to a small volume of nitrogen liquid. Media (15 ml) was 
placed into a T75 flask and pre-warmed for 30 min at 37°C in a 5% CO2 
air-humidified atmosphere. The frozen cells were placed into a bath at 
37°C. When 90% of the cell suspension was defrosted, cells were 
carefully transferred under a Class II biosafety hood into the pre-
warmed media and incubated at 37°C in a 5% CO2 air-humidified 
atmosphere over night. The day after, the media in the flask was 
changed in order to eliminate the residual DMSO and to re-feed the 
cells. 
2.2.3  In vitro cell treatments 
2.2.3.1  NShh treatment 
CAFs and MSCs were plated in 24 or 6 well plates depending on the 
experimental plan: 8 x 104 cells were plated into each well of 24-well 
plates, and 2 x 105 cells were plated into each well of 6-well plates, and 
incubated under standard culture conditions overnight. The media used 
include MSCM with 5% FBS, PCA or DMEM with 5% FBS. The day 
after, the media were aspirated and the cells treated with 5 nM and 10 
nM human sonic hedgehog N-terminal (NShh) (R&D System, Abingdon, 
UK) for 2, 3 and 6 days. These concentrations were chosen for being 
successfully used in the literature [Taipale et al 2000]. Moreover, cells 
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were also treated with much higher concentration of NShh (50 nM) for 
48 h as found in the literature [Bailey et al 2008]. In each experiment a 
control sample (i.e. untreated cells) was run in parallel. Two replicates 
were plated for each treatment performed. After each experiment, cells 
were harvested for RNA extraction as described below. Data analysis 
was performed by comparing each variable to the control sample 
(single culture of stromal-like cells).   
2.2.3.2  7*)ȕWUHDWPHQW 
Based on the literature [Hu et al 2003; Bardeesy et al @ 7*)ȕ
treatment was used in this study in order to investigate its effect on 
06&V DFWLYDWLRQ Į60$ H[SUHVVLRQ DQG LWV LQWHUDFWLRQ ZLWK WKH +K
pathway in these cells.  
Cells were harvested and plated in a T25 or a T75 flask depending on 
the experimental plan: 105 cells were plated in a T25 flask and re-
suspended in 5 ml of growing media, 106 cells were plated in a T75 
flask and re-suspended in 15ml of growing media. The day after, the 
growing medium was aspirated and substituted with a 10 ng/ml 
(concentration suggested by WKH PDQXIDFWXUHU VROXWLRQ RI 7*)ȕ
(Humanzyme, Chicago USA) in the medium required for the 
experimental purpose. The following media were tested for this 
treatment: DMEM with 0.5% FBS; PCA; MSCM 5% FBS with no GF 
(growth factors) added and MSCM 5% FBS). Cells were incubated for 3 
RU  GD\V XQGHU VWDQGDUG FXOWXUH FRQGLWLRQV 7KH7*)ȕ ZDV UHSODFHG
every 2 days. Control samples (i.e. untreated cells) were run in parallel. 
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Data analysis was performed by comparing treated and untreated 
samples grown under the same experimental conditions. 
2.2.3.3  Cell harvesting from in vitro cell treatment assays for RNA 
extraction and immunofluorescence (IF) 
Assays performed in 24 well plates were used exclusively for gene 
expression analysis. For this purpose the medium was aspirated and 
then replaced with 500 µl of TRI-reagent (Sigma-Aldrich) and incubated 
for 5 min in order to lyse the cells. The lysate was then transferred into 
1.5 ml Eppendorf tubes then used immediately for RNA extraction or 
was frozen at -80°C for future analysis.  
The experiments performed in 6 well-plates or inT25 flasks were plated 
for analysis of gene expression by q-RT-PCR and protein expression by 
IF (using half of the cells for each analysis). For this purpose the media 
were aspirated and then the wells/flasks washed with PBS in order to 
remove the residual medium and any dead cells, before harvesting. The 
cells for RNA extraction were re-suspended in 1 ml of TRI-reagent and 
stored at -80°C. Cells harvested for IF staining were fixed with 500 µl of 
4% (v/v) paraformaldehyde (PFA in PBS) for 10 min, before 
centrifugation and re-suspension in 600 µl 70% (v/v) EtOH and storage 
at 4°C for less than one week. 
2.2.4  Transwell co-culture  
The transwell assay performed in this study was used to co-culture 
different types of cells by separating them with a permeable membrane. 
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This system establishes paracrine signalling processes between the 
two cell populations, and allows analysis of the separated cell types. In 
this study 12-well and 6-well transwell plates were used (12 mm and 24 
mm of membrane diameter, respectively) (Corning Life Sciences, 
Amsterdam, The Netherlands) in order to have enough cells for 
subsequent gene and protein expression analysis. The transwell 
membranes had pores of 0.4 µm that permitted the migration of drugs 
and molecules but not of cells. The material used for the permeable 
support was polyester (PET) in the optimisation phase of the 
experiments then polycarbonate (PC). PET membranes are transparent 
and allowed the visibility of the cells plated in the inserts. At the start of 
the experiment the number of cells and their growing conditions were 
important factors to check. Once the experimental conditions of co-
culture (number, time and media) were optimised, the PET membranes 
were substituted with PC membranes which are less visible but contain 
a higher number of pores and so should permit improved 
communication between the two cell types. 
In the 12- and 6-well transwell plates the total number of cells plated 
(epithelial cells and CAFs or MSC) was 7x104 and 1.8x105 cells/well, 
respectively, in epithelial cells: CAF or epithelial cells: MSC ratios of 3:1. 
Epithelial cell were plated in the well plate and CAFs/MSCs were plated 
in the insert of the trans-wells, and cells were cultured in MSCM 5%. 
For each assay performed, control trans-wells were prepared by plating 
a single cell population (epithelial cells or MSCs/CAFs) either in the well 
plates or in the inserts. In the control well/insert units the same final 
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number of cells as in the co-culture well/insert units was plated. Both 
controls and co-cultures were cultured for 3 days in MSCM 5% (v/v) 
FBS without changing the media.  
 At the end of the experiment, cells were harvested for RNA and IF 
analysis following the protocol described in section 2.2.3.3 
Statistical analysis was performed by comparing the gene and protein 
expression in the co-cultured stroma like cells with the gene and protein 
expression detected in the control samples (single culture of CAFs or 
MSCs).  
2.2.5  Direct co-culture 
2D direct co-culture is an in vitro assay that allows direct cell-cell 
contact and communication.  
CAFs were co-cultured by using this assay with pancreatic tumour 
epithelial cells in epithelial cells: CAFs ratio of 3:1. 8x104 total cells were 
plated in each well of a 24 well plate. Control wells containing 8x104 of 
unmixed CAFs were plated in parallel and grown in the same media 
and culture conditions. Mixed and unmixed cells were plated in 
replicates in order to confirm the results achieved. The co-cultures and 
the control wells were cultured for 3 days without changing the media. 
Data analysis was performed by comparing each variable to the control 
sample (single culture of CAFs cells).   
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2.2.5.1  Cell harvesting from direct co-culture for RNA extraction 
At the end of the culture, the medium was aspirated and the cells 
washed with PBS. Once detached, cells were re-suspended in 1 ml of 
PBS containing 0.1% (w/v) bovine serum albumin (BSA) in a sterile 
Eppendorf tube. 25 ȝl of magnetic beads (Dynal, Norway) pre-coated 
with an anti-EpCAM (epithelial cell adhesion molecule) antibody were 
then added to the cell suspension in order to bind the epithelial cells. 
The cells were then tumbled 20 min at 4qC, before EpCAM-positive 
epithelial cells were harvested using a magnet. The remaining 
supernatant containing the fibroblast cells was carefully aspirated and 
transferred to other eppendorf tubes. In order to isolate a pure fibroblast 
population the suspension was then incubated with magnetic beads 
coated with an anti-CD90 antibody (a specific marker for mesenchymal 
cells). As for the epithelial cells, the fibroblasts cells, bound to the CD90 
antibody-beads complex were isolated using a magnet. Both cell types 
were then washed 3 times with 500 Pl PBS/0.1% BSA. After washing, 
both cell lines were lysed with TRI-reagent prior to RNA extraction. 
2.2.6  Optimisation of in vitro mesenchymal stem cell niche models  
In order to optimise an in vitro mesenchymal stem cell niche model, 
different cell ratios, times of culture, culture media, and type of stromal 
cells were co-cultured by using a 2D direct co-culture assay. 
MSCs at low passage (P3-P4), and maintained in MSCM to keep them 
in an undifferentiated state, were co-cultured with MF-like cells in 1:1, 
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1:3 and 3:1 ratios or with CAFs in a 1:1 ratio. MF-like cells were 
obtained by culturing MSCs in MSCM without adding the supplement of 
*)DQGE\WUHDWLQJWKHPZLWK7*)ȕIRUZHHk as indicated in Section 
2.2.3.2. CAFs were cultured in MSCM 5%FBS (demonstrated to be the 
best growing condition for these cells) until the start of the co-culture. 
Once calculated, the concentration of cells, the correct volume (defined 
by the dilutions to perform) was taken from the cell suspensions 
(performed in DMEM 10%) of MSCs and transferred into a T25 flask. 
MF-like cells or CAFs, as for the MSCs, were counted and the 
appropriate volume (performed in DMEM 10%) (defined by the ratios to 
perform) was transferred into the same flask as the MSCs. Finally, up to 
5 ml of the culture medium (DMEM 10%) was added and the flask 
rocked in order to well mix the cells well and distribute the cells in the 
flask. The total number of cells per T25 flask was 1.8x105 cells. 
All four mSCN models (MSCs:MF-like cells ratios of 1:1, 3:1; and 1:3, 
and MSCs:CAFs ratio of 1:1) were cultured in DMEM 10% media and 
harvested after 3, 12 and 21 days. In parallel, MSCs alone and MF-like 
cells alone or CAFs alone were cultured and harvested under the same 
conditions as the mSCN models. 
Due to the high number of cells required in each experiment, each 
assay was performed once; however, as explained in the results, the 
same experimental conditions were repeated two or three times in the 
context of different experimental design, in order to confirm the results 
obtained. At the end of the experiment, cells were harvested and used 
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for RNA extraction and IF analysis by following the protocol illustrated in 
paragraph 2.2.3.3. 
2.2.6.1  Transwell co-culture between in vitro mSCN models and 
epithelial cancer cells 
Different mSCN in vitro models were prepared by mixing MSCs and 
MF-like cells and/or by changing the growing condition of these two 
populations in order to co-culture them in a transwell assay with the 
pancreatic epithelial cell line PANC1. PANC1: mSCN models were 
plated using a 1:3 ratio. The final cell number in each insert/well unit 
was 1.8 x 105 cells. Therefore, all mSCN models were plated in the 
insert with a final number of 4.5 x 104 cells. The transwell assay was run 
for 3 days and then the cells were harvested following the methods 
described in section 2.2.4.2.  
Five mSCN in vitro models were performed in this assay: 
x MSCs single population (MSCs S.P): As negative control of the 
experiment, MSCs maintained at low passage were plated in the 
insert. The cells were defrosted and left to recover for 3 days in 
MSCM 5% before being harvested, counted and re-suspended 
as described in Section 2.2.2. Once counted, the equivalent 
volume of cell suspension to 4.5 x 104 cells was transferred in 
MSCM 5% into the insert of a 6-well transwell plate. These cells, 
named MSCs single population (MSCs S.P.), were then co-
cultured with PANC1 cells (plated in the well plate) in MSCM 5% 
for 72h. 
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x mSCN model 1: This model was obtained by culturing MSCs in 
DMEM 10% for 1 week before plating them in the insert of the 
transwell. These cells were harvested and 4.5 x 105 cells added 
to the insert of a 6-well transwell plate, then co-cultured with 
PANC1 cells in DMEM 10% media for 72 h. 
x mSCN model 2: MSCs S.P. with a low passage number (P4) 
after a short recovery (around 3 days from being defrosted) were 
harvested, and 2.25 x 105 cells added to the insert of a 6-well 
trans-well plate. In parallel MF-like cells (obtained by treating 
MSCs with TGF-ȕ IRU  ZHHN DV GHVFULEHG LQ 6HFWLRQ 
were harvested and 2.25 x 105 cells were mixed with MSCs S.P. 
and added to the insert of the transwell in MSCM 5%. Hence, in 
this model MSCs and MF-like cells were plated in a 1:1 ratio and 
the final number of cells plated in the insert was 4.5 x 105. Once 
plated, mSCN model 2 was co-cultured with PANC1 cells (plated 
in the well plate) in MSCM for 72 h. 
x mSCN model 3: The set-up and the cells used in this model 
(MSCs S.P. mixed in a 1:1 ratio with MF-like cells) were the 
same as the previous mSCN model 2, but after being plated in 
the insert, mSCN model 3 was co-cultured with PANC1 cells in 
DMEM 10% medium for 72 h. 
x mSCN model 4: MSCs were cultured for 1 week in DMEM 10%. 
The cells were then harvested, counted and re-suspended in 2 
ml MSCM 5%. In parallel MSCs with low passage number (P4) 
were defrosted (MSCs S.P.). After a short recovery, MSCs S.P. 
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were then harvested, counted and re-suspended in MSCM 5%. 
The correct volume of MSCs and MSCs S.P. (equivalent to 2.25 
x 105 cells each) were mixed and re-suspended in MSCM 5% in 
the insert in order to co-culture them in a 1:1 ratio. Once plated, 
the mSCN model was co-cultured with PANC1 cells in MSCM 5% 
for 72 h. 
x mSCN model 5: The set up and the cells used (MSCs cultured 
for 1 week in DMEM 10% mixed with MSC S.P in a 1:1 ratio) in 
this model was the same as the previous model (mSCN model 4), 
except that the mSCN model 5 was co-culture with PANC1 cells 
in DMEM 10% medium for 72 h. 
For each mSCN model a control sample comprising the equivalent 
mSCN model in the absence of PANC1 cells, plated both in the insert 
and in the plate, was run in parallel.  
2.2.7  Tumour conditioned media (TCM) assay  
In order to prepare the TCM, tumour epithelial cells (106 cells) were 
cultured in a T75 flask with 20 ml of MSCM 5% (v/v) FBS for 3 days 
before the medium was harvested and filtered. Control CM was 
prepared by growing the CAFs or MSCs in the same conditions of 
epithelial cells. The conditioned medium (50% CM, 50% MSCM) was 
used to culture stromal-like cells (CAFs or MSCs) for 72 h or 14 days, 
with the medium replaced twice a week.  
The CAFs and MSCs were plated in T25 flasks. The number of cells 
plated was optimised taking into account the growth profile of each cell 
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line (105 cells for P5T CAFs and MSCs and 3 x 105 cells for P3T CAFs). 
The cells were harvested, re-suspended and counted as indicated in 
Section 2.2.2. Control samples were cultured in parallel in each 
experiment and were obtained by culturing CAFs or MSCs in the control 
CM for the same amount of time as the other experimental conditions. 
Due to the high number of cells required for this experiment no 
replicates were plated. Data analysis was performed by comparing 
gene and protein expression detected in the conditioned sample to the 
gene and protein expression detected in the samples grown in the 
control CM. At the end of the experiment, cells were harvested and 
used for RNA extraction and IF analysis by following the protocol 
illustrated in paragraph 2.2.3.3. 
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2.3  Molecular Techniques 
2.3.1  RNA extraction from cells 
Total RNA was extracted from cells lines TRI reagent, a monophasic 
solution for RNA extraction (Sigma-Aldrich).  
5-10 x 106 cells were lysed in 1 ml TRI-reagent, prior to the addition of 
ȝOFKORURIRUPYLJRURXVPL[LQJDQGFHQWULIXJDWLRQDW13,000 rpm for 
15 min at 4oC. The upper aqueous phase was mixed with 500 µl 
propan-2-ol, and the RNA allowed precipitating for 10 min at room 
temperature, prior to centrifugation at 13,000 rpm for 10 min at 4϶C. The 
RNA pellet was washed with 1 ml 70% (v/v) ethanol, centrifuged at 
13,000rpm for 10 min, air dried, re-suspended in 50 µl RNase-free 
water and stored at -80϶C. 
2.3.2  RNA extraction from tissues 
Human pancreatic tissues for RNA extraction were kept in bank tubes 
with 10 µl of RNAlater per mg of tissue at -80°C. RNAlater is a reagent 
able to stabilise the RNA in the tissues. 
Total RNA, along with genomic DNA, was isolated from tissue samples 
using the AllPrep DNA/RNA Micro kit (Qiagen, Crawley, UK). Once 
defrosted at room temperature, tissue was removed from the RNAlater 
and transferred to a plastic petri dish and a piece roughly 1.5 mm cubed 
(approximately 5 mg tissue) was removed. The piece was then snap 
frozen in liquid nitrogen and ground to a powder using a pestle and 
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mortar. When the nitrogen had evaporated the tissue was covered with 
350 µl RTL Plus containing 10 µl/ml 2-mercaptoethanol, and the lysate 
transferred to a QIAshredder spin column (Qiagen) and centrifuged at 
maximum speed for 2 min. The supernatant was transferred to an All-
prep DNA spin column placed in a 2ml collection tube and centrifuged 
for 30 s at 15,000 x g. During this step the genomic DNA bound to the 
filter of the spin column, whereas the RNA remained in solution. The 
DNA spin columns were transferred to an empty 2 ml collection tube 
and stored at 4°C for subsequent genomic DNA extractions. 
To the flow-through containing the RNA was added 350µl 70% (v/v) 
ethanol to precipitate the RNA, and the mixture transferred onto a RNA 
MinElute spin column to bind the total RNA, placed in a 2 ml collection 
tube and centrifuged for 15 s at 15,000 x g. The flow-through was 
GLVFDUGHGDQGWKHFROXPQZDVKHGZLWKO%XIIHU5:WKHQȝO
Buffer RPE for 15 s each at 15,000 x g. A final wash was performed 
using 80% (v/v) ethanol 2 min at 15,000 x g. The column was dried by 
centrifugation for 5 min at full speed. RNA was eluted from the column 
by the addition of 10µl RNase-free water to the RNA Min-Elute spin 
column placed in a 1.5 ml Eppendorf tube and centrifugation for 1 min 
at full speed. 
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2.3.3  cDNA synthesis. 
For each RNA extraction, one positive cDNA sample and one cDNA 
negative control (no primers and no superscript enzyme) were prepared. 
The RNA samples were reverse transcribed into cDNA using 
Superscript II Reverse Transcriptase enzyme (Invitrogen). 
10µl RNA was mixed with 1 µl of random hexamers (Invitrogen) (1 µl of 
water for the negative control) and incubated for 10 min at 70϶C 
followed by rapid cooling on ice in order to remove tertiary structures 
from the RNA. To each tube was added 4 ȝO[)LUVW6WUDQG%XIIHU, 2 ȝO
0.1 M dithiothreitol, 0.6 ȝO mM dNTPs (Sigma-Aldrich), 3 ȝOQXFOHDVH-
free water, and 0.4 ȝO 6XSHU6FULSW ,, HQ]\PH (Invitrogen) (or water 
instead of enzyme for the negative controls). The mixtures were 
incubated at 25϶C for 10 min, 42϶C for 60 min, and 95϶C for 5min in an 
Applied Biosystems GeneAmp PCR System 9700 thermal cycler, prior 
to the addition of 80 ȝOQXFOHDVH-free water. The cDNA was stored at -
Û& 
2.3.4  Quantitative Real-time Polymerase chain reaction (qPCR). 
The qPCR is a powerful method commonly used in research for the 
investigation of gene expression. It is based on a polymerase chain 
reaction in which double-stranded DNA (dsDNA) is amplified and the 
product are detected in real-time. The gene expression analysis by 
qPCR start with the RNA extraction from cells or tissue and its 
conversion in cDNA (paragraph 2.3.3) in order to amplify a sequence 
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corresponding to a segment (In this study design to be 150bp long) of 
the gene under investigation. This amplification is possible using 
forward and reverse primers with sequences that perfectly match 
UHVSHFWLYHO\WRWKHH[WUHPLWLHV¶WR¶DQG¶WR¶RI WKHVHJPHQWWREH
amplified. The DNA amplification is characterised by an exponential 
phase that terminates with a plateau determined by the complete 
FRQVXPSWLRQRIWKHUHDJHQWVLQFOXGHGLQWKHUHDFWLRQ>³5HDO-Time PCR: 
IURPWKHRU\WRSUDFWLFH´³5HDO7LPH3&5+DQGERRN´QG@ 
 Currently, there are two common qPCR techniques defined by the use 
of non-specific fluorescent dye or sequence-specific DNA probes 
>³5HDO-7LPH3&5IURPWKHRU\WRSUDFWLFH´@ 
The sequence-specific DNA method is based on the use of an 
oligonucleotide probe with a specific sequence that hybridises with a 
segment of the gene investigated and on the activity of the Taq DNA 
SRO\PHUDVH D ¶ HQGRQXFOHDVH HQ]\PH %ULHIO\ WKH ROLJRQXFOHRWLGH
sequence is labelled with a fluorescent reporter and a quencher that 
inhibits the fluorescent signal. During the cDNA template amplification, 
the TaqMan polymerase cleaves the oligonucleotide sequence causing 
the detachment of the quencher from the probe, which enables the 
reporter to emit a detectable signal. The specificity of this amplification 
is conferred by the reverse and forward primers and by the 
oligonucleotide probe 
[http://www.ncbi.nlm.nih.gov/genome/probe/doc/TechQPCR.shtml]. 
The PCR non-specific probe method is based on the use of a 
fluorescent probe (Sybr Green) able to bind exclusively to DNA double 
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strand sequences. During the process of amplification guided by the 
forward and reverse primers and the DNA polymerase the cDNA 
template is exponentially duplicated over a number of PCR cycles. The 
Sybr Green probe binds to every new amplicon (dsDNA amplified) 
allowing the quantification of the new product generated. The specificity 
of this reaction is guaranteed by the primer design [Ponchel et al 2003; 
³5HDO-Time PCR: from theory to praFWLFH´  ³5HDO 7LPH 3&5
+DQGERRN´QG@$GLVDGYDQWDJHRIWKHXVHRIDQRQ-specific dye is the 
risk of false positive signal generation as a consequence of the binding 
of the dye to non-specific double strand DNA sequence. For this reason, 
in this context, the qPCR system generates a melt curve at the end of 
the reaction in order to check the purity of the amplification. The melting 
curve (or dissociation curve) represents the dsDNA dissociation into 
single strand DNA (ssDNA) as a consequence of the rise of the 
temperature. The melting curve then shows the relationship between 
the Sybr green fluorescence signalling and the melting temperature and 
LV SORWWHG DV ¨)¨W FKDQJH LQ IOXRUHVFHQFHFKDQJH LQ WHPSHUDWXUH
against the temperature. The melting point (Tm) represents the 
temperature at which all dsDNA is dissociated and coincides with the 
pick of the melting curve. Non-specific double strand construct (like 
primer dimerisation) show different melting points than that for the 
specific cDNA of interest and so only a single dissociation curve with a 
single peak will guarantee the purity of WKH SURGXFW DPSOLILHG >³5HDO
7LPH3&5+DQGERRN´QG@ 
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In this studies both qPCR methods described above were applied, 
however, the Sybr Green method was predominantly used. 
In general, each PCR reaction is characterised by a baseline value 
represented by the number of PCR cycles in which the signalling 
emitted by the probe is still not detectable by the machine, which means 
that the amount of DNA amplified is still too low to be quantified. The 
baseline also influences the threshold value, considered an arbitrary 
level of fluorescence that lies within the exponential phase of 
amplification of the cDNA and is higher than the base line. Every signal 
detected above the threshold is considered a real signal. In line with this, 
an important parameter for the gene expression quantification is the 
threshold cycle value (Ct) value. It represents the minimal number of 
cycles necessary to detect a value of fluorescence higher than the 
threshold. The higher the Ct value, the lower the gene expression level. 
[Ponchel et al ³5HDO-7LPH3&5IURPWKHRU\WRSUDFWLFH´@,Q
order to reduce the quantitation variability caused by differences in the 
DNA amount added to each reaction, and to distinguish for differences 
in efficiency of RNA extraction and cDNA synthesis between test and 
control samples, the expression of the gene investigated is normalised 
to the gene expression of an endogenous control (a gene constitutively 
H[SUHVVHG LQ DOO H[SHULPHQWDO VDPSOH UHIHUHQFH JHQH >³5HDO-Time 
3&5IURPWKHRU\WRSUDFWLFH´ ³5HDO7LPH3&5+DQGERRN´QG@
The final gene expression is expressed as 2-¨&W LQZKLFK¨&t = Ct target 
gene-Ct   reference gene [Livak et al 2001].  
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In this study, the qPCR reactions were carried out in 96 well plates 
(Applied Biosystems, Warrington, UK) containing 5 µl of cDNA and 20 
µl of a reaction mixture. The reaction mixture was prepared with 10 µl 
2x SYBR Green Master Mix (Applied Biosystems), plus 4 µl nuclease-
free water and 1 µl primers (forward and reverse primers combined 5 
ȝ0Hach). 
The reactions were performed in a StepOnePlus Real Time PCR 
machine (Applied Biosystems) using the following conditions: 
denaturation at 95϶C for 10 min, followed by 40 cycles of 95϶C for 15 
sec and 60϶C for 60 sec), and a final melt curve stage of 95϶C for 15 
sec, 60϶C for 1 min and 95϶C for 15 min). 
IHH gene was amplified using a different qPCR method that, instead of 
using the SYBR green dye, used TaqMan reagents. The reason of this 
choice was the difficulty found in designing primers highly specific for 
this gene. The sequence-specific qPCR method (TaqMan polymerase 
system), by adding a new level of specificity (the oligonucleotide probe) 
to that conferred by the primers, was considered more appropriate in 
this context. Gene detection was performed by using 10 µl of 2x Taq-
man real time PCR master mix (Applied Biosystems), 1 µl of a specific 
solution of IHH Taq-man probe and IHH primers (Applied Biosystems) 
and 4 µl nuclease-free water. This final solution was then mixed with 5 
µl of cDNA obtained from the cells under investigation. 
For every sample analysed, a negative cDNA control was run to detect 
any potential contamination, such as genomic contamination or primer 
dimerisation. 
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Primers were designed by using the primer design centre (i.e. 
www.ncbi.nlm.nih.gov/tools/primer-blast) by following strict criteria to 
achieve the maximal efficiency and specificity in the gene amplification. 
The PCR product size had to be between 50 and 150 bp and the 
melting temperature was around 58°C. Finally, primers had at least two 
mismatches with unintended targets and were separated by 
introns >1000 bp in order to prevent amplification from any 
contaminating genomic DNA. All primers, once designed, were tested 
on positive cell controls and their efficiency checked by comparing the 
slope of the expression curve of the gene amplified in serial cDNA 
dilutions with the slope of the same curve obtained for hypoxanthine-
guanine phosphoribosyltransferase (HPRT) housekeeping gene 
expression [Livak et al 2001]. Good primers efficiency was obtained 
when the difference between the gradient of the two slopes was < 0.1. 
The following table shows the primers used for the amplification of the 
genes analysed in this study. 
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                            Table 2.4 Primers utilised for qPCR 
 
Gene Forward Primer (5'-3') Reverse Primer (5'-3') 
HPRT ATTATGCTGAGGATTTGGAAAGGG GCCTCCCATCTCCTTCATCAC 
SHH CGACCGCAGCAAGTACGGCA CGATTTGGCCGCCACCGAGT 
DHH GCAACAAGTATGGGTTGCTG CGGACCGCCAGTGAGTTA 
IHH Hs01081801_m1   
GLI1 ATCAGGGAGGAAAGCAGACTGA AGTCATTTCCACACCACTGTCTGTA 
SMO CCTGACCGCTTCCCTGAA TCCGAACCAAGGGCACTTC 
PTCH1 CCGCGTTAATCCCAATTCC CATGGCAAAATTGAACACCACTA 
PTCH2 TGGAACAGCTCTGGGTAGAAG CCCAGCTTCTCCTTGGTGTA 
ACTA2 AACATGGCATCATCACCAACTG GCAACACGAAGCTCATTGTAGAA 
CDH1 GAACAGCACGTACACAGCCCT GCAGAAGTGTCCCTGTTCCAG 
VIM AAAACACCCTGCAATCTTTCAGA CACTTTGCGTTCAAGGTCAAGAC 
HGF TGTTTCACAAGCAATCCAGAGGTA CTCCCCATTGCAGGTCATG 
POSTN ACACACCCGTGAGGAAGTTGC TGAGAACGACCTTCCCTTAATCGTC 
NES AAC-AGA-GGT-TGG-AGG-GCC-GC TGCTGCCGACCTTCCAGGAC 
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2.3.4.1  RT-PCR data analysis. 
The data obtained from qPCR was determined from the cycling 
threshold (Ct) value detected, considered, as explained, the minimum 
number of cycles necessary for detecting SYBR green fluorescence 
incorporated into the new DNA synthesised.  
All samples were analysed in triplicate and each Ct value was 
normalised to the triplicate Ct values obtained for expression of the 
housekeeping gene HPRT in the same cDNA sample. 
Gene expression was expressed as 2-¨&W LQZKLFK¨&t = Ct target gene-
Ct   reference gene (HPRT) [Livak et al 2001]. 
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2.4  Protein expression analysis 
The expression of the main proteins of the Hh pathway was analysed 
by the following two staining methods: immunohistochemistry (IHC) and 
IF.  
IHC was used in order to investigate the expression of Shh and Ptch1 in 
human pancreatic tissues and to determine their localisation within the 
stroma or within the epithelium. Moreover, quantification of the stromal 
component was performed by IHC staining of Vimentin. 
Finally IF was chosen to analyse the expression of Shh and Ptch1 and 
expression of stem ceOOQLFKHPDUNHUVĮ60$DQG3RVWQZLWKLQepithelial 
and stromal-like cells used for in vitro studies. 
2.4.1  Immunohistochemistry 
Immunohistochemistry is a technique frequently used in the literature, 
including for Hh pathway investigation [Yan et al 2013; Hinterseher et al 
2013; Thayer et al 2013]. 
In order to prepare the slides with the tissues to stain using IHC, the 
paraffin blocks, obtained following the embedding process illustrated in 
paragraph 2.1, were cooled on ice and then cut using a Leica RM2135 
PLFURWRPHDWDVWDQGDUG WKLFNQHVVRIȝP7KHVOLFHG WLVVXHVHFWLRQV
were then carefully floated onto the surface of warm water in a bath (R. 
A. Lamb E65), then transferred onto labelled poly-lysine coated slides 
(Thermo Scientific, Braunschweig, Germany). Finally, the tissues were 
left to dry over-night before staining. 
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In this study, IHC staining was performed for Shh (Abcam, Cambridge 
UK), Ptch1 (United States Biological, Newmarket UK) and Vimentin 
protein expression following a process of optimisation: different antigen 
retrieval methods, primary and secondary antibody concentrations and 
negative controls were all tested to find the best protocol to be applied. 
2.4.1.1  IHC staining of Shh and Ptch1 Hh proteins in pancreatic tumour 
and normal tissues 
The final protocol obtained from the optimisation process was similar for 
both Shh and Ptch1 proteins.  
Sections of paraffin embedded tissue on poly-lysine coated slides were 
de-waxed in two xylene baths for 5 min each, washed in two 100% 
methanol baths for 1 min each, then rinsed in running tap water for 1 
min.  
Tissues were then blocked for endogenous peroxidase using 1% 
hydrogen peroxide in 100% methanol for 15 min. Tissue sections were 
rinsed twice in 100% methanol baths then under running tap water.  
In order to increase the staining efficiency, antigen retrieval was 
performed by microwaving slides in 10 mM citric acid pH 6.0 at 98°C for 
20 min. This treatment was used to expose the antigens to the primary 
antibody, normally hidden by methylene bridges with proteins as a 
consequence of the fixation process.  
After this, the sections were quenched immediately in running tap water 
and then washed in PBS for 5min.  
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The tissue sections were then incubated for 15 min in a blocking serum 
from the same species as the secondary antibody (swine serum for 
both Shh and Ptch1) diluted 1/5 in 1% (w/v) bovine serum albumin 
(BSA) in PBS to reduce non specific binding due to hydrophobic 
reactions. This process is a common step in immunohistochemistry to 
reduce the cross reaction of secondary antibody with endogenous 
immunoglobulines.  
Tissue sections were then incubated for 60 min with primary antibody 
diluted in PBS (1/100 dilution for Shh antibody and 1/300 dilution for 
Ptch1 antibody).  
Each section was also stained using a negative control. The goal of 
using a negative control was to test and guarantee that the eventual 
stain observed was a consequence of real expression of the proteins 
investigated and not due to nonspecific background staining The 
negative controls used (rabbit serum) came from the same species and 
were diluted in a PBS-BSA1% solution at the same concentration as 
Shh and Ptch1 primary antibody.  
After this incubation the sections were rinsed in PBS and then 
incubated with a biotinylated swine anti-rabbit secondary antibody at 
1/300 in PBS for 30min.  
After this, the secondary antibody was rinsed off by washing the tissues  
with PBS (3 times 5min), and then incubated for 20 minutes with avidin-
biotin complex  (ABC) (Vector Laboratories, Peterborough, UK) 
containing avidin bound to biotinylated horseradish peroxidise. The 
binding of this complex to the biotinylated secondary antibody results in 
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amplification of the signal and the conjugation of the primary-secondary 
antibodies with the HRP enzyme. The HRP enzyme is a 40 KDa protein 
that catalyses the conversion of hydrogen peroxide into water and 
atomic oxygen. In order for this reaction to proceed electron donors 
(polyphenols or nitrates) that drive the reaction and become oxidated, 
are needed. In IHC the electron donors are usually chromogens that 
once oxidated become coloured. Based on this, in order to stain the 
primary-secondary antibody complex, the tissues were washed in PBS 
and then incubated with 3'-Diaminobenzidine liquid chromogenic 
substrate kit (DAB Liquid system, Dako). DAB is a chemical agent that 
acts like electron donor in presence of HRP, and produces a brown 
colour at the site of protein expression. Sections were then rinsed with 
water and counter stained with Haemalum (Mayers' aqueous) (Fisher 
Scientific, Loughborough, Uk). Tissue were then dehydrated by using 
100% alcohol bath and then cleared in Xylene prior to mounting with 
DPX (Sigma). 
2.4.1.2  IHC staining of Vimentin in pancreatic tumour and normal 
tissues 
As for the Hh protein staining, the primary tissues were subjected to the 
de-waxing process in xylene and washed in 100% methanol baths (2 
times for 1 min) 
In order to eliminate the methanol, the slides were then washed under 
running tap water for 1min and in PBS 3 times for 3 min.  
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The antigen retrieval was performed by microwaving the slides in citric 
acid buffer (10mM pH6.0) at 98°C for 20 min. At the end of this 
incubation, the tissues were quenched in running tap water. 
The tissues were then incubated for 10 min in a solution of 3% 
hydrogen peroxide and distilled water. Tissue sections were then rinsed 
twice in water baths (5 min each) and washed in PBS 3 times for 5 min. 
The blocking step was performed by using PBS 5% rabbit serum for 30 
min.  
At the end of the blocking process, the tissues were incubated for 30 
min at RT with Mouse IgG1 anti-human vimentin clone V9 (Dako) at 
1/50 dilution in PBS 5% rabbit serum. The negative controls were, in 
parallel, incubated for 30 min with mouse IgG1 control (1/24 dilution) in 
PBS 5% rabbit serum. 
After the primary antibody incubation, tissues were rinsed in PBS (3x 5 
min) and then incubated 30min with a biotinylated rabbit anti-mouse 
1/300 diluted in PBS 5% rabbit serum.  
The secondary antibody was then rinsed off by washing the slides 3x 5 
min with PBS and incubated with the ABC complex for 30 min.   
After this incubation, the tissues were washed 3 times for 3 min in PBS 
and then incubated with the DAB.  
Finally, sections were rinsed with water and incubated with Haemalum 
for 1 min. The tissues were then dehydrated by using 100% alcohol 
bath and then cleared in Xylene. 
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2.4.1.3  Data analysis of IHC 
19 paired normal and tumour primary pancreatic tissues plus 1 unpaired 
tumour tissues (39 total samples) were analysed for Shh and Ptch1 
protein expression. Considering the extent of tumour differentiation, 
tissue organisation and type of cells, tissue sections were classified as 
normal, or moderately and poorly differentiated tumours, as obtained 
from the histopathologist' s report. 
The IHC protein expression quantification was performed by using 
different methods dictated from the experimental purpose. The methods 
used were the H-score quantification, the DAB quantification and the 
stromal and epithelial staining quantification by eye. 
The overall protein expression in each tissue was the result of the 
average of the H-score of 6 images at 20x objective from the same 
section. The H-score was calculated by taking into consideration three 
levels of staining intensity: low, medium and high [H score= (3x 
percentage of high intensity value) + (2x percentage of medium 
intensity value) + (1x percentage of low intensity value)], giving a range 
from 0 to 300.  
Vimentin staining was performed by measuring the DAB staining in 6 
area of each section. The final staining was the average of the staining 
of the 6 areas. This quantification method was chosen in order to 
measure the overall vimentin staining. In this context, taking into 
account the contribution of the different staining intensity levels, as in 
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the H-score, was considered not relevant to the final goal of the assay: 
stromal quantification. 
For both these analyses a semi-automated system was implemented 
using either the H score or the DAB quips routine written in Qwin 
standard (leica microsystem). Both the H score and DAB programme 
software, used in this thesis, are illustrated in details in the Software 
Programmes Appendix.  
Shh and Ptch1 protein expressions were also assessed in the stroma 
and epithelial separately. For this analysis the staining was quantified 
by eye in 6 different images of the same tissue and the final result was 
the average of the 6 estimated percentages. The quantification was 
confirmed by a second blinded observer. Data was then analysed for its 
normal distribution and statistical comparison was performed between 
the Shh and Ptch1 protein expression in the different tumour 
classifications and between stroma and epithelial compartments.  
2.4.2  Immunofluorescence (IF) 
Protein expression analyses for the in vitro cell experiments were 
performed in this study using IF staining. As for IHC, a strict process of 
optimisation was initially performed to optimise the protocol to be used. 
Each optimisation process was performed by using positive controls 
(cells known to highly express the protein to be stained).The aspects 
that were investigated, in order to obtain the efficient protocol, were: 
types of negative control (normally an isotype control was preferred to 
the use of general serum); types of primary antibody; concentrations of 
Chapter 2 -Materials and Methods 
  
126 
 
the primary and secondary antibodies; times of primary antibody 
incubation; concentrations of the blocking solution. This optimisation 
process was carried out for the following proteins: Shh, Ptch1, Postn 
DQGĮ60$ 
Cells for IF were harvested from flasks or plates and processed as 
described in Section 2.2.2 above. Approximately 4 x 104 FHOOV  ȝO
IURPD WRWDO YROXPHRIȝORI IL[HGFHOOVZHUHF\WRVSXQRQWRSRO\-
lysine coated slides using a Thermo Scientific Shandon Cytospin. 
In order to reduce the risk of cross-reaction of the secondary antibody 
with non-specific immunoglobulines and permeabilise the cells to help 
the primary antibody intake, the cells were incubated in a solution of 
PBS containing 0.1% (v/v) Tween-20, 1% (w/v) BSA, 10% (v/v) normal 
serum, and 0.3M glycine for 1 h.  
The cells were then incubated for 16 h at 4°C with 100 µl of the primary 
antibody diluted in a BSA-PBS 1% solution (w/v). 
In order to ascertain the reliability of the staining, negative controls were 
carried out in parallel, by substituting the primary antibody with an 
Isotype control at the same concentration of the primary antibody.  
The slides were then washed in PBS 3 times for 5 min each and then 
incubated for 60 min with a secondary antibody conjugated with a 
fluorescent dye (AlexaFluor488) diluted in a BSA-PBS 1% (w/v) solution. 
The secondary antibody was then washed away by soaking the slides 
in PBS 3 times for 5 min.  
A drop of ProLong® Gold antifade reagent with DAPI (Invitrogen) was 
then added on the cell ring and then covered with a cover-slip. The 
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slides were then left to dry at room temperature in the dark. When dried 
the slides were stored at 4°C in order to avoid the fading of the 
fluorescence and finally analysed by microscopy.  
The following table 2.3 show the material used for the staining of the 
protein investigated in this project.-------------------------------------------------- 
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Table 2.5 Material chosen in the IF staining 
Protein 
Investigated Primary Antibody Secondary Antibody 
Blocking 
Serum 
Negative 
CTRL 
Shh 
Rat monoclonal  to Sonic 
Hedgehog (Abcam) 
(1/25 dilution) 
Alexa fluor® 488 chicken 
polyclonal to rat Ig        
(Molecular Probes, Paisley, 
Uk) 
(1/1000 dilution) 
Chicken 
serum 
Rat IgG 
isotype 
CTRL 
Ptch1 
Rabbit Anti- Human 
Patched Polyclonal 
Antibody (USBiological) 
(1/70 dilution) 
Alexa Fluor® 488 goat anti-
rabbit    IgG (H+L)      
(Molecular Probes) 
(1/1000 dilution) 
Goat 
Serum 
Rabbit 
Serum 
 
Į60$ 
Alpha-SMA mouse IgG 
antibody Clone 1A4 
(Sigma Aldrich) 
(1/100 dilution) 
Alexa Fluor® 488 rabbit anti-
mouse IgG (H+L)        
(Molecular Probes) 
(1/1000 dilution) 
Rabbit    
Serum 
Mouse IgG 
isotype 
CTRL 
Postn 
Rabbit polyclonal anti 
periostin (Abcam) 
(1/100 dilution) 
Alexa Fluor® 488 goat anti-
rabbit    IgG (H+L)             
(Molecular Probes) 
(1/1000 dilution) 
Goat 
Serum 
Rabbit 
serum 
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2.4.2.1  Data Analysis of IF staining 
IF quantification was performed in triplicate by manual observation, 
taking into account the average of the staining intensity and of the 
number of cells stained in each replicate. The success of the IF was 
assured from the staining of positive and negative controls. Each 
experiment was stained at the same time in order to have the same 
staining efficiency and the time of exposure during image capture from 
the fluorescence microscope was always kept strictly constant.  
The changes in fluorescence intensity observed under different 
experimental conditions will be properly quantified, as a next step of this 
project, by using a semi-quantitative ranking system. 
Figure 5.30 and 5.31 of chapter 5 show an example of this IF 
quantification. Each IF staining was quantified by analysing 3 images 
for each slide at 20x magnification. 
(DFKLPDJHZDVWKHQVSOLWWHGLQHTXDOVL]HGUHJLRQVRILQWHUHVW52,¶V
in order to increase the power of the analysis by improving counting 
accuracy and increasing the sample size. The number of cells with 
strong, medium and weak staining was assessed by manual 
observation in each ROI and a final H score (one for each ROI, 4 for 
each image) was calculated by using the following formula: H score= 
(3x percentage of high intensity value for the ROI) + (2x percentage of 
medium intensity value for the ROI) + (1x percentage of low intensity 
value for the ROI)], giving a range from 0 to 300. The H-score values 
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was then ranked (e.g. values between 0 and 100 = 1, 100-200=2; 200-
300=3). 
The threshold to quantify the high, low and medium level of intensity 
was decided considering the level of expression detected in a positive 
CTRL (i.e. cells known to highly express the protein analysed). 
A version of the thesis in PDF format is available at the back of the 
thesis to allow more detailed review of the IF images. 
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2.5  Statistics 
Data in each experiment was tested for normal distribution using the 
'¶$JRVWLQR 	 3HDUVRQ RPQLEXV WHVW 7KH DQDO\VLV RI WKH GLIIHUHQFHV
between groups of data was then performed by using one or two-way 
ANOVAs (considering the number of variables included in the 
experiment) for normally distributed data, or the Kruskal & Wallis test for 
non-parametric data distribution. In the case of comparison between 
only two groups a T-test for paired or unpaired data were considered. 
Correlation analysis was performed by using Spearman and Pearson 
for non-parametric and parametric data distribution respectively. 
In the case of two replicates for each data Kruskal & Wallis non-
parametric assay was performed between the (2-¨&W) control and the 
treated samples. 
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3.1  Introduction 
Evidence from the literature shows Hh pathway over-expression in non-
small cell lung cancer and its role in epithelial to mesenchymal 
transition (EMT) promotion in lung tumour cells [Yuan et al. 2007; 
Maitah et al 2011]. Moreover, treatment with SMO inhibitors results in 
reduced cell viability in lung tumour cells reinforcing the idea of a role of 
the Hh pathway in this cancer [Singh et al 2011]. Interestingly all these 
studies suggest autocrine transmission of the Hh pathway in this kind of 
tumour [Yuan et al 2007; Maitah et al 2011; Singh et al 2011]. 
On the other hand, pancreatic cancer is one of the main tumour types in 
which paracrine transmission of this pathway between epithelial cells 
and stroma cells that constitute the tumour microenvironment, has been 
observed [Bailey et al 2008; Tian et al 2009; Olive et al 2009]. 
Taking into consideration such evidence, lung and pancreatic primary 
tumours were analysed in this study as representative of two types of 
cancer in which Hh signalling, through different routes of transmission, 
contributes to tumour development and progression. 
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3.2  Screening of Hh pathway gene expression in 
pancreatic and lung tumour tissues  
3.2.1  Investigation of Hh pathway signalling in pancreatic samples 
Initially, overexpression of the Hh pathway in pancreatic primary tumour 
samples was examined and compared to normal samples in order to 
verify and confirm what had been observed in the literature. In order to 
achieve this aim, 14 paired pancreatic normal and tumour tissues 
(Figure 3.1) were screened for Hh pathway ligand gene expression by 
qRT- PCR. 
Gene expression of SHH and IHH ligands was significantly higher (non-
parametric paired T test) in pancreatic tumours in comparison to the 
equivalent normal tissues (Figure 3.1 A; C) suggesting a role of the Hh 
pathway in this type of cancer. Only two patients (P6 and P9) showed a 
higher SHH expression in tumour tissues than in normal tissues. 
Interestingly, in one of these two patients (P9) also IHH expression 
resulted to be higher in the tissue section (Figure 3.1 A; C). No 
significant difference between the 2 groups analysed (normal and 
tumour) was observed in DHH expression and 5 different patients 
showed a higher expression of DHH in the normal tissue in comparison 
to the tumour tissue (Figure 3.1 B). Moreover, a number of normal and 
tumour samples showed no expression of either IHH or DHH (Figure 
3.1 B and C). Moreover, the comparison of median values in tumour 
samples for all 3 ligands showed a 8.6 and 3 times higher levels of SHH 
than DHH and IHH (p<0.05 for both comparisons, Figure 3.1 A,B,C), 
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indicating that this ligand was the main one expressed in pancreatic 
cancer at gene level. 
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Figure 3.1 Screening of the gene expression Hh ligands in 
normal and tumour pancreatic tissues.  A) SHH expression 
in 14 normal (blue circles) and 14 tumour (red triangles) primary 
pancreatic tissues selected from the same patients. B) and C) 
DHH and IHH ligands were analysed in the same 28 primary 
pancreatic tissues. Significant difference between normal and 
tumour samples was observed (non parametric paired t-test) for 
SHH (*p<0.05) and IHH (*p<0.05) expression. The horizontal 
line represents the median of the SHH (A), DHH (B), IHH (C) 
gene expressions either in normal or tumour samples. Statistical 
analysis for DHH  expression (p=0.22) did not show any 
significance. 
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Hh pathway expression was then investigated for its correlation with 
tumour differentiation in order to see if it was possible to co-localise this 
signalling in a particular phase of tumour development or progression. 
In order to achieve this goal, Hh ligand expression was compared 
between moderately (MDT) and poorly differentiated (PDT) pancreatic 
tumours (as defined by assessment carried out by a histopathologist) 
(Figure 3.2 A;B;C). No significant difference between MDT and PDT 
was observed for any of the ligands. However, the lack of significance 
in this comparison could be a consequence of a too low number of PD 
samples. 
 
 
 
 
 
 
 
 
 
 
138 
 
 
 
 
Figure 3.2 Hh ligand expressions in different tumour stage of primary pancreatic tissues.  A) Comparison of SHH expression 
between moderately differentiated tumour (MDT) (blue circles) and poorly differentiated (PDT) pancreatic tumour (red triangles). B) and 
C) DHH and IHH respectively expression in MDT (blue squares) and PDT (red triangles). Non parametric t-test was used to analyse 
the difference between MDT and PDT. No significance was observed for any of the ligands. 
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In the same pancreatic samples, investigation of GLI1, PTCH1 and 
PTCH2 gene expression (Figure 3.3) as indicators of Hh pathway 
activity was also performed. In agreement with the observation for SHH, 
GLI1 (Figure 3.3A) was slightly higher (p<0.05, non-parametric T test 
for paired samples) in pancreatic tumour samples. The expression of 
PTCH1 (Figure 3.3B) and PTCH2 (Figure 3.3C) was very similar 
between the normal and matched tumour samples and the difference 
was not significant. 
These data do not prove, but are suggestive, of overexpression of the 
Hh pathway in pancreatic cancer. 
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Figure 3.3 Hh pathway activity in primary pancreatic tissues.  A) GLI1 gene expression in normal (blue circles) 
and tumour samples (red squares). B) PTCH1 gene expression comparison between 15 normal and tumour samples 
obtained from the same original patients. C) Same analysis in same samples was performed for the other potential Hh 
pathway receptor and gene target PTCH2. Statistical analysis between normal and tumour samples was performed by 
using non parametric paired t-test. GLI1 expression was significantly (* p<0.05) upregulated in tumour samples. No 
significant over-expression was detected for PTCH1 and PTCH2 expression. 
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3.2.2  Hh pathway expression in normal and NSCLC tumour lung 
primary tissues 
SHH gene expression was also investigated by qRT-PCR in 47 primary 
lung normal and tumour samples and the comparison between normal 
and tumour tissues was performed to study its role in this kind of cancer. 
Lung samples were also analysed for SHH expression according to 
tumour stage (T1, T2 and T3) in order to investigate a possible 
association between tumour aggressiveness and Hh ligand expression 
(Figure 3.4). The SHH screening in lung tissues (Figure 3.4 A) indicated 
very low expression of this ligand in tumour tissues with significantly 
lower expression (p<0.01, non-parametric paired T test) than in normal 
samples and a high percentage (24%) of tumour samples completely 
lacking expression. Finally, no difference between classification groups 
was observed in lung tumour tissues (Figure 3.4B). 
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As carried out for pancreatic primary tissues, lung normal and tumour 
tissues were then studied for their expression of Hh pathway activity 
through analysis of GLI1 gene expression. PTCH1 and PTCH2 gene 
expression, which when included in the previous examination of 
Figure 3.4 Screening of SHH gene expression in normal and tumour 
lung tissues. A) SHH expression analysis performed in 12 normal (blue 
circle) and 35 tumour (red triangles) lung tissues. Normal and tumour 
samples were obtained from the same 12 patients. B) Comparison of 
SHH gene expression between different lung tumour stages (the level of 
tumour aggressiveness increase with the numbers): T1 (blue squares); 
T2 (green triangles); T3 (red triangles). Statistical analysis (non 
parametric t-test) showed significant higher SHH expression (**p<0.01) in 
normal samples in comparison to tumour samples. No significant 
difference for SHH expression was observed between tumour stages. 
Chapter 3 -Results: Analysis of Hh signalling in primary tissues 
  
143 
 
pancreatic tissues did not show any differences between normal and 
tumour samples (suggesting lower sensitivity for Hh pathway activity 
detection) were not included in this analysis. There was no significant 
difference in GLI1 expression between normal and tumour samples.  
 
 
 
 
 
 
 
 
 
 
 
Considering the higher expression of SHH in normal lung samples 
(Figure 3.4) and the similar expression of Hh pathway activity between 
normal and tumour samples (Figure 3.5), pancreatic, rather than lung 
tumour was focused on as a model for investigation of the Hh pathway 
in cancer. 
 
 
Figure 3.5 Screening of GLI1 gene expression in normal and 
tumour lung tissues. GLI1 gene expression performed in 12 normal 
(blue circles) and 34 tumour (red triangles) lung tissues. Normal and 
tumour samples were obtained from the same 12 patients, two (one 
normal and one tumour) primary tissues showed no expression of GLI1 
gene. No significance difference (no-parametric paired t-test) between 
normal and tumour samples was observed. 
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3.2.3  Protein expression analysis of Hh pathway in primary 
pancreatic tumour tissues 
Since gene expression analysis may not be sensitive enough to detect 
the Hh pathway expression and activity in primary tissues (because 
RNA is an unstable molecule and expression may be localised to 
individual populations of cells within each sample), protein expression 
was also analysed. 
Shh and Ptch1 protein expression were investigated by 
immunohistochemistry (IHC). Quantification of protein expression was 
performed by considering the general intensity of Shh and Ptch1 
staining and their relative levels of expression in the epithelial and 
stromal areas.  
3.2.4  Hh ligand protein expression analysis in pancreatic tissues 
IHC analysis of Shh was performed in a panel of 19 paired primary 
normal and  tumour tissues plus 1 unpaired tumour tissue (39 total 
samples). Negative controls, obtained by substitution of the primary 
antibody with a serum from the same species, were performed for each 
sample. 
Initially, Shh staining intensity was analysed based on the average H-
score detected in 6 different images of each section (Figure 3.6 and 
3.7). In order to investigate the role of Shh in pancreatic ductal 
adenocarcinoma (PDAC) and its correlation with the level of tumour 
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differentiation, normal pancreatic tissues were compared to moderately 
and poorly differentiated PDAC tumours (Figure 3.6 and 3.7). 
 An increase in Shh expression was observed in increasingly 
aggressive (poorly differentiated) tumours. Moreover, the difference 
between poorly differentiated tumour (PDT) and normal tissues was 
significant (p<0.05; 1 way ANOVA test) (Figure 3.7) highlighting a role 
for Shh in pancreatic cancer especially in the late stage of tumour 
development. In this analysis one normal sample was eliminated, as it 
was histologically poorly-differentiated with tumour characteristics, as 
well as two tumour tissues, since their histological classification was 
unknown. The presence of tumour characteristics in a normal tissue 
could be due to the fact that normal tissues were taken from near 
tumour and so may not really be normal.
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Shh Staining Figure 3.6 Shh protein 
expression in primary pancreatic 
normal and tumour 
tissues..Examples of IHC for Shh 
staining in normal tissue NT; 
moderately differentiated tumour 
MDT and poorly differentiated 
tumour PDT. The level of staining 
increased in more aggressive 
tumours (PDT). Red arrows 
indicate the Shh expression in 
epithelial cells in pancreatic ducts. 
Black arrows indicate Shh 
expression in stromal cells. In PDT 
samples the expression was 
present at both the stromal and 
epithelial level. On the bottom row: 
negative control (rabbit serum). 
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Vimentin has been used as a valuable marker of stromal-like cells 
[Shaw et al 2008; Mishra et al 2008; Brentnall et al 2012]; therefore, in 
order to identify the stromal component in tumour and normal tissues, 
vimentin staining by IHC was performed in this study. The quantification 
of vimentin staining was quantified as the average area stained, 
measured in 6 different images of the same section and for each 
sample a negative control was performed (in which the primary antibody 
was substituted by a serum from the same species of the primary 
antibody) to check the reliability of the staining.  
In the same set of 19 normal and 20 pancreatic tumour samples (39 
total samples), analysed for Shh protein expression, there was an 
increase of stroma in moderately and poorly differentiated tumour in 
Figure 3.7 Quantification of Shh protein expression in 
primary pancreatic normal and tumour tissues.. Shh 
staining intensity was quantified by using H-score. A 
significant (*p<0.05) Shh expression increase was observed 
in PDT in comparison to NT (1 way ANOVA test). 
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comparison to normal samples, but the difference between these 
groups was not statistically significant (Kruskal-Wallis non-parametric 
test) (Figure 3.8 A, B).----------------------------------------------------------------
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A) 
Figure 3.8 Vimentin expression in normal and pancreatic 
tumour tissues .A) Example of vimentin staining in normal tissue 
(NT); moderately differentiated tumour (MDT); poorly differentiated 
tumour (PDT). The black arrows indicate the localisation of 
staining in stroma like cells. On the bottom: Negative Control of 
the same tissue sections. B) Vimentin staining quantification was 
compared between normal NT (blue circle); moderately 
differentiated tumour MDT (green squares) and poorly 
differentiated tumour  PDT (red triangle). No significat difference 
(Kruskal-Wallis non parametric test) was observed between these 
three groups. 
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In parallel, quantification of the percentage of Shh staining in stroma 
and epithelium separately showed a significant correlation of both with 
the amount of stroma (Figure 3.9 A, B) suggesting an effect of Shh 
expression on the induction of desmoplasia.  
 
The analysis of Shh staining separately in the epithelial and stromal 
component showed that Shh protein expression in the stroma paralleled 
staining in epithelial cells (Figure 3.10, p=0.028, Spearman rank 
correlation). These data indicate the expression of Shh not just at 
epithelial level but at the stromal level too. 
 
 
 
 
 
Figure 3.9 Shh epithelial and stromal expression correlates with % 
stromal component. .Percentage of Shh staining at epithelial (A) and stromal 
(B) level was investigated for correlation with vimentin protein expression in 
the same tissue sections. Significant correlation (Spearman rank test) was 
observed between the % of vimentin staining and either the % of Shh at 
epithelial (p<0.05) or at stromal level (*p<0.05). 
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Moreover, there was a significant increase (Kruskal-Wallis non-
parametric test) in Shh protein staining at the stromal level in more 
aggressive tumors (Figure 3.11). In this analysis only samples in which 
stroma were present were included.------------------------------------------
Figure 3.10 Shh expression in the stromal component increases 
in proportion to the level of staining in the epithelial 
component.. Shh staining was quantified as an average of 6 
different images from the same sample both in the stromal and in the 
epithelial components of the same section. Samples with higher Shh 
expression in the stroma showed the highest expression at the 
epithelial level. Statistical analysis showed a significant (* p<0.05) 
correlation (Spearman test) between the epithelial and the stromal 
staining. 
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Figure 3.11 Shh was expressed at the stroma level 
and increased with tumour aggressiveness.. A) 
Example of Shh staining by IHC in different grades of 
tumour differentiation (PDT and MDT). Red arrows 
indicate Shh expression in ductal epithelial cells. 
Black arrows in samples show Shh expression in 
stroma like cells. Bottom Row: negative controls of the 
same tissue sections. B) Comparison between Shh at 
stroma level in normal NT (blue circle); Moderate 
differentiated tumour MDT (green square); Poorly 
differentiated tumour PDT (red triangle). Protein 
expression of Shh significantly (Kruskal-Wallis non-
parametric test) increased (*p<0.05) in more 
aggressive tumours in comparison to normal samples. 
A) 
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In order to investigate the activity of the Hh pathway in pancreatic 
tissues at the stromal and epithelial levels and to better understand the 
type of transmission (autocrine or paracrine) occurring in this pathway 
in the tumour microenvironment, in the next section the protein 
expression of Hh target Ptch1 was analysed. 
3.2.5  Investigation of the activity of the Hh pathway in pancreatic 
tissues 
In this section, Ptch1 was used as an indicator of the Hh activity by 
paracrine or autocrine activation. In the absence of autocrine signaling 
at the epithelial level, Ptch1 should be mainly expressed in stroma [Tian 
et al 2009], and no expression should be detected in epithelial cells.  
Initially in order to compare Ptch1 expression between normal and 
tumour samples, Ptch1 staining, was quantified for its overall 
expression in the pancreatic tissues  (19 normal paired and 20 tumour 
pancreatic tissues, 39 samples in total) included in the Shh screening of 
paragraph 3.3.1 and 3.3.2. This quantification, as for Shh (Figure 3.7) 
was based on the average of the H-score detected in 6 different images 
of the same tumour or normal pancreatic tissue sections. Negative 
controls obtained by substitution of the primary antibody with a serum 
from the same species of the primary antibody were performed for each 
sample. Quantification of Ptch1 staining intensity showed the same 
level of expression in normal tissue, and in moderately and poorly 
differentiated tumours (Figure 3.12 A and B).
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Figure 3.12 Ptch1 protein expression analyses in 
normal and tumour pancreatic tissues.. A) Example of 
Ptch1 staining by IHC in different grades of tumour 
differentiation (PDT and MDT). Red and black arrows 
indicate Ptch1 expression mainly in epithelial ductal 
cells, and in stromal cells, respectively. Bottom Row: 
negative controls in the same tissue sections. B) 
Comparison between Ptch1 staining intensity in normal 
NT (blue circles); moderately differentiated tumour MDT 
(green squares); poorly differentiated tumour PDT (red 
triangles). The quantification of Ptch1 expression was 
achieved by H-score. Statistical analysis (Kruskal-Wallis 
non parametric test) between the NT, MDT and PDT 
groups of samples did not show any significance. 
A) 
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In order to localise the Ptch1 expression and to investigate if there is a 
correlation between the Hh pathway activity at the epithelial and stromal 
levels in pancreatic cancer, Ptch1 staining was also quantified based on 
percentage of staining, in the epithelial and stromal component of each 
of the 39 sections included in this study.  
In contrast with Shh (figure 3.10), Ptch1 protein expression did not 
increase in epithelial cells in parallel with increased stromal staining 
(Figure 3.13 A). Moreover, no significant (Spearman test) correlation 
between the percentage of staining detected in the stroma and that 
measured in epithelium (Figure 3.13 B) was observed.  In this analysis, 
as for Shh analyses, only samples with a visible and detectable stromal 
component were included. Many normal tissues and some MDT were in 
fact characterised by the absence of a stromal component. 
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Ptch1 percentage expression at the epithelial and stromal levels was 
then analysed and correlated with the stromal component, quantified by  
vimentin staining. There was no correlation (Spearman correlation 
analysis) between Ptch1 epithelial (Figure 3.14 A) and stromal staining 
(Figure 3.14 B) with the stromal component in contrast to what was 
observed for Shh protein expression (Figure 3.10). However, statistical 
analysis between Ptch1 stroma staining and stromal component was on 
the limit of significance (P=0.05). 
  
Figure 3.13 Ptch1 expression at the stromal level does not correlate with 
its expression in the epithelial component.. A) The trend of Ptch1 
expression at stroma level was compared with its expression in the epithelial 
component contained in the same sample. B) Correlation analysis between 
the percentage of Ptch1 expression in the stroma and in the epithelial 
component was calculated by Spearmen correlation test (p=0.62) 
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In order to further investigate if Hh pathway transmission occurs 
through autocrine signalling at the epithelial level or can be 
paracrine/autocrine at the stromal level, Ptch1 expression in stromal 
and epithelial cells was compared. From this analysis Ptch1 was higher, 
but not significantly (Figure 3.15), in the epithelial component.  
 
 
Figure 3.14 Expression of Ptch1 within the epithelial and stroma 
compartments do not correlate.. A) Percentage Ptch1 staining in the 
epithelial component of normal and tumour sections was compared with 
the percentage staining in the stroma component detected by vimentin 
staining and the correlation analysed by Spearman correlation test 
(p=0.57). B) Trend of variation of Ptch1 in stroma component of 
pancreatic tissues was compared with the stroma component in the 
same tissue. As in figure (A) correlation analysis was investigated by 
using Spearman correlation test. The correlation was on the limit of 
significance (p=0.05). 
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Stromal 
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Ptch1 staining
Figure 3.15 Ptch1 is highly expressed in the epithelial component of normal and tumour pancreatic 
tissues . Examples of Ptch1 staining at epithelial and stromal level. Red arrows: Ptch1 staining in epithelial 
component. Black arrows: Ptch1 staining in the stromal component. Ptch1 was expressed in both epithelial and 
stromal components but higher staining intensity was observed in the epithelium. Bottom Row: negative 
controls of Ptch1 staining in pancreatic samples. 
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Since Shh and Ptch1 were both expressed at the epithelial and stromal 
levels, the possibility that Hh pathway activity in the tumour 
microenvironment was a result either of paracrine activation or of an 
autocrine signal within stromal cells was suggested. 
No significant correlation was observed between Shh protein 
expression in epithelial cells and Ptch1 protein expression when 
expressed in epithelial cells (Figure 3.16 A) (reducing the possibility of 
induction of the Hh pathway at the epithelial level). However, significant 
correlation was observed between epithelial Shh expression and 
stromal Ptch1 expression (Figure 3.16 B) (increasing the possibility of 
paracrine activation of the pathway). Finally, significant correlation was 
detected between Shh and Ptch1 expression in stromal cells (Figure 
3.16 C) (supporting the possibility of an autocrine Hh signal at stromal 
level). 
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Figure 3.16 Correlation analysis between Shh and Ptch1 protein expressions in pancreatic normal and tumour 
tissues. A) Spearman correlation analysis between Shh expression at epithelial level and Ptch1 expression in epithelial 
cells. The analysis was performed to investigate the existence of an Hh autocrine signal in epithelial cells. No significant 
correlation was observed in this analysis (p=0.21) B) Correlation analysis (Spearman correlation test) between Shh 
epithelial expression and Ptch1 expression at stromal level in order to investigate the paracrine induction of Hh pathway 
in the tumour microenvironment. Significant correlation was observed in this analysis (p<0.0001)  C) Correlation analysis 
(Spearman correlation test) between Shh expression in stromal cells and Ptch1 expression at stromal level in order to 
investigate the autocrine signalling transmission of the Hh pathway in the stromal cells of pancreatic tissue. Significant 
correlation was observed in this analysis (***p< 0.001). 
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3.4 Summary of results 
In this chapter the following results were demonstrated: 
 
x No over-expression of the Hh pathway, based on SHH and GLI1 
expression, was detected in lung tumour tissues in comparison to 
normal samples 
x  SHH and GLI1 genes were highly expressed in pancreatic 
tumour samples in comparison to normal samples.  
x The analysis of the expression of the other two Hh ligands IHH 
and DHH showed no or low expression in normal and tumour 
samples suggesting SHH is the main ligand acting in pancreatic 
tumour. 
x Overall, Shh protein expression was significantly more highly 
expressed in more aggressive pancreatic tumour (PDT) than in 
normal samples. 
x Shh protein was not just expressed at the epithelial level but at 
the stromal level too. Moreover, the percentage of Shh epithelial 
staining increased in parallel with percentage of staining at the 
stromal level. 
x Shh expression in epithelial and stromal cells both correlated 
with the stromal component evaluated by vimentin staining. 
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x Ptch1 protein expression did not correlate with tumour 
aggressiveness and no correlation was observed between its 
expression at epithelial and stromal level. 
x Correlation analysis between Shh protein expression at the 
epithelial level and Ptch1 protein expression in epithelial cells 
decreased the probability of an autocrine Hh signalling pathway 
transmission in epithelial cells. However, correlation between 
Ptch1 expression in stromal cells and Shh expression at the 
epithelial and stromal level left open the possibility of both 
paracrine and autocrine Hh signalling transmission in the stromal 
component. 
Taken together these results show an important role for Shh in 
pancreatic cancer and its expression in the stroma, suggesting a 
potential role for this molecule in the stromal compartment. The 
expression of Ptch1 protein expression both in epithelial and stromal 
cells and the correlation between Shh and Ptch1 protein expression in 
the epithelial and stromal cells raises the possibility of both epithelial 
autocrine and paracrine Hh pathway transmission in the tumour 
microenvironment with both paracrine and autocrine transmission in the 
stromal cells. 
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4.1  Introduction  
Overexpression of the Hh pathway in pancreatic cancer has been 
demonstrated in the literature [Bailey et al, 2008; Tian et al, 2009] and 
confirmed in chapter 3 of this thesis. Pancreatic cancer is characterised 
by having a high stromal component; this, together with the observation 
of Hh pathway paracrine induction in stromal cells, makes pancreatic 
cancer a good candidate for investigation of the role of Hh pathway 
signalling in the formation and maintainance of the stroma and its effect 
on the epithelial component [Bailey et al, 2008; Tian et al, 2009]. In 
particular, few studies have so far included primary CAFs in the 
exploration of the role of the Hh pathway in tumour progression, making 
this study a further step in this investigation. 
In this chapter a panel of pancreatic fibroblasts and epithelial cells, 
including fibroblasts derived from primary tumour samples, were 
profiled for Hh pathway expression at the gene and protein level, 
providing important information about the presence of components of 
the Hh pathway in fibroblast cells and guiding the choice of cells to be 
used in future experiments. Finally, Hh paracrine induction in primary 
pancreatic CAFs was further investigated by treatment of these cells 
with NShh molecule or tumour-conditioned media (TCM), and use of 2D 
direct and trans-well co-cultures with pancreatic epithelial tumour cells. 
A higher resolution of the IF images showed in this chapter is available 
in the CD version of the thesis. 
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4.2  Screening of pancreatic epithelial and fibroblast cells 
4.2.1  Hh pathway expression in pancreatic cancer epithelial and 
primary-derived fibroblasts cells 
In order to characterise the pancreatic cancer cells to be used in the in 
vitro investigation of Hh pathway cross-talk between cancer cells and 
the stromal microenvironment, a panel of pancreatic epithelial cells 
(PANC1, BXPC3, P308T, PAN1) and CAFs were profiled by qRT-PCR 
for gene expression of the main components of the Hh pathway (SHH, 
DHH, IHH, GLI1, SMO, PTCH1, PTCH2). The same cells were also 
investigated for gene markers of epithelial (CDH1) and mesenchymal 
phenotypes (VIM and HGF) to confirm and characterise their identity in 
the tumour context. CDH1, VIM and HGF are all genes that encode 
proteins involved in the EMT process. For this reason they are normally 
used as identification markers of the loss or acquisition by epithelial 
cancer cells of a mesenchymal phenotype [Frixen et al 1991; Tuxhorn 
et al 2002; Adegboyega et al 2002; Zhang et al 2012]. CDH1 (gene of 
E-cadherin protein) is normally highly expressed in cancer cells with an 
epithelial phenotype and its down-regulation is correlated with 
increased invasiveness and mesenchymal phenotype acquisition of 
cancer cells [Frixen et al 1991]. On the other hand, HGF and VIM have 
been used in many studies as markers of myofibroblasts or CAFs in the 
tumour microenvironment and their expression tends to increase when 
epithelial cells acquire a mesenchymal phenotype [Shaw et al. 2009; 
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Spaeth et al. 2009, Dandachi et al 2001; Tuxhorn et al 2002 ;Zhang et 
al 2012]. Moreover, their expression is an indicator of an activated and 
aggressive state that seems to support tumour growth and progression 
[Shaw et al. 2009; Tuxhorn et al 2002]. Using these markers, the 
epithelial or mesenchymal phenotype of cancer epithelial cells and 
CAFs was assessed and correlated with Hh pathway expression in this 
study. 
The two cell-types (epithelial cells and CAFs) were compared for 
epithelial/mesenchymal and Hh markers in the following graphs: Figure 
4.1A in which the expression of epithelial and fibroblast markers are 
shown and Figure 4.1B in which the main genes of the Hh pathway 
expression are shown. 
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Figure 4.1 Screening of epithelial cells, CAFs and MSCs for the main genes associated with the Hh pathway and 
epithelial/ myofibroblast markers. A) Screening of 4 pancreatic epithelial cancer cells, 10 pancreatic primary CAFs and 1 MSC 
line for the expression of an epithelial phenotype marker (CDH1) and the expression of mesenchymal phenotype markers (VIM 
and HGF). B) Screening of the same cell lines for the main genes involved in the Hh pathway: 3 ligands SHH, DHH and IHH and 4 
genes involved in the signalling transmission (PTCH1, PTCH2, GLI1, and SMO). GLI1 and PTCH1/2 are also gene target of the 
Hh pathway and so indicators of its activity. Statistics between different cell lines were performed by using non-parametric t Test 
(*p<0.05), (**p<0.01), (***p<0.001). 
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Analysis of myofibroblast and epithelial markers showed higher 
expression of CDH1 (p<0.05) in epithelial cells in comparison to CAFs 
and MSCs. Moreover, significantly higher HGF expression (p<0.01) was 
observed in CAFs and MSCs in comparison to epithelial cells (Figure 
4.1A). Both these observations are consistent with the expected 
phenotypes of the cell lines analysed [Frixen et al 1991; Spaeth et al 
2009]. However, a high level of VIM expression was observed in both 
cell types (epithelial and CAFs) (Figure 4.1A). The analysis of the 
expression of the main Hh pathway genes confirmed significantly 
highest expression (p<0.05) of Shh ligand in epithelial pancreatic 
tumour cells in comparison to CAFs. Moreover, SHH was also highly 
expressed in pancreatic epithelial cells in comparison to DHH (non 
significant difference) and IHH (p<0.05) (the others two ligands of the 
Hh pathway)(Figure 4.1B). DHH expression was, in fact, generally 
expressed at a low level both in pancreatic epithelial (except in PANC1s) 
and fibroblast cells, limiting the importance of this ligand in this type of 
cancer. IHH as well as DHH was poorly expressed in epithelial cancer 
cells when compared with the level of SHH expression; however, much 
higher expression of IHH was present in epithelial than fibroblast cells 
(p=0.0006) (Figure 4.1B). Interestingly SMO (p<0.01), GLI1 (p<0.01), 
PTCH2 (p<0.05) expression were significantly higher in CAFs than 
epithelial cells suggesting a higher activity of the downstream Hh 
pathway signalling in these cells. PTCH1 expression analysis did not 
show any significant difference between the pancreatic epithelial and 
Chapter 4 -Results: Characterisation of Hh pathway in epithelial and 
stromal cells 
  
169 
 
fibroblast cells suggesting its expression in both types of cell lines 
(Figure 4.1B). In view of this observation, even if PTCH1 gene 
expression is considered a marker of the Hh pathway activity [Hidalgo 
and Ingham 1990], due to the negative feedback exerted on the 
pathway [Goodrich et al 1999], its gene expression could be partly 
inhibited and as a consequence it may not always perfectly reflect Hh 
pathway activity. However, considering the frequent use of Ptch1 gene 
and protein expression in different studies [Tian et al 2009; Lee et al 
2013] and the fact that GLI1 expression (the other gene target of Hh 
pathway used to analyse its activity) can in some cases be activated by 
non-canonical pathways, its investigation at the gene and protein levels 
was included in this study taking into account the potential changes in 
its gene expression.  
Correlation analysis (Spearman test) between Hh pathway and 
epithelial and mesenchymal markers showed a significant association 
between SHH and CDH1 expression (p<0.01). Moreover, CDH1 also 
correlated with GLI1 (p<0.05) and SMO (P<0.001) expression. These 
results suggest Hh pathway activity in cells with an epithelial phenotype. 
However, SMO expression was also significantly correlated with VIM 
(p<0.05) and HGF (p<0.05), and PTCH2 was positively associated with 
VIM (p<0.05). These results support the possibility of Hh autocrine 
signal in cells with epithelial phenotype but also suggest the existence 
of the pathway activity in mesenchymal-like cells. 
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4.2.2  Protein expression analysis of Hh ligand expression in 
cancer epithelial cells 
In order to confirm at the protein level the results achieved by gene 
expression analysis and select the epithelial cells to include in a model 
to investigate Hh paracrine induction in the tumour microenvironment, 
some of the epithelial cell lines included in this study were also 
investigated for Shh and Dhh protein expression by 
immunofluorescence staining. 
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Figure 4.2 Shh and Dhh protein expression analyses by IF in epithelial 
pancreatic cancer cells. A) Shh protein expression (green staining) in 
PANC1, P308T and BXPC3 pancreatic cancer cells. Top row: cells with nuclei 
highlighted (DAPI blue staining). Bottom row: Shh staining without combined 
nuclear staining. B) Dhh protein expression (red staining) with (top) and 
without (bottom) DAPI nuclear staining 
 
Shh protein (Figure 4.2 A) was highly expressed in PANC1 cell lines 
and, although at a lower level, in P308T and BXPC3 lines. Dhh protein 
expression analysis showed low expression in P308T and BXPC3 and 
very low levels in PANC1 cell lines. In this and in the previous analysis 
(Figure 4.1), the comparison between Shh and Dhh protein expression 
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in the same pancreatic cell lines (PANC1, P308T, and BXPC3) clearly 
showed highest expression of Shh, supporting the conclusion that it is 
the main Hh ligand acting in pancreatic cancer. 
As in chapter 3, Gli1 expression was investigated as a measure of Hh 
pathway activity as it is not just a transcription factor involved in the 
pathway but also, as consequence of positive feedback, a gene target 
of the pathway. For this reason, Gli1 protein expression was analysed 
in the same pancreatic epithelial cells lines used for investigation of Shh 
and Dhh protein. 
 
 
 
 
 
 
 
 
 
 
Figure 4.3 Gli1 expression in pancreatic epithelial cancer cells . Gli1 
protein expression analysis by IF (green staining) in PANC1, P308T and 
BXPC3 pancreatic cancer cells. Images on top: cells with nuclei highlighted 
(DAPI blue staining); images on bottom: Gli1 staining without combined 
nuclear staining. 
 
 
Higher Hh signalling pathway activity was observed in BXPC3 and low 
level activity in PANC1 and P308T epithelial cells indicating that the 
pathway is not always fully active in cancer epithelial cells but can be 
expressed at higher (BXPC3 cells) or lower (PANC1, P308T) 
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background levels in different cell lines. Consistent with these 
observations, different Hh pathway basal activity levels was previously 
observed in a panel of pancreatic epithelial cells including PANC1 and 
BXPC3 [Yauch et al 2008]. 
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4.3  Investigation of pancreatic CAF responsiveness to 
exogenous Hh stimuli 
In order to investigate Hh paracrine induction in cancer stromal cells, a 
panel of pancreatic CAFs (screened for Hh pathway expression in 
section 4.2), were analysed for their ability to respond to Hh ligand in 
response to NShh treatment or tumour-conditioned medium and in 2D 
co-culture assays. Pancreatic epithelial cancer cells (PANC1, BXPC3 
and P308T) characterised in this study for Shh gene and protein 
expression (sections 4.2.1 and 4.2.2) were included in this investigation 
as examples of cells with different levels of Hh ligand expression with 
potential to cause paracrine signalling.  
4.3.1  Investigation of the mesenchymal-like phenotype in CAFs 
stroma cells  
Evidence from the literature describes myofibroblast cells in the tumour 
PLFURHQYLURQPHQWDVILEUREODVWFHOOVZLWKKLJKH[SUHVVLRQRIĮ60$DQG
vimentin (Shaw et al 2009; Spaeth et al 2009). The expression of these 
two markers indicates an activated phenotype that correlates with a 
more aggressive behaviour able to support tumour growth and 
progression [Shaw et al 2009; De Wever et al 2008; Mishra et al 2008; 
Spaeth et al 2009; Tuxhorn et al @&HOODFWLYDWLRQLQFUHDVHGĮ60$
expression) is believed to be triggered as a result of interplay between 
tumour stromal FHOOVDQGHSLWKHOLDOFDQFHUFHOOV)RUWKLVUHDVRQĮ60$
expression was monitored to investigate if the level of cell activation 
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affects the cells¶ responsiveness, and if activation can be affected by Hh 
paracrine signalling from tumour cells as shown previously [Bailey et al 
2008]. 
Initially, ACTA2 Į60$ JHQH DQG Į60$ SURWHLQ H[SUHVVLRQ was 
determined in CAFs cultured over time (Figure 4.4). No changes in 
gene expression over time were observed in pancreatic CAFs, and 
protein expression analysis confirmed the expression of this protein in 
this type of cell suggesting their activation. However, these data do not 
yet indicate the effect of FBS percentage contained in the media and 
the level of expression detected (high or low) in comparison with other 
cell lines, factors that will be further investigated later in this study.  
 
 
ɲSMA Negative CTRL
Figure 4.4 &$)FHOOVH[SUHVVĮ60$FHOODFWLYDWLRQPDUNHU. A) ACTA2 
gene expression in pancreatic CAFs on day1; 3; 4 and 7 (D1, D2, D3, D7) 
of cell culture. Two repetition wells were performed for each time point. 
The bars with the same pattern show the gene expression detected in the 
VDPHZHOO%Į60$ protein expression in pancreatic CAFs and negative 
CTRL (Sample stained by substituting primary antibody with  Isotype IgG). 
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4.3.2  Investigation of responsiveness of CAFs to NShh treatment 
Several studies (Taipale et al 2000; Chen et al 2002; Bailey et al. 2008; 
Zacharias et al 2011,) have shown induction of the Hedgehog pathway 
in myofibroblast cells, detected as increased Gli1 gene and protein 
expression, following NShh treatment. NShh is a palmitoyl and 
cholesteryl modified polypeptide, able to trigger the Hh pathway in the 
targeted cell by binding to the Ptch1 receptor and inhibiting its function.  
A dose of 5nM and time point of 48h was used to investigate 
responsiveness (Figures 4.5; 4.6), but in addition higher concentrations 
(10-20nM), previously used successfully (Taipale et al 2000) were also 
included. In a first experiment the responsiveness of the CAFs (P3T 
and P5T) to NShh induction was evaluated via GLI1 (gene target of Hh 
pathway) and SMO gene expression analysis. Moreover, the effect of 
Shh exogenous treatment on ACTA2 gene expression was also 
investigated (Figure 4.6). The CAFs used (P5T) did not show an 
induction of GLI1 and SMO expression after 48h of treatment (Figure 
4.5 A and B). Increasing and decreasing but inconsistent effects on 
ACTA2 expression were observed in both cell lines (Figure 4.5C). 
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Figure 4.5 Investigation of the responsiveness of CAFs to NShh.. (A) 
GLI1, (B) SMO and (C) ACTA2  gene expression in CAFs after treatment 
with 5nM and 10nM of NShh.  P5T is a primary tumour-derived cell line. 
Each bar in these graphs shows the result of the average gene expression 
detected in treated samples from three replicates (two from well replicates 
performed during the same experiment and one from a different 
experiment) normalised to that detected in the samples control. Statistical 
analysis of this experiment was performed by using Krustal-Wallis non 
parametric test. No significance was observed between the CTRL and the 
treated samples for any of the genes analysed. 
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NShh treatment was then repeated to test the responsiveness to Hh 
stimuli at different time points (3 and 6 days). The rationale of this 
experiment was not just to test the reproducibility of previous data 
(Figure 4.5A), but also to analyse the level of cell activation (ACTA2 
expression) with time in culture and determine if it could affect or be 
affected (as observed in Bailey et al, 2008 and Zacharias et al, 2011) by 
response to the Hh pathway.  
 
 
 
 
 
 
 
 
 
 
 
 
 
. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6 GLI1 and ACTA2 gene expression induction in 
pancreatic CAFs treated with NShh..A) GLI1 and B) ACTA2 
gene expression in pancreatic CAFs (P5T) grown for 6 days in 
MSCM 5% FBS and treated with 10nM NShh. The gene 
expressions in treated cells was normalised to the expression 
observed in control samples. The treatment was renewing every 
2 days during culture. The two graphs above compare the 
results, represented by double bars, of two well replicates 
performed under the same experimental conditions during the 
same single experiment.  
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GLI1 and ACTA2 gene expression analysis did not show a response to 
NShh treatment at any of the time points analysed (Figure 4.6). Thus it 
proved difficult to show an effect of treatment on cell activation. 
4.4  Investigation of the CAF responsiveness to paracrine 
signals in 2D co-culture and using tumour-conditioned 
medium (TCM) 
4.4.1  TCM effect of Hh signalling pathway paracrine induction in 
CAFs 
A TCM assay was used to further test the CAF responsiveness to Hh 
paracrine signalling from epithelial pancreatic cells. The principle of this 
assay is that epithelial cancer cells release growth factors, cytokines, 
and chemokines into the growth medium. This medium can then be 
used to investigate the effect on fibroblast cells. Evidence from the 
literature previously showed the validity of this assay in studies focused 
on the investigation of paracrine interactions between different types of 
cells [Karnoub et al, 2007; Mishra et al 2008; Mishra et al, 2009; 
Kurcekova et al, 2010]. The effect of TCM on Hh pathway activity in 
fibroblast cells and the responsiveness of activated cells grown in this 
media were therefore investigated in this section.   
In order to prepare the TCM, a panel of pancreatic tumour epithelial 
cells expressing Shh ligand (PANC1, P308T, PAN1, BXPC3) were 
grown in MSCM 5% FBS for 72h, as this media supported growth of the 
CAF cells better than other media tested. Pancreatic CAFs (P3T and 
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P5T) were then cultured in those media for 3 and 14 days. Effects on 
Hh signalling activity was assessed by gene expression analysis of Hh 
target genes (GLI1; PTCH1) (Figure 4.7).  
The effect on CAF activation was also assessed by measuring ACTA2 
expression. Pancreatic CAFs (P3T and P5T) showed variable Hh 
pathway induction and decrease (Figure 4.7). Reduced GLI1 gene 
expression in P3T cells was observed after 3 days of conditioning 
(Figure 4.7 A).  However, an increase in GLI1 expression after BXPC3 
and P308T TCM exposure was observed on day 14 in P3T cells. The 
same effect was observed in P5T cells grown in PAN1 TCM, although 
this was not confirmed by the other TCMs tested on this cell line.  
The same decrease or lack of effect of TCMs was observed on PTCH1 
(Figure 4.7B) gene expression on day 3 in both cell lines included in this 
assay. However, again, some, but not consistent effects on PTCH1 
expression were observed on day 14 both in P3T and in P5T CAFs.  
Finally ACTA2 expression (Figure 4.8C) showed a fairly consistent 
increase after 14 days of exposure to P308T TCM both in P3T and P5T 
CAFs. However, the other TCMs tested showed variable small effects in 
both cell lines at both time-points.  
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Figure 4.7 Pancreatic TCM effect on Hh pathway expression in 
CAFs.. GLI1 (A); PTCH1 (B), and ACTA2 (C) expression was 
investigated by PCR-RT in pancreatic CAFs (P3T and P5T)cultured 
for 7 and 14 days in TCM obtained by growing epithelial cancer cells 
(BXPC3, PANC1, P308T, PAN1) in MSCM 5% for 72h . Each bar 
represent the gene expression detected in CAFs grown in CM 
obtained from tumours cells, normalised to the sample control CM 
(CTRL). Each bar represents the results of one single experiment. 
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Summarising these results (Figure 4.7) it seemed that day 14 may be a 
better time point to test the effect of TCM on gene expression. However, 
the variability observed between the effect of different TCMs and the 
general small changes observed, led to use of a further approach (2D in 
vitro co-culture) to investigate Hh pathway paracrine signalling. 
4.4.2  Investigation of Hh pathway paracrine induction in stromal-
like cells by 2D in vitro co-culture assays 
Direct and trans-well in vitro co-culture assays were chosen and 
performed in this study for their ability to provide continuous stimulation 
of the fibroblast cells by the tumour epithelial cells mixed or cultured 
with them. Several studies in the literature support the ability of 2D co-
cultures to demonstrate reciprocal interaction between stroma and 
cancer cells resulting in effects on the behaviour of both cell lines. 
(Spaeth et al 2009, Kucerova et al 2010; Karnoub et al 2007) 
4.4.2.1  The pancreatic CAFs responsiveness in a trans-well system. 
In a first co-culture experiment primary P5T CAFs and P308T primary 
tumour epithelial cells (chosen for being a primary-derived cell line and 
so believed to better reproduce the in vivo context and for its relatively 
high expression of Shh protein, Figure 4.2) were grown in a trans-well 
system in order to investigate paracrine induction of the Hh signalling in 
CAFs. The modulation of the Hh pathway in fibroblasts after 72h of co-
culture with epithelial cells was analysed via GLI1 and SMO gene 
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expression normalised to their expression in control samples 
(fibroblasts in both compartments). ACTA2 gene expression was also 
investigated.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Small increases in GLI1 and SMO gene expression in the CAFs was 
observed after trans-well co-culture (Figure 4.8) and no changes in cell 
activation (ACTA2 expression) were seen in this assay. 
As a next step, a new trans-well assay was performed by co-culturing 
pancreatic cancer (PANC1) epithelial cells (that showed the highest 
level of Shh protein expression in comparison to all other cell lines 
included in this study, Figure 4.2) with P5T pancreatic CAFs, at a range 
of time points in order to exclude time as a cause of no responsiveness 
Figure 4.8 Investigation of paracrine interaction between P5T 
pancreatic fibroblast and P308T primary epithelial cancer 
cells. GLI1, SMO and ACTA2 gene expression in P5T cells 
co-cultured with P308T epithelial cancer cells for 3 days. Each bar 
represents the gene expression detected in each of two different 
well repetitions (bars with same colors but different patterns) 
performed under each experimental condition. The gene 
expression detected in co-cultured samples was normalised to the 
gene expression detected in control samples. .
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in the previous assay (Figure 4.8). Finally PTCH1 Hh target gene was 
used to further confirm that the results observed was due to canonical 
Hh pathway activation and not involvement of other pathways. Since 
the SMO gene expression is not a direct target of the pathway, its 
detection was excluded in this and in the next assays.  
Cells were plated in a 12-well trans-well plate and harvested after 2 or 5 
days. GLI1 (Figure 4.9 A), PTCH1 (Figure 4.9 B), and ACTA2 (Figure 
4.9 C), gene expression were assessed. 
Hh pathway gene targets (GLI1 and PTCH1) did not show any induction 
in CAFs after 2 and 5 days of co-culture with epithelial cells but a 
decreasing effect on the pathway (GLI1; PTCH1 expression reduction) 
was observed after 5 days. No changes of ACTA2 expression was 
observed in CAFs after 2 or 5 days co-culture 
185 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9 Time-course of Hh pathway paracrine induction in 
pancreatic CAFs. GLI1(A) and PTCH1 (B) Hh signalling pathway gene 
targets and ACTA2 (C) marker of cell activation expression in 
pancreatic CAFs (P5T). CAFs were co-cultured for 2 and 5 days with 
PANC1 pancreatic cancer cells and the gene expression detected in 
them was normalised to the gene expression in CAF control samples 
(CAFs co-cultured with themselves). Each double bar represents the 
2 ¨¨&W gene expression of 2 different wells performed under each 
experimental condition.  
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A final trans-well experiment (Figure 4.10) was then included to test the 
effect on the Hh pathway paracrine induction in CAFs of a larger panel 
of epithelial pancreatic cancer cells (BXPC3, PANC1 and P308T). All 
these cancer epithelial cells showed different levels of Shh expression 
at protein level (Figure 4.2), so the rationale of this experiment was to 
test if a ligand dose-dependent induction was visible in pancreatic CAFs. 
The experiment was run once by including two well repetitions under 
each experimental condition tested. 
No consistent changes in Hh gene target expression were observed in 
any of the pancreatic CAFs tested (P3T Figure 4.10A and P5T Figure 
4.10B) after trans-well co-culture with pancreatic tumour cells. An 
increase by 10 times in the ACTA2 gene expression was observed in 
one of the two well repetitions after co-culture of P5T cells with BXPC3 
cancer cells. However, the difference between the two well repetitions 
for this experimental condition was quite high (2.6 times), compromising 
the reliability of these data. 
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Figure 4.10 Investigation of pancreatic CAFs dose-
dependent responsiveness to Hh ligands paracrine 
induction. GLI1, PTCH1, ACTA2 gene expression analysis in 
P3T (A) and P5T (B) pancreatic CAFs after 2 days of co-culture 
with a panel of pancreatic cancer cells with different level of 
ligand expression. The gene expression of all target genes was 
showed for two different wells (bars with the same colours but 
different patterns) performed under the same experimental 
conditions as part of the same single experiment and was 
normalised to their level of expression detected in samples CTRL 
(CAFs co-cultured with them-selves).  
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4.4.2.2  The responsiveness of pancreatic CAFs in a direct co-culture 
system. 
In order to exclude that the variability of GLI1, PTCH1 and ACTA2 
expression observed in CAFs after treatment with TCM or the non-
responsiveness after trans-well co-culture was not due to the absence 
of direct contact between CAFs and cancer epithelial cells, a direct co-
culture experiment was carried out with pancreatic CAFs (P5T). After 
48h co-culture, the Hh pathway was analysed in CAFs separated from 
epithelial cells using magnetic beads conjugated with antibodies able to 
bind specific fibroblast and epithelial markers expressed on the surface 
membrane of cells (CD90 and EpCam, respectively). GLI1 and ACTA2 
expression increased after co-culture with BXPC3 cancer epithelial cell. 
However, neither GLI1 nor ACTA2 expression increases were 
consistent in the two well repetitions performed under the same 
conditions. 
No other changes for GLI1, ACTA2 and PTCH1 expression in CAFs 
following co-culture with a panel of pancreatic cancer cells were 
observed (Figure 4.11). 
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Figure 4.11 Epithelial pancreatic primary fibroblast direct co-
cultures. GL1, PTCH1, ACTA2 gene expression analysis in P5T 
pancreatic CAFs after 48h of direct co-culture with pancreatic 
cancer cells (BXPC3 and PANC1). The gene expression of all 
target genes was showed for two different wells (bars with the 
same colors but different patterns) performed under the same 
experimental conditions as part of the same single experiment and 
was normalised to their level of expression detected in samples 
CTRL.  
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4.5  Summary of chapter 
Summarising the results observed in this chapter: 
x Shh gene and protein expression analysis was highly expressed 
in epithelial cancer cells and correlated with CDH1 expression 
suggesting that cancer epithelial cells are able to secrete the Hh ligand. 
x SMO and PTCH2 genes and Gli1 gene and protein were highly 
expressed in CAFs but a background level was also observed in 
epithelial cancer cells. GLI1 and SMO correlated with E-Cadherin 
(CDH1) but also with Vimentin and HGF supporting the possibility of Hh 
autocrine signal in cells with epithelial phenotype and a background 
pathway activity in fibroblast cells. 
x Hh pathway expression and the cell activation detected in CAFs 
after NShh treatment, TCM and 2D co-culture was variable and within 
experimental error leading to the idea that these cells were not able to 
respond to paracrine stimuli in vitro.  
This aspect and its reason will be further investigated in the next 
chapter. 
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5.1  Introduction  
 The paracrine induction of the Hh pathway investigated in CAFs in 
Chapter 4 showed the inability of these cells to respond to Hh 
exogenous stimuli. A reason for this result could be that since CAFs are 
DOUHDG\DFWLYDWHGKLJKH[SUHVVLRQRIĮ60$DQGGLIIHrentiated they are 
not able to respond to Hh stimuli. In agreement with this hypothesis, it 
has been observed that Shh can promote stromal cell differentiation into 
myofibroblast-OLNH FHOOV WHVWHG DV LQFUHDVH RI ĮSMA at the gene and 
protein levels) [Bailey et al. 2008; Zacharias et al 2011] suggesting that 
the cells able to respond to Hh paracrine stimuli are cells that are not 
fully activated or, more precisely, cells that are capable of becoming 
activated.  
To test this hypothesis, in the first part of this chapter, the 
responsiveness to Hh paracrine stimuli was tested in bone-marrow 
derived MSCs using TCM and 2D transwell assays, since MSCs are still 
undifferentiated and not DFWLYDWHGORZOHYHORIĮ60$H[SUHVVLRQ1H[W
the effect of the medium used to grow stem cells on cell activation was 
investigated; to then investigate the ability of MSCs to form an in vitro 
model of the mSCN (mesenchymal stem cell niche) (a mixed population 
comprising MSCs and myofibroblast-like cell). In Quante et al 2011 the 
formation of this mixed population was correlated with an increase in 
SHH expression. The expression of protein Shh at the stromal level 
observed in Chapter 3 of this study, also suggested the need to 
investigate Shh as a possible marker of the mSCN in aggressive 
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pancreatic tumours. Finally, the mSCN as the best context for 
investigation of the response to Hh exogenous stimuli was examined. 
A higher resolution of the IF images showed in this chapter is available 
in the CD version of the thesis. 
5.2  Investigation of the responsiveness of MSCs to Hh 
paracrine stimuli 
5.2.1  NShh treatment of MSCs 
In order to investigate the activation of the Hh pathway in bone marrow-
derived MSCs by exogenous stimuli, the cells were treated with 10nM 
NShh for 48h and harvested at different time points (3, 6 and 9 days). 
As in previous assays (Chapter 4), the Hh pathway activity was 
detected via GLI1 gene expression analysis and the effect of this 
pathway on cell activation was tested via ACTA2 gene expression 
variation (Figure 5.1). 
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A similar pattern of gene expression was observed after NShh 
treatment for both GLI1 and ACTA2. GLI1 analysis showed a fairly 
constant level of basal gene expression over time (data not shown) that 
increased, but not significantly, after NShh treatment, on day 3 and day 
9 of the culture (Figure 5.1). ACTA2 expression was also generally 
constant at a low level. No effect on ACTA2 gene expression was as 
well observed following NShh treatment (Figure 5.1).  
In order to further investigate the correlation between GLI1 and ACTA2 
gene expression, MSCs were cultured for up to 21 days and ACTA2 
and GLI1 gene expression monitored at different time points. 
Considering the previous results (Figure 5.1) NShh treatment was not 
Figure 5.1 MSC responsiveness to NShh treatment.. GLI1 and 
ACTA2 gene expression in MSCs treated with 10nM NShh. Cells were 
harvested on day 3, 6 and 9 of culture in MSCM 5%. The treatment was 
refreshed every 2 days. Each bar represents the average between the 
gene expressions detected in cells grown in two different wells. This 
value in treated samples was then normalised to the gene expression in 
CTRL samples.  A very similar trend was observed for both genes after 
NShh treatment.  
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included on this occasion. This experiment was repeated twice and the 
average of the results of two experiments is showed in Figure 5.2. 
 
 
 
 
 
 
 
 
The GLI1 and ACTA2 expression measured in this assay (Figure 5.2) 
showed a similar trend over time and the correlation analysis showed a 
significant value (Pearson P<0.01), confirming the relationship between 
these two genes and suggesting a possible interaction between the Hh 
pathway and cell activation which will be further investigated. 
5.2.2  Effect of TCM on Hh paracrine activation in MSCs 
Using the same approach used for pancreatic CAFs (chapter 4), the 
effect of tumour-conditioned medium on Hh pathway paracrine 
induction was analysed in MSCs to investigate if they are more 
responsive since they are less activated and differentiated.  
Figure 5.2 GLI1 expression correlated with ACTA2 gene expression. 
 A) GLI1 and ACTA2 expression in MSCs cultured for 21 days. Each bar 
represents the average value between two experiments. No significant 
differences in GLI1 and ACTA2 expression were observed between different 
time points (1 way ANOVA) B) Significant correlation (p<0.01) (Pearson 
correlation test) of GLI1 and ACTA2 gene expressions over time. 
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TCM was prepared by growing a panel of epithelial cancer pancreatic 
cells (BXPC3, P308T, PANC1, and PAN1) for 72h in MSCM 5%. In 
parallel, a conditioned medium (CM) to be used as control (CTRL) was 
prepared by growing MSCs under the same condition as epithelial 
cancer cells for 72h. All media were then used to grow MSCs for 3 and 
14 days. MSCs with different passage numbers (P5 and P11), which 
should have different levels of activation, were used. It is in fact 
believed that MSCs tend to become activated and produce 
myofibroblast-OLNHFHOOVLQFUHDVHRIĮ60$RYHUWKHFXOWXUH>4XDQWHet 
al 2011]. Hh pathway activity was detected via GLI1 and PTCH1 Hh 
pathway gene expression and changes in cell activation were identified 
via ACTA2 gene expression analysis (Figure 5.3).  
The analysis of ACTA2 showed low and no consistent effect of TCM in 
the induction of cell activation (Figure 5.3 C). 
 
 
197 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3 Effect of pancreatic tumour conditioned medium 
(CM) on Hh pathway expression in MSCs. .GLI1 (A), PTCH1 
(B), ACTA2 (C) gene expression analysis in MSCs grown for 3 
and 14 days in TCM prepared from a panel of epithelial pancreatic 
cancer cells (BXPC3, PANC1, P308T, and PAN1). Each gene 
expression detected in each sample was normalised to the 
sample control (MSCs grown in Control TCM). Each bar 
represents the gene expression detected in one single 
experiment. ND: not detected value (below detection limit). 
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GLI1 and PTCH1 Hh gene expression in MSCs after 3 and 14 days of 
culture showed low (<2) and inconsistent (increase and decrease) 
changes in the gene expression in comparison to the sample control 
(Figure 5.3 A, B) and so it was difficult to consider these changes a 
consistent result. However, a strong increase in GLI1 gene expression 
was observed in MSC P11 after 14 days of tumour (BXPC3, PANC1 
and PAN1) conditioning (Figure 5.3 A) suggesting that MSCs are able 
to respond to paracrine stimuli following long exposure to Hh ligand. 
The analysis of ACTA2 showed low and no consistent effect of TCM in 
the induction of cell activation (Figure 5.3). 
From the above, the only MSCs responsive to the stimuli were the late 
passage MSCs (P11) expected to be the cells with higher ACTA2 
expression. However these two cells lines (earlier and later passages) 
came from different batches and so their level of ACTA2 was not 
directly comparable as MSCs originating from different human patients 
even if at the same passage number in culture, could have different 
levels of activation. Actually, whereas CAFs were believed to be 
completely activated (figure 4.4) and so with maximal ACTA2 
expression, the activation of MSCs could be induced by a number of 
factors and so may change over time in culture. This aspect means that 
use of the same MSCs, grown in the same media and harvested at 
different passages, essential for a direct comparison between the level 
of cell activation at low and later passages. For this reason, the ability of 
MSCs to differentiate and increase ACTA2 over time in culture, a 
comparison between early and late passages of MSCs from the same 
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batch of cells was performed and the effect of ACTA2 expression on 
cell responsiveness to exogenous signals was taken into consideration. 
MSCs were grown in this assay (Figure 5.4) for 14 days considering the 
fact that this was the time point in which an effect on GLI1 expression 
was observed previously (Figure 5.3).  
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Figure 5.4 MSCs passage effects on Hh pathway paracrine 
responsiveness to TCM stimuli.. GLI1, PTCH1, ACTA2 gene 
expression analysis in MSCs at earlier (P5) (A) and later passages 
(P11) (B). MSCs were grown in TCM obtained from pancreatic tumour 
cells (BXPC3, PANC1, P308T, PAN1) for 14 days. Each bar represents 
the gene expression detected in one single experiment. 
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The analysis of PTCH1 gene expression in MSCs of higher passage 
grown in pancreatic TCM for 14 days seems to suggest some induction 
of the Hh pathway (Figure 5.4). However, the size of the changes in 
gene expression observed in this assay is still too low to be considered 
reliable and moreover, GLI1 gene expression analysis did not confirm 
the induction observed in the previous experiment (Figure 5.3), 
suggesting that these experimental conditions are not suitable for 
demonstrating paracrine induction in MSCs. 
5.2.3  Effect of 2D transwell co-culture on Hh paracrine activation 
in MSCs 
In order to further investigate the responsiveness of MSCs to Shh 
ligands and to allow a direct comparison with the CAF assays 
performed in chapter 4, MSCs at earlier and later passages from the 
same batch were grown in a trans-well co-culture assay with a panel of 
pancreatic epithelial cancer cells (BXPC3, P308T, PANC1), previously 
characterised for Shh gene and protein level (Figure 4.2). The data 
were normalised to the sample control (mesenchymal cells grown in 
trans-well with other MSCs) (Figure 5.5). 
No paracrine induction of Hh pathway gene targets (GLI1, PTCH1) was 
observed in most of the cell-lines tested after 3 days (chosen because 
is the time point when maximum confluence is reached for the cells in 
the insert) of co-culturing (Figure 5.5) suggesting no responsiveness of 
these cells in these experimental conditions. ACTA2 gene expression 
remained stable in all co-cultures performed (Figure 5.5). 
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Figure 5.5 MSCs passage effects on paracrine responsiveness 
to Hh pathway stimuli in 2D co-culture.. GLI1, PTCH1, ACTA2 
gene expression analysis in MSCs at earlier and later passages, 
co-cultured in a trans-well system with a panel of pancreatic 
epithelial cells (PANC1, BXPC3, P308T) with different levels of Shh 
gene and protein expression. Each bar represents the average 
between the gene expressions detected in two replicated wells. No 
significant differences in GLI1, ACTA2 and PTCH1 expression were 
observed between co-cultured samples and CTRL sample (Kruskal-
Wallis test). 
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In summary, NShh, TCM and 2D co-culture assays showed some MSC 
responsiveness, but only after 14 days of stimulation. An explanation of 
these results could be that the medium used to carry out all these 
assays, designed to culture stem cells, tends to maintain the MSCs in 
an inactivated and undifferentiated phenotype, but occasionally at later 
time points it could happened some level of activation. This could also 
be the reason for the variability and difficulty to see responsiveness to 
Hh exogenous stimuli in MSCs even if more responsiveness in general 
was seen with MSCs compared to CAFs.  
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5.3  Investigation of the effect of different media on MSC 
activation and Hh pathway activation 
Based on the above results, MSCM 5%, previously used in all assays 
for the investigation of stromal-like cell responsiveness to Hh ligands, 
was tested for its ability to prevent cell activation. In order to test this 
K\SRWKHVLV D FRPSDULVRQ EHWZHHQ WKH Į60$ JHQH DQG SURWHLQ
expression in MSCs at low passage (and so still able to differentiate) 
cultured in MSCM 5% and in a new free-differentiation medium was 
performed. The new medium selected to grow the MSCs in this assay 
was PCA (DMEM medium with 20% FBS), chosen for its high 
percentage of FBS, that should encourage the cell activation and 
differentiation (this is an example of a "free differentiation medium"). 
Į60$ JHQH DQG SURWHLQ H[SUHVVLRQ ZDV WKHQ DQDO\VHG RYHU WLPH LQ
MSCs grown in PCA medium and compared with that in MSCs grown in 
MSCM and harvested at the start of the experiment (sample control) 
(Figure 5.6). 
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Figure 5.6 Gene and protein expression analysis of Į60$LQ06&VFXOWXUHGin free differentiation medium. . A) ACTA2 
expression analysis in MSCs grown for 3, 7 and 14 days in DMEM 20% FBS (PCA medium), normalised to the gene 
expression detected in MSCM at the start of the experiment. Each bar represents the gene expression detected in one single 
experiment. B) 3URWHLQH[SUHVVLRQDQDO\VLVRIĮ60$ in MSCs grown in MSCM and harvested on day 0 of experiment and after 
3, 7 and 14 days in PCA medium. Squares on top: blue staining represent cells nuclei stained with DAPI and green staining 
UHSUHVHQWĮ60$H[SUHVVLRQ6TXDUHVRQWKHERWWRPĮ60$SURWHLQH[SUHVVLRQZLWKout combined DAPI staining. 
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Interestingly, after 3 days ACTA2 gene expression increased in MSCs 
grown in the PCA medium 2.5 fold. No further changes were detected 
after 7 days. After 14 days it increased an additional 2.5 times (total 5 
times) (Figure 5.6A) indicating their activation in comparison to the 
FRQWURO VDPSOH 3URWHLQ H[SUHVVLRQ RI Į60$ )LJXUH  % FRQILUPHG
the increase of the population of activated cells in PCA media. 
Moreover, immunofluorescence images on day 3, 7 and 14 suggests 
WKDW GHVSLWH D SHDN RI  Į60$-positive cells (myofibroblast-like 
population) on day 3, that dropped off at later time points (50% and 40% 
RQ GD\  DQG  UHVSHFWLYHO\ WKH PHVHQFK\PDO VWHP FHOO Į60$
negative cells survive over time (day 7, day 14) resulting in a mixed 
population.  
To further investigate the effect of MSCM (preventing differention 
medium) in maintaining MSCs in an undifferentiated or inactivated state, 
a direct comparison of the effect of GLIIHUHQWPHGLDRQĮ60$JHQHDQG
protein expression was carried out with all cells cultured in each media 
(including the medium control MSCM 5% FBS) for the same number of 
days. 
The cells were harvested at time 0 of the experiment after being grown 
in MSCM for 3 days and then split and grown in the following media: 
PCA medium (DMEM 20% FBS); DMEM 0.5% FBS; MSCM 5% FBS 
and MSCM without GF (thought to induce stem cell self-renewal) but 
containing 5% FBS (MSCM no GF). Cells were tested for the effect on 
cell activation after 72h of culture (time point already demonstrated to 
be able to induce stem cell activation). The media effect on cell 
Chapter 5 -Results: The Stem Cell Niche 
  
206 
 
activation was, as previously, tested via Į60$ SUotein and gene 
expression analysis (Figure 5.7). The aim of this experiment was to test 
if MSC cells would remain undifferentiated in MSCM, while an increase 
RIĮ60$H[SUHVVLRQLQDOO'0(0PHGLDDQGSUREDEO\LQ06&0ZLWKQR
GF added (all considered free differentiation media) was anticipated. 
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Figure 5.7 MSCM prevented the activation of MSCs over time.. A) ACTA2 expression in MSCs grown for 72h in different 
media with different percentage of FBS (MSCM 5% FBS, DMEM 0.5% FBS, MSCM no GF 5% FBS, PCA 20% FBS). Each bar 
UHSUHVHQWV WKHUHVXOWVRIRQHVLQJOHH[SHULPHQW%Į60$SURWHLQH[SUHVVLRQ LQ06&VJURZQIRUK in the same media of 
)LJXUH$7RSURZ06&VZLWKQXFOHLVWDLQHGZLWK'$3,EOXHDQGĮ60$VWDLQHGLQJUHHQ%RWWRPURZVDPHLPDJHVZLWKRXW
DAPI staining. 
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ACTA2 gene and protein expression (Figure 5.7 A and B) increased in 
all media considered ³free differentiation medium´  WLPHV LQ'0(0
0.5% and 3.2 times in PCA media) in comparison to cells grown in 
MSCM and MSCM with no GF for 72h. This result seems to suggest no 
role for the growth factors normally added to MSCM in preventing cell 
differentiation. Moreover, no increase in Į60$SURWHLQH[SUHVVLRQZDV
observed after 72h of MSCs cultured in MSCM and MSCM with no GF 
in comparison to MSCs harvested from MSCM at day 0 of culture 
(Figure 5.7B). These data strongly suggest that MSCM slow down the 
activation of MSCs that, when free to differentiate, tend to form a mixed 
population. 
5.3.1  In vitro investigation of Hh pathway in MSCs cultured in 
µ¶IUHHGLIIHUHQWLDWLRQ¶¶PHGLXP 
In order to investigate the role of the Shh ligand expression in the 
stromal context observed in chapter 3 and to further investigate the 
relationship between the Shh pathway and cell activation, Shh, Ptch1 
and Gli1 expression were investigated in MSCs grown for 14 days in 
PCA medium. GLI1 expression increased in PCA medium (Figure 5.8 
A), supporting the idea that Hh pathway activation increases in parallel 
with the increase of myofibroblast-like cell differentiation. Moreover, the 
SHH expression showed an increase of 2.6 times after 3 days of culture 
in PCA medium in comparison to the level of gene expression detected 
in cells grown in MSCM (Figure 5.8A). Consistent with gene expression 
analysis, Shh protein expression increased on day 3 (80% Shh positive 
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cells) and, aVIRUĮ60$SURWHLQ expression (Figure 5.6B), dropped again 
after 7 (60% Shh positive cells) and 14 (40% Shh positive cells) days 
(Figure 5.8B). 
In this assay, Ptch1 expression was also investigated at the protein 
level as further confirmation of the results observed. From this analysis 
(Figure 5.8C) a similar trend for Ptch1 protein expression to that 
observed for the Shh protein expression trend was observed (Figure 
5.8B). An important aspect of this result is that Ptch1 gene and protein 
expression do not match. This apparent inconsistency of results could 
be a consequence of the negative feedback that Ptch1 exerts on the Hh 
pathway [Goodrich et al 1999]. Therefore, in future experiments protein 
expression rather than gene expression was measured as a more 
reliable indicator of Hh pathway activity.  
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Figure 5.8 Hh pathway expression in MSCs 
cultured in free differentiation medium .A) SHH, 
PTCH1, and GLI1 expressions in MSCs grown in 
PCA media for 14 days. The cells were harvested 
after 3, 7 and 14 days of culture and the gene 
expression was normalised to samples control (MSCs 
grown in MSCM until the start of the experiment) 
Each bar represents the results of one single 
experiment. B) Shh and C) Ptch1 protein expression 
in the same cells as (A). IF staining for each protein 
analysed (green) was shown either with (top) or 
without (bottom) nuclear DAPI. 
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The Hh pathway was also studied in the MSCs cultured in free 
differentiation media (Figure 5.9) previously WHVWHGIRUĮ60$expression 
(Figure 5.7). 
Interestingly SHH gene expression increased in DMEM 0.5% 
reinforcing the idea that it was expressed when a myofibroblast-like 
population was present. However, no increase was observed at the 
gene level in PCA medium (Figure 5.9A). GLI1 expression (Figure 5.9B), 
as confirmation of Hh pathway activation when myofibroblast-like cells 
were present, increased in free-differentiation media (DMEM 0.5%; 
PCA) as well as in MSCM no GF confirming the results achieved so far. 
Moreover, consistent with the gene expression analysis, Shh (Figure 
5.9 C) and Ptch1 (figure 5.9D) protein were highly expressed (80% of 
Shh positive cells) in free differentiation media (DMEM 0.5%; PCA and 
MSCM no GF) in comparison to MSCM.  
In summary, the above data suggest a tendency for MSCs to become 
myofibroblast-like DFWLYDWHG FHOOV Į60$ LQFUHDVH 0RUHRYHU, 
expression of the Shh signalling pathway seems to occur when the 
myofibroblast-like population forms. 
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Figure 5.9 Media effect on Shh signalling pathway expression in MSCs..  SHH (A) and GLI1 (B) expression in MSCs grown in 
DMEM 0.5% FBS, MSCM 5% FBS, MSCM no GF 5%, PCA 20% FBS media for 72h. The gene expression was normalised to 
samples control (MSCs grown in MSCM for 72h from the start of experiment).Each bar represents the results of one single 
experiment. Shh (C) and Ptch1 (D) protein expression in MSCs grown in MSCM 5% FBS and harvested at the start of the 
experiment, and also grown for 72h in MSCM 5% FBS, DMEM 0.5% FBS, MSCM no GF 5% FBS and in PCA medium. IF staining 
for each protein analysed was shown either with (rows on top) and without (bottom rows) nuclei stained in blue with DAPI. 
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5.4  Investigation of the effect of TGF-ȕ RQ WKH
differentiation of MSCs and Hh pathway expression 
The role of TGF-ȕ LQ WKHDFTXLVLWLRQ of a myofibroblast-like phenotype 
either as a result of MSC differentiation or EMT has been shown in the 
literature demonstrating the importance of this factor in the tumour 
context and in its progression [Hu et al 2003; Bardeesy et al 2006]. 
Therefore, the role of TGF-ȕ IXQFWLRQ in stimulating MSCs to 
differentiate into myofibroblasts and the consequent effects on Hh 
pathway activation was analysed. 
5.4.1  TGF-ȕHIIHFWRQ06&DFWLYDWLRQ 
Initially, MSCs grown in PCA media (DMEM 20%) for 14 days were 
treated with TGF-ȕ (10 ng/ml), with treatment refreshed every 2 days. 
As controls, MSCs were grown in PCA medium without any TGF-ȕ 
treatment. ACTA2 gene expression detected in treated samples was 
normalised to the gene expression in samples control (untreated cells). 
7KH FHOOV ZHUH KDUYHVWHG DQG DQDO\VHG IRU Į60$ gene and protein 
level on day 3, day 7 and day 14 (Figure 5.10).  
In this experiment, ACTA2 expression increased after the treatment 
suggesting MSC responsiveness to TGF-ȕ WUHDWPHQW Figure 5.10A). 
However, Į60$ SURWHLQ H[SUHVVLRQ DQDO\VLV GLG not confirm the 
induction observed at the gene level (Figure 5.10B). This discrepancy 
could be due to the fact that often changes in gene expression require 
more time to be visible at the protein level.
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Figure 5.10 Effect of TGF-ȕ on MSCs activation in PCA free differentiation media.. Į60$ JHQH (A) and 
protein (B) expression in MSCs grown in PCA medium and harvested after 3, 7, 14 days of culture. Gene 
expression in treated samples were normalised and compared respectively to the samples control (untreated cells 
harvested on day 3, 7 and 14 of the culture). Each bar represents the results of one single experiment. IF staining 
was shown with (top row) and without (bottom row) blue nuclei stained with DAPI. 
B) 
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To test the effect of FBS concentration on TGF-ȕ UHVSRQVLYHQHVV 
MSCs (same cells used in Figure 5.7) were treated with 10 ng/ml TGF-ȕ
in different media with different percentages of FBS (DMEM 0.5%FBS; 
PCA; MSCM 5% FBS; MSCM 5% FBS with no GF).  
HLJKHU Į60$ expression both at the gene and protein level was 
observed in TGF-ȕ treated samples when grown in free differentiation 
media (DMEM 0.5%; PCA) and in MSCM with no GF, in comparison to 
control samples (untreated cells grown in the same media), confirming 
the role of TGF-ȕ in the induction of myofibroblast-like differentiation 
(Figure 5.11 A and B). Finally, immunofluorescence images suggest a 
PRUHKRPRJHQHRXVSRSXODWLRQRIĮ60$SRVLWLYHFHOOV (80-90% in both 
FDM) than the population observed in the controls suggesting a role of 
TGF-ȕ treatment in pushing inactivated cells to an activated state 
resulting in a single, activated population rather than a mixed population 
(Figure 5.11B). 
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Figure 5.11 Different media effect on TGF-ȕtreatment of MSCs.. Į60$JHQH(A) and protein expression (B) in MSCs grown for 
72h in DMEM 0.5% FBS; PCA; MSCM 5% FBS; MSCM 5% FBS with no GF (only gene expression analysed). In figure (A) treated 
samples were normalised and compared to the sample controls (untreated cells grown for 72h in all media tested). Each bar shows 
the results of one single experiment.  IF staining was shown with (top row) and without (bottom row) blue nuclei stained with DAPI. 
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5.4.2  TGF-ȕ(IIHFWRQWKH Hh pathway 
In order to investigate the TGF-ȕeffect on the Hh pathway, Shh gene 
and protein expression and Ptch1 protein expression were investigated 
in MSCs grown for 3, 7 and 14 days in PCA medium and treated with 
10 ng/ml TGF-ȕ and in MSCs grown in different media with different 
percentage of FBS (DMEM 0.5% FBS, PCA, MSCM 5% FBS, MSCM 
with no GF) treated with the same concentration of TGF-ȕQJPODV
above. The MSCs included in both these assays were the same ones 
used in sections 5.2 and 5.3.1.  
The aim of this analysis was to investigate the role of TGF-ȕ in the 
promotion of Shh gene and protein expression and its downstream Hh 
gene pathway activity (GLI1, PTCH1), and provide information on the 
FRUUHODWLRQEHWZHHQĮ60$SRVLWLYHFHOOVDQG6KKexpression under the 
effect of TGF-ȕWUHDWPHQW. 
SHH gene expression in MSCs grown in PCA medium  (Figure 5.12A) 
showed a small increase after 3 days of culture, but in general, a 
reduction in expression was observed both for Shh at gene (Figure 5.12 
A) and protein (Figure 5.12 C) expression and Ptch1(Figure 5.12 D) at 
protein expression on day 7 and 14. These results seem to suggest an 
inhibitory effect of TGF-ȕ RQ +K SDWKZD\ Interestingly, GLI1 gene 
expression (Figure 5.12 B) showed an independent trend very similar to 
ACTA2 gene expression (Figure 5.10 A). 
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Figure 5.12 Effect of TGF-ȕWUHDWPHQWRQ+KSDWKZD\H[SUHVVLRQLQ06&Vcultured in PCA free differentiation media.. SHH (A), GLI1 
(B) expression in MSCs grown in PCA medium for 3, 7 and 14 days. Gene expression in treated samples was normalised and compared 
respectively to the samples control (untreated cells harvested on day 3, 7 and 14 of the culture). Shh (C) and Ptch1 (D) protein expression 
before and after treatment with 10ng/ml TGF-ȕ,)VWDLQLQJZDVVKRZQIRUHDFKSURWHLQZLWK(top row) and without (bottom row) blue nuclei 
stained with DAPI. 
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In agreement with the results observed in PCA medium (Figure 5.12), 
GLI1 gene expression (Figure 5.13 A), unlike other Hh pathway genes 
tested, increased markedly in MSCs grown in various media after TGF-
ȕ treatment with the GLI1 expression pattern matching that of ACTA2 
(Figure 5.11) as already observed also in section 5.2 where no 
treatment was included (Figure 5.2). These results seem to indicate that 
the correlation observed is more a consequence of D7*)ȕ-dependent 
non-canonical pathway than an effect due to Hh signalling activation. 
Consistent with what was observed in the previous assay performed in 
PCA media (Figure 5.12), TGF-ȕ treatment of MSCs cultured in 
different media (Figure 5.13), resulted in a decrease in Hh pathway 
gene expression detected as SHH (Figure 5.13 B) in all media tested.  
 
 
 
Figure 5.13 TGF-ȕWUHDWPHQWHIIHFWRQ+KSDWKZD\gene expression in 
MSCs grown in different media.. GLI1 (A) and SHH (B) expression +/- 
TGF-ȕWUHDWPHQWIRUKLQ06&Vcultured in DMEM 0.5%FBS, MSCM 5% 
FBS, MSCM no GF 5% FBS, PCA 20% FBS medium. Each bar represents 
the results of one single experiment. 
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Nevertheless, Shh and Ptch1 protein expression analysis did not show 
the same effect (Figure 5.14), but an increase in expression especially 
in medium with lower amounts of FBS. It seems probable that the high 
OHYHORI)%6LQWKH3&$PHGLXPFRXOGKDYHKLGGHQWKHHIIHFWRI7*)ȕ
treatment. The discrepancy between gene and protein expression may 
be due to a cross-reaction between the Gli1 non canonical activation 
from TGF-ȕSDWKZD\DQGWKH*OLUHJXODWLRQIURPWKH+KSDWKZD\  
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Figure 5.14 Effect of TGF-ȕ WUHDWPHQWRQ+KSDWKZD\H[SUHVVLRQ LQ06&VJURZQ LQ different media.. Shh and 
Ptch1 protein expression in MSCs +/- TGF-ȕWUHDWPHQWSHUIRUPHG in DMEM 0.5%FBS, MSCM 5% FBS, MSCM no GF 
5% FBS, PCA 20% FBS medium. IF staining for each protein analysed, was shown either with (rows on top) and without 
(bottom rows) nuclei stained in blue with DAPI. 
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.Correlation analysis of ACTA2 and GLI1 expression after 7*)ȕ
treatment (Figure 5.15) supported the hypothesis of ACTA2 and GLI1 
FRUUHODWLRQ XQGHU 7*)ȕ WUHDWPHQW showing a significant relationship 
between these two genes. 
 
 
 
 
 
 
 
 
 
This raises questions about the relationship between Shh DQG Į60$
expression that will be further investigated in the next section of this 
chapter. 
 
 
 
 
 
Figure 5.15 Correlation analyses between GLI1 and ACTA2 gene 
expression after TGF-ȕWUHDWPHQW. Pearson correlation analysis  
(*P<0.05) of ACTA2 and GLI1 expression after 10ng/ml TGF-ȕ
treatment of MSCs cultured in different media. 
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5.5  The mesenchymal stem cell niche and the 
establishment of an in vitro model 
In previous sections, the expression of Shh gene and protein 
expression increased, especially after 3 days of culture, when MSCs 
cultured in free differentiation medium became activated. A study has 
previously suggested the ability of MSCs to form a mSCN by 
differentiating into myofibroblast-like cells, with SHH gene expression 
only found in a mixed population formed by mixing bone marrow MSCs 
and myofibroblast cells but not in either population alone (Quante et al 
2011). Moreover, the role of the Hh pathway in the stem cell niche was 
hypothesised and supported by the literature [Yeung et al 2011; Quante 
et al 2011; Alison et al 2012]. 
Considering the results in this chapter so far, the in vitro formation of 
the mSCN was analysed by artificially mixing MSCs and myofibroblast-
like cells or primary pancreatic CAFs, in order to further investigate the 
role of Shh in this context and to understand if it can be considered a 
marker of the mSCN; this could be important in understanding the role 
of the Hh pathway in pancreatic cancer.  
The constitution of the mSCN model was analysed by investigating not 
MXVW 6KK EXW DOVR H[SUHVVLRQ RI Į60$ WR examine the formation of 
myofibroblast cells in this context) and the expression of two new 
markers, Nestin (a marker of mesenchymal stem cells) and Periostin (a 
marker of myofibroblast cells that is highly expressed when these cells 
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are part of the mesenchymal stem cell niche) [Mendez-Ferrer et al 2010; 
Quante et al, 2011;Malanchi et al 2012]. 
5.5.1  Investigation of Shh as marker of the stem cell niche 
In order to investigate the Shh gene and protein expression in the stem 
cell niche context, an in vitro model of the mSCN model was 
established by mixing MSCs, treated ZLWK7*)ȕ for one week in MSCM 
with no GF added (medium that showed the highest induction of ACTA2 
expression after 7*)ȕ treatment (Figure 5.11 A)), with MSCs at low 
passage (P4 PD3) and cultured in MSCM until the moment of mixing in 
order to keep them undifferentiated. The mixed population was then 
cultured for 12 days and analysed on day 0, day 2 and day 12. The 
DMEM 10% FBS was chosen as the media to be used in this and the 
following experiments. 10% of FBS concentration was chosen as being 
high enough to keep the cells healthy for 12 days of culture (higher than 
0.5% FBS previously used for cell cultures not longer than 3 days), but 
not high enough to push the activation process too far (as the PCA 
medium in figure 5.14). The effect of the mSCN model on SHH gene 
expression was investigated by calculating the difference between the 
level of expression detected in the mSCN compared with the level of 
expression attained as a result of calculating the average between the 
expression values detected in the original single populations (MSCs 
and myofibroblast like cells (MF-like)) i.e. [(MSCs 2-¨&W)/2 + (MFs 2-
¨Ct)/2]. The SHH expression increased by 25 times in the mixed 
population after 2 days of culture (Figure 5.15A). However, this effect 
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did not persist over time, and by day 12 no difference was observed 
(Figure 5.16A).  
Shh protein expression (Figure 5.16B) analysis confirmed the high 
expression in the mixed population, but only after 12 days rather than 
after 2 days, as expected from the gene expression, perhaps due to the 
fact that the increase in protein expression requires more time to 
become visible. Shh gene and protein expression (Figure 5.16B and C) 
also increased in MSCs on day 2 and day 12 in comparison to day 0. 
The same analysis in the MF-like population showed instead a much 
lower level of Shh gene and protein expression, reinforcing the idea of 
Shh being expressed less in highly differentiated populations.  
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 Figure 5.16 Investigation of SHH gene expression in a stem cell niche in vitro model.. A) Comparison between the SHH 
expression calculated by using the formula [(MSCs 2-¨&W)/2 + (MFs 2-¨&W)/2] and the actual SHH expression measured by qPCR-RT in 
the 1/1 Niche= MSCs/MF. Each bar represents one single experiment. B) Protein expression in MSCs, myofibroblast-like cells, and 
mixed population (1/1 ratio of MSCs and MF-like cells) All cell populations included were cultured for 12 days in DMEM 10% FBS. IF 
images show cells with (first, third and fifth column) and without (second, fourth and sixth columns) the nuclei stained with blue 
(DAPI). C) SHH gene expression in single populations: MSCs and MF-like cells. 
MSC D0                                                                                                  MF D0
MSC D2                                     Niche 1/1 D2                                        MF D2
MSC D12                                   Niche 1/1 D12                                   MF D12
Shh Expression
B) 
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The same samples ZHUHDOVR LQYHVWLJDWHGIRUĮ60$JHQHDQGSURWHLQ
expressions and POSTN and NES gene expressions to better 
characterise their stem cell niche properties. The basal expression of 
POSTN (5.17A) is believed to increase in MF-like cells when they are 
part of a mixed population in comparison to single population. Therefore, 
higher expression of POSTN was expected in the mSCN model (the 
actual value higher than the calculated value) in comparison to the 
single populations (MSCs and MF-like population) that constitute the in 
vitro mSCN. However, no differences were observed in this comparison 
(Figure 5.17A).  
ACTA2 (Figure 5.17B) and NES (Figure 5.17C) gene expressions were 
used, as explained, to assess the presence of MF-like and MSC 
populations respectively over time. Both ACTA2 and NES, being 
markers of single populations, were expected not to show any 
difference between the actual and the calculated values in the in vitro 
mSCN model. The ACTA2 expression analysis did confirm this 
expectation, both after 2 and 12 days of culture. The NES gene 
expression, like the ACTA2 expression, did not show differences 
between the actual and calculated value in the mSCN model after 2 
days of culture. However, a small change (2 times) was observed after 
12 days of culture.  
Interestingly, POSTN and ACTA2 in the mSCN model (Niche 1/1) 
(Figure 5.17A and B) and in MSCs(Figure 5.17D and E) increased over 
time, indicating the generation of MF-like cells in these two populations 
(as already observed in a previous section (5.3) of this chapter, and in 
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agreement with Quante et al 2011). This result confirmed the ability of 
unmixed MSCs to be activated and to form a myofibroblast-like cell 
population when grown in a free differentiation medium. MF-like cells 
showed a variable but high level of POSTN (Figure 5.17D) and ACTA2 
(Figure 5.17E) gene expressions consistent with the cells being 
activated. The decrease in these two genes on day 2 in the MF-like 
FHOOVPD\EHGXHWRVWRSSLQJ7*)ȕWUHDWPHQWDQGVHHPVWRVXJJHVWD
reversibility of cell activation when no stimuli are present. NES gene 
expression (Figure 5.17 C and F) was fairly constant over time in all the 
populations tested, suggesting that Nestin is not a good marker for 
detecting changes in the stem cell population in the mSCN model. 
However, it will be further investigated in other mSCN models analysed 
later in this chapter.  
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Figure 5.17 Investigation of stem cell niche marker gene expression in a 
stem cell niche in vitro model. .Comparison between POSTN (A), ACTA2 
(B) and NES (C) gene expression calculated by using the formula: [(MSCs 2-
¨Ct)/2 + (MFs 2-¨&W)/2] and their actual expression measured by qPCR-RT in the 
1/1 Niche= MSCs/MF. POSTN (D), ACTA2 (E), NES (F) gene expression in 
MSCs and myofibroblast-like cells (MF). All cell populations were cultured for 
12 days in DMEM 10% FBS. The cells were harvested on day 0, 2 and 12 of 
the culture. Each bar is the result of one single experiment
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ĮSMA protein expression analysis (Figure 5.18) as well as the gene 
expression (5.17 B and E) increased over time in the mSCN model and 
LQ06&V0RUHRYHUĮ60$SURWHLQH[SUHVVLRQDOVR LQFUHDVHGRYHUWLPH
in the MF-like cells.----------------------------------------------------------
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Figure 5.18 Investigation of Į60$protein expression in a stem cell niche in vitro model.. Į60$
protein expression in MSCs, mSCN model (Niche 1/1) and myofibroblast-like cells (MF) cultured for 12 
days in DMEM 10% FBS. The cells were harvested on day 0, 2 and 12 of the culture. IF images shows 
cells with (first, third and fifth column) and without (second, fourth and sixth column) nuclei stained with 
DAPI (blue). 
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Considering the results observed in the previous assay, the SHH 
expression was also tested using different ratios of MSCs and MF-like 
FHOOV DJDLQ REWDLQHGE\ WUHDWLQJ 06&V ZLWK 7*)ȕ IRU RQH ZHHN DQG
was compared to MSCs and MF-like cell single populations. As 
previously, a direct comparison between the data for Niche 3/1 
[(3*(MSCs 2-¨&W) + (MFs 2-¨&W))/4] and Niche 1/3 [(3*(MFs 2-¨&W) + (MSCs 
2-¨&W))/4] and the calculated values (used as representative values of the 
contribution of the single populations to the gene expression in the 
niche models) was performed. The assay was run for a longer time (21 
days) in order to further investigate the effect of Shh over time, and 
harvested on days 0, 2, 12, and 21. Interestingly, the greatest `up-
regulation of SHH gene expression in the mSCN model (Figure 5.19) 
was observed exclusively in the Niche 1/3 model. In fact, the 
comparison between the SHH gene expression value in Niche 1/3 
model calculated as :[(3*(MFs 2-¨&W) + (MSCs 2-¨&W))/4] and the actual 
values on day 2 , day 12 and day 21 were increased 1.3, 2.1 and 2.8 
times respectively. The same comparison between Niche 3/1 model 
calculated as :[(3*(MSCs 2-¨&W) + (MFs 2-¨&W))/4] and the actual value did 
not show a SHH expression increase either on day 2 or day 12 or day 
21.  Moreover, the SHH gene expression level in this experiment 
remained high on day 21 both in the Niche 3/1 and in the Niche 1/3 
samples, without any decrease as observed in the previous assay 
(Figure 5.19 A). 
Even if the SHH expression increase observed in the mSCN model 1/3 
ratio was not as high as that observed in the previous experiment 
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)LJXUHLQWKLVODWHUH[SHULPHQWDWLPHSRLQW¶VGHSHQGHQWLQFUHDVH
was shown, reinforcing the reliability of this evidence. 
The analysis of SHH expression in the single populations (MSCs and 
MF-like cells) showed, consistent with the previous experiment, (Figure 
5.16) an increase in MSCs of  2.15 times on day 2 that drops down on 
day 12 and day 21(Figure 5.19B). SHH expression in MF-like cells even 
if increased in comparison to day 0 ( 4 and 5.7 times respectively on 
day 12 and day 21), maintained a lower level of expression in 
comparison to the other cell populations (MSCs and Niche 3/1)(Figure 
5.19B).---------------------------------------------------------------------------
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Figure 5.19 Investigation of SHH gene expression in different 
ratios of MSCs and MF-like cells in the mSCN in vitro model.. A) 
Comparison between SHH expression detected in Niche 1/3 model 
and the calculated value [(3*(MFs 2-¨&W) + (MSCs 2-¨&W))/4] and between 
SHH expression in Niche 3/1 model and the calculated value 
[(3*(MSCs 2-¨&W) + (MFs 2-¨&W))/4 on day 2, 12 and 21. B) SHH 
expression in MSCs and myofibroblast-like cells (MF) single 
populations cultured for 2, 12, 21 days in DMEM 10% FBS. Each bar 
represents one single experiment. 
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Consistent with the results on the SHH gene expression analysis 
(Figure 5.18A), POSTN expression (Figure 5.20 A) slightly increased 
exclusively in the 1/3 Niche model on day 12 (i.e POSTN expression 
increased 1.4 times in the Niche 1/3 model in comparison to the single 
populations as shown from the comparison between the 
calculated :[(3*(MFs 2-¨&W) + (MSCs 2-¨&W))/4] and the actual value). 
However, this increase was quite low, it was not present on day 2 and it 
dropped down on day 21. The comparison between the calculated and 
actual values for ACTA2 (Figure 5.20 B) and NES (Figure 5.20 C) 
expressions in the Niche 1/3 and in the 3/1 models did not show any 
difference confirming the hypothesis. ACTA2 and POSTN gene 
expressions in the single populations (MSCs and MF-like cells) (Figure 
5.20 D and E) showed a significant increase in MF-like cells (ACTA2, 
POSTN positive cells) over time. The NES gene expression (Figure 
5.20 F) showed a constant expression over time in all cell populations 
tested.---------------------------------------------------------------
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Figure 5.20 Investigation of mSCN marker gene expression in different mSCN model co-culture ratios.. Comparison of 
the POSTN (A) ACTA2, (B), NES (C) expression between the actual and calculated values in 2 mixed population (3/1 and 1/3  
ratio of MSCs and MF like cells) cultured for up to 21 days in DMEM 10% FBS. The cells were harvested on days 0, 2, 12, and 
21 of the culture. POSTN (D), ACTA2 (E), NES (F) expression in MSCs, myofibroblast-like (MF) cells cultured for 21 days in 
DMEM 10% and harvested on day 2, 12 and 21.Each bar represents one single experiment. 
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Finally, the effect of mixing in 1/1 ratio [that previously showed an 
increase of SHH gene expression (figure 5.16)] MSCs and primary 
pancreatic CAFs on Shh gene and protein expression was tested over 
21 days in culture (Figure 5.21 A). As previously, cells were harvested 
on day 2, 12 and 21 and the effect of cell mixing was analysed as the 
difference between the calculated [(MSCs 2-¨&W)/2 + (CAFs 2-¨&W)/2]   and 
the actual SHH gene expression (Figure 5.21 A). In this experiment Shh 
gene (Figure 5.21 A) and protein expression (Figure 5.21 C) increased 
in the mixed population in comparison to both single populations after 2 
days of culturing (Figure 5.20 A and B). However, the level of SHH 
gene expression in the Niche  (MSCs + CAFs) 1/1 model on day 2 was 
around 4 times and 64 times lower than in the previous experiment 
(Figure 5.19 A) and in the first experiment (Figure 5.16 A) respectively, 
suggesting a less strong effect of CAFs on the mSCN model than MF-
like cells. As for one of the experiments with MF-like cells (Figure 5.16), 
the increasing effect on SHH gene expression in the mSCN model was 
not observed on day 12 and 21 (Figure 5.21 A).  The SHH expression in 
single populations (MSCs and MF-like cells) strongly increased, as in 
the previous experiments (figure 5.16A and 5.19A), in the MSCs after 2 
days and moreover the increase was maintained over time. 
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Figure 5.21 Investigation of the effect of CAFs on mSCN in vitro 
model and SHH gene and protein expression. A) Comparison between 
SHH actual gene expression value and the calculated one in the mixed 
population Niche 1/1 (1/1 proportion of MSCs and CAFs) after 2, 12 and 21 
days of culture in DMEM 10% media. B) SHH gene expression in MSCs 
and pancreatic tumour-derived CAFs grown for 2, 12, 21 days in DMEM 
10% FBS. Each bar represents one single experiment. C) Comparison 
between Shh protein expression on day 2 in co-cultured MSCs and CAFs 
cells (Niche 1/1) with MSC and CAF single populations harvested at the 
same time point. All cell populations were grown in DMEM 10% free 
differentiation medium. IF images shows cells with (top row) and without 
(bottom row) nuclei stained with DAPI (blue). 
C) 
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Interestingly, POSTN expression analysis (Figure 5.22 A) showed a 
15.8 and 4 times higher actual value than the calculated one after 12 
and 21 days respectively. The same analysis performed for ACTA2 
(Figure 5.22 B) and NES (Figure 5.22 C) expressions, as expected, did 
not show relevant differences between the calculated and the actual 
values (Figure 5.22 B and C). POSTN (Figure 5.22 A and D) and 
ACTA2 (5.22 B and E) gene expressions generally increased over time 
in all cell populations tested (MSCs, mSCN model, CAFs) confirming 
earlier observations. Interestingly, POSTN gene expression in CAFs 
(Figure 5.22 D) showed a lower level of expression in comparison to the 
other populations, confirming the hypothesis that it increases its 
expression in fibroblasts when part of a mSCN. Consistently, a much 
higher POSTN expression was observed in the mSCN model in 
comparison to single populations at all time points tested (18.6 and 90.2 
times on day 2; 69.3 and 9.5 times on day 12; 2.2 and 16.5 times on 
day 21 in comparison to MSCs and CAFs respectively) (Figure 5.22 A 
and D).  
The NES gene expression (Figure 5.20 C) did not change in any 
population tested and the fact that it is also expressed in CAFs  
demonstrates that it is not suitable as a marker of stem cells in the 
mSCN niche model and for this reason it was no longer used. 
7KH 3RVWQ )LJXUH  DQG Į60$ )LJXUH  SURWHLQ H[SUHVVLRQ
increased over time in all population including an unexpected increase 
in CAF cells (believed to be cells already fully activated).
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Figure 5.22 Investigation of the effect of CAFs on mSCN marker expression in an in vitro model.. Comparison between the 
actual and calculated value of the POSTN (A), ACTA2 (B), NES (C) gene expression in a mSCN model (1/1 MSCs/CAFs ) after 2, 12 
and 21 days of culture in DMEM 10%. POSTN (D), ACTA2 (E) and NES (F) gene expressions in MSCs and pancreatic CAFs grown 
for 2, 12, 21 days in DMEM 10% FBS. Each bar represents one single experiment. 
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MSC D2                        Niche 1/1 D2                           CAFs D2
MSC D12                      Niche 1/1 D12                        CAFs D12
MSC D21                       Niche 1/1 D21                       CAFs D21
Figure 5.23 Investigation of the effect of CAFs on Postn protein expression in a mSCN in vitro model .Postn 
protein expression in MSCs, pancreatic CAFs and mixed population Niche 1/1 (1/1 proportion of MSCs and CAFs) 
grown for 2, 12, 21 days in DMEM 10% FBS. IF images shows cells with (first, third and fifth column) and without 
(second, fourth and sixth column) nuclei stained with DAPI (blue). 
242 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ɲ^D
MSC D2                        Niche 1/1 D2                           CAFs D2
MSC D12                      Niche 1/1 D12                        CAFs D12
MSC D21                       Niche 1/1 D21                       CAFs D21
Figure 5.24 ,QYHVWLJDWLRQRIWKHHIIHFWRI&$)VRQWKHĮ60$SURWHLQH[SUHVVLRQLQDmSCN in 
vitro model. Į60$SURWHLQH[SUHVVLRQLQ06&VSDQFUHDWLF&$)VDQGPL[HGSRSXODWLRQ1LFKH
(1/1 proportion of MSCs and CAFs) grown for 2, 12, 21 days in DMEM 10% FBS. IF images shows 
cells with (first, third and fifth column) and without (second, fourth and sixth column) nuclei stained 
with DAPI (blue). 
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Summarising the results in this section: 
x Shh gene and protein expression increased in a mSCN in vitro 
model obtained by mixing MSCs and MF-like in different ratios. 
An increase in Shh was also observed in MSCs alone over time, 
WRJHWKHU ZLWK DQ LQFUHDVH LQ Į60$ DQG Postn suggesting that 
MSCs alone when cultured in FDM are able to form a mixed 
population that is maintained over time. This may explain why at 
times the mixed population does not appear to maintain 
increased Shh gene and protein expression in comparison to 
component populations. 
x MF-like cells showed an increase in Shh expression, albeit at a 
low level, that suggests this cell population is an impure single 
population consisting of a low proportion of MSCs and a high 
proportion of MF-like cells.  
x POSTN expression seems to be good markers of MF-like cells 
population and it is express at higher level when MF-like 
cells/CAFs are mixed with MSCs (mSCN in vitro models). 
x  7KH LQFUHDVHRI WKHĮ60$DQG3RVWQH[SUHVVLRQ LQ&$)FHOOV
over time revealed that on day 0 of the cell culture they cannot 
be considered fully activated cells. It also suggests WKDW Į60$
and Postn are markers of cell activation rather than 
differentiation and shows how their expression depends on 
external signals such as growth factors in free differentiation 
media, presumably also present in the tumour microenvironment. 
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5.5.2  Investigation of Shh expression in the mesenchymal stem 
cell niche  
The previous data do not assess if Shh is expressed from MF-like cells 
that expand over time in a culture of MSCs grown in free differentiation 
medium or is exclusively expressed, probably from MF-like cells, in 
mixed and not single populations. A direct comparison between the 
mSCN model with CAFs (activated cells) and MSC single populations 
over time had not been carried out since the previous experiments were 
all performed in free-differentiation media in which MSCs can become a 
mixed population over time. Even the MF-like cells used in this study, 
RULJLQDWHGIURP06&VWUHDWHGZLWK7*)ȕDVVDLGFRXOGEHFRQVLGHUHG
a mixed population with a high number of MF-like activated cells. 
For this reason, in this section, WKHVWHPFHOOQLFKHPDUNHUV6KKĮ60$ 
and Postn), used so far, were analysed on day 2, 12 and 21 in MSCs 
cultured in MSCM throughout their culture (named MSC single 
population, MSC S.P.), in a mSCN model obtained by growing MSCs in 
free differentiation medium (DMEM 10 %) and in CAFs grown in DMEM 
10% demonstrated to be an activated population when cultured in this 
medium. The comparison between the mSCN model and the 2 single 
populations analysed in this assay showed the gene(Figure 5.25 A)  
and protein (Figure 5.25 B) expression of Shh exclusively in the mixed 
population and confirmed the ability of MSCs alone to form a mSCN in 
vitro model when grown in FDM. Very low Shh gene and protein 
expression was observed on day 2 in all cell populations, but increased 
Shh expression was detected on day 14 and day 21 in MSCs grown in 
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free differentiation medium (mSCN model) (Figure 5.25 A and 
B).....««««««««««««««««««««««««««.
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Figure 5.25 Investigation of Shh as marker of stem cell niche.. Shh gene (A) and protein expression (B) in MSCs single 
population (S.P.), mSCN in vitro model and CAFs differentiated cells. Each bar represents one single experiment. IF images 
show cells with (first, third and fifth column) and without (second, fourth and sixth column) nuclei stained with DAPI (blue). 
Shh
MSC S.P. D2                 SCN Model D2                     CAFsD2
MSCs S.P. D21                     SCN model D21                   CAFs D21
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Further analysis of these samples showed that there was an increase in 
activated Postn-positive cells (Figure 5.26 A and B) in the mSCN model 
and in the CAFs cells and a very low increase of these markers in MSC 
S.P.  POSTN expression strongly increases in the mSCN model on day 
21 showing a higher expression than in the single populations, 
consistently with its definition as a marker of MF-like activated cells that 
increases when they are part of a mixed population. The increase of 
expression of Postn in CAFs is steady with their activation over time in 
a free-differentiation medium but at lower level than in the mSCN model.  
Į60$ JHQH DQG SURWHLQ H[SUHVVLRQ )LJXUH  $ DQG % VXFK DV
Postn, increased mainly in the mSCN model and in the CAFs cells and 
at lower level in MSCs. These results were in agreement with the 
previous results and so with the experimental expectations.   
Interestingly, no expression of Shh was observed in the MSC single 
population and no expression of Shh was observed in CAFs at any of 
the time points (Figure 5.25) although an LQFUHDVHLQĮ60$DQG3RVWQ
positive cells was observed over time (Figure 5.26 and 5.25), 
dissociating these two markers from the expression of Shh. 
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 Figure 5.26 Comparison between Postn marker in the mSCN model and single populations .Postn gene (A) and protein 
(B) expression in MSCs single population (S.P), mSCN in vitro model and CAFs. Each bar represents one single experiment. 
IF images show cells with (First, third and fifth column) and without (second, fourth and sixth column) nuclei stained with DAPI 
(blue). 
Postn
MSC S.P. D2                    SCN Model D2                           CAFs D2
MSC S.P. D12                   SCN Model D12                        CAFs D12
MSC S.P. D21                    SCN Model D21                       CAFs D21
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MSC S.P. D2                    SCN Model D2                          CAFs D2
MSC S.P. D12                   SCN Model D12                        CAFs D12
MSC S.P. D21                    SCN Model D21                        CAFs D21
Figure 5.27 &RPSDULVRQEHWZHHQĮ60$PDUNHULQWKHmSCN model and single populations . Į60$JHQH$DQGSURWHLQ
(B) expression in MSCs single population (S.P), mSCN in vitro model and CAFs. Each bar represents one single experiment. IF 
images show cells with (First, third and fifth column) and without (second, fourth and sixth column) nuclei stained with DAPI 
(blue). 
B) 
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5.6  Investigation of paracrine responsiveness to Hh 
pathway stimuli in the stem cell niche model  
Based on the above data, MSC (section 5.2) and CAF (Chapter 4) 
single populations are not able to respond to Hh paracrine stimuli from 
pancreatic cancer epithelial cells and do not express Shh at the gene 
and protein level (section 5.4). Shh seems to be exclusively expressed 
in the mSCN model and for this reason can be considered a marker of 
the mSCN. Moreover, Shh has been shown to be expressed in 
advanced stages of PDAC at the stromal level (Chapter 3). Therefore, 
we hypothesised that the mesenchymal stem cell niche is formed and 
increased in advanced stages of pancreatic cancer and that this could 
be the best context in which a response to Hh paracrine stimuli from 
cancer cells can be detected. 
In order to investigate this, the mSCN in vitro model was tested for its 
responsiveness to Hh paracrine stimuli (evaluated via GLI1 and Ptch1 
expression). Various mSCN in vitro models were also included in this 
investigation to further characterise and compare them. 
5.6.1  Investigation of the effect of pancreatic TCM and NShh on 
Hh pathway activation in the mSCN in vitro model 
Initially,  MSCs cultured in PCA free differentiation medium were used 
as a mSCN model to test for Hh paracrine induction. The cells were 
grown in TCM from PANC1 and P308T pancreatic epithelial cell lines. 
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The effect of Hh pathway induction was investigated via analysis of the 
Hh gene target GLI1.  
GLI1 gene expression was detected after 3, 7 and 14 days of culture in 
TCM obtained by culturing pancreatic epithelial cancer cells (PANC1 
and P308T) in PCA medium for 72h and their values were normalised 
to MSCs cultured for the same time points in control conditioned 
medium (CM CTRL). 
Some induction of GLI1 was observed in this assay (Figure 5.28) after 
14 days of treatment with PANC1 TCM. Over time (with formation of the 
mSCN model) there was an increase in sensitivity to Hh paracrine 
stimuli. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
On day 3 and 7, GLI1 expression slightly decreased after TCM 
treatment suggesting no Hh pathway induction by pancreatic cancer 
cells under this experimental condition. An explanation could be that the 
Figure 5.28 TCM effect on mSCN in vitro model. .GLI1 expression 
in MSCs cultured in PCA TCM from pancreatic epithelial cells 
(PANC1, P308T) for 3, 7, and 14 days. Gene expression detected in 
samples grown in TCM was normalised to control samples (CM 
CTRL). Each bar is the results of one single experiment. 
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very high percentage of serum in PCA medium (20% of FBS) hides the 
effect of ligand released in the conditioned media.  
To further investigate Hh pathway paracrine induction, MSCs cultured in 
PCA media or in DMEM with 5% FBS were treated for 48h with ȝJPO 
NShh.  The NShh concentration used was based on Bailey et al  2008, 
in which, stromal cells from  pancreatic tumours significantly increased 
*OL DQG Į60$ JHQH DQG SURtein expression after treatment and was 
100 times higher than that used previously (chapter 4 and 5). 
Since, as shown previously, GLI1 gene expression may be affected by 
cross-reaction with a non-canonical pathway, the effect of NShh 
treatment was assessed not just via GLI1 gene expression but also via 
Ptch1 protein expression analysis. 
GLI1 expression also increased in PCA medium after NShh treatment; 
however, the degree of change was very low making it difficult to draw 
firm conclusions (Figure 5.29 A). On the other hand, protein expression 
analysis of Ptch1 showed a clear increase after treatment in both media 
tested (Figure 5.29 C and D) suggesting responsiveness of MSCs to Hh 
stimuli under these conditions. 
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C) D) CTRL NShh 
PCA Media
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NShh 
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Figure 5.29 Effect of NShh and FBS concentration on the paracrine responsiveness of the Hh pathway in a mSCN in 
vitro model.. GLI1 gene expression in MSCs grown for 72h in PCA (A) and DMEM 5% (B) +/- NShh treatment for 48h. Each 
bar was the results of one single experiment. C) and D) Ptch1 protein expression in MSCs cultured in PCA medium and 
DMEM 5% FBS. IF images show cells with (top row) and without (bottom row) nuclei stained with DAPI (blue). 
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These data support the hypothesis of the mixed population as a 
responsive context for paracrine stimuli; however, to further investigate 
this, a direct comparison of the responsiveness of MSCs between 
single populations and the stem cell niche model needed to be 
performed. 
5.6.2  Comparison between the responsiveness of MSC single 
population and mSCN model to Hh paracrine stimuli 
To ascertain if cells in the mSCN context respond better to Hh paracrine 
stimuli than single populations, a trans-well (TW) 2D system was used 
in which epithelial pancreatic cancer cells (PANC1) were co-cultured 
with MSCs for 3 days in DMEM 10% free differentiation medium (mSCN 
model) or in MSCM (single population). Higher expression of the Hh 
pathway gene and protein targets (Gli1; Ptch1) was expected in the 
mSCN model than the single population. In the same experiment MSCs 
treated with TGF-ȕ were also included and the treatment was 
maintained throughout the co-culture (Figure 5.30). The rationale for 
maintaining the TGF-ȕ treatment was to allow investigation of the 
response of a myofibroblast-like single population to paracrine stimuli, 
since TGF-ȕ was shown (figure 5.10 and 5.11) to promote MSCs 
differentiation into myofibroblast cells. In parallel, treatment with NShh 
ȝJPOwas used to further investigate paracrine induction specifically 
via this ligand (Figure 5.31 A, B and C).  
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Ptch1
MSC S.P. CTRL MSC S.P. (PANC1) SCN CTRL SCN (PANC1)
B) 
Figure 5.30 Comparison between MSC single population and 
mSCN model responsiveness to Hh paracrine stimuli in a 
transwell (TW ) system .A) GLI1 gene expression in MSC single 
population (S.P.), mSCN model and MF-like cells co-cultured with 
PANC1 pancreatic cancer cells in a trans-well (TW) system for 72h. 
Each bar was the results of a single experiment. B) Ptch1 protein 
staining by IF in MSC S.P. and mSCN model co-cultured with PANC1 
cells (same condition as Figure A) IF images show cells with (top row) 
and without (bottom row) nuclei stained with DAPI (blue) C) Ptch1 
protein expression quantification in MSC S.P. and mSCN model co-
cultured with PANC1 cells in a transwell system for 72h. 
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MSC S.P. CTRL MSC S.P. NShh SCN CTRL SCN NShh
Ptch1
Figure 5.31 Comparison between MSC single 
population and mSCN model responsiveness to NShh 
stimuli .A) GLI1 gene expression in MSC S.P. and mSCN 
model+/- NShh. Each bar is the results of one single 
experiment. B) Ptch1 protein staining by IF in MSC S.P. 
and mSCN model+/- NShh treatment. IF images show 
cells with (top row) and without (bottom row) nuclei stained 
with DAPI (blue) C) Ptch1 protein expression 
quantification in MSC S.P. and mSCN model+/- NShh. 
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GLI1 expression showed a greater increase in the mSCN model than in 
the MSC single population (S.P.) both after co-culture with PANC1 
(Figure 5.30 A ) and NShh treatment (Figure 5.31 A) in comparison to 
control samples. Moreover, in accordance with the niche theory, trans-
well co-culture as well as NShh treatment induced a Ptch1 protein 
expression increase only in the mSCN in vitro model as indicated by the 
IF images (Figure 5.30 B and 5.31B) and from the quantification 
analysis (Figure 5.30C and 5.31C). However, only the increase of Ptch1 
expression observed in the SCN model co-cultured with PANC1 
epithelial cell line showed significance in comparison to the control 
sample ( SCN model co-cultured with SCN model )  (P<0.05) (Figure 
5.30 C). Finally, TGF-ȕ WUHDWHG cells (MF-like cells) did not show any 
responsiveness to paracrine stimuli from pancreatic epithelial cells in 
the 2D trans-well system as measured by GLI1 gene expression (Figure 
5.30 A). These results confirmed that the completely activated single 
cell population is not able to respond to Hh exogenous stimuli. 
Summarising the results described in this section, the mSCN in vitro 
model seems to be the best context in comparison to MSC and CAF 
single populations for a response to Hh paracrine stimuli.  
5.6.3  Comparison between responsiveness of different mSCN 
models to Hh paracrine stimuli 
The observation of Shh higher expression in co-cultured MSCs with 
MF-like cells (Figure 5.16) suggests the need to also test the 
responsiveness of this and other stem cell niche models to Hh 
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paracrine stimuli, in order to further characterise them and understand 
the best way to reproduce the mSCN in vitro. The responsiveness of all 
mSCN in vitro models to Hh paracrine stimuli was tested using a trans-
well system with PANC1 pancreatic epithelial cells. MSC S.P. obtained 
by culturing low passage MSCs for as few days as possible in MSCM 
(in order to keep them undifferentiated) was also included as a negative 
control.  
The mSCN models tested in this experiment are the following: 
1) MSCs cultured in DMEM 10% for 1 week (mSCN model 1) 
2) MSCs S.P. mixed in 1/1 proportion with MF-like cells (obtained by 
treating MSCs with TGF-ȕ IRU  ZHHN). This co-culture was 
performed in MSCM (mSCN Model 2) 
3) MSCs S.P. mixed in 1/1 proportion with MF-like cells (obtained by 
treating MSCs with TGF-ȕ IRU  ZHHN). This co-culture was 
performed in DMEM 10% medium (mSCN Model 3) 
4) MSCs cultured for 1 week in DMEM 10% (considered in this context 
as source of MF-like cells) and mixed with MSC S.P.  This co-culture 
was performHG LQ 06&0 LQ RUGHU WR ³IL[´ WKH VWDJH RI FHOO
differentiation (mSCN model 4) 
5) MSCs cultured for 1 week in DMEM 10% (considered in this context 
as source of MF-like cells) and mixed with MSC S.P. This co-culture 
was performed in DMEM 10% (mSCN Model 5) 
The Hh paracrine induction in these models was analysed via GLI1 
gene expression and Ptch1 protein expression. 
Chapter 5 -Results: The Stem Cell Niche 
  
259 
 
GLI1 gene expression (Figure 5.31) and Ptch1 protein expression 
(Figure 5.33) showed an increase in all models (mSCN model 3 and 5) 
performed in free differentiation media (DMEM 10%) but no changes 
were observed neither in GLI1 gene expression nor in Ptch1 protein 
expression in mSCN Model1 [MSC cultured in free differentiation media 
(DMEM10%) for 1 week]. An unexpected result was the increase of the 
Hh pathway activity in the negative control (MSC S.P.) after co-culture 
with pancreatic epithelial cells. However, all other models performed in 
MSCM did not show any stimulation of the pathway. mSCN model 5 
[MSC cultured for 1 week in DMEM 10% (considered in this context as 
source of MF-like cells) mixed with MSC S.P. showed the highest Hh 
paracrine induction by epithelial cancer cells. 
Thus, the ratio between the two populations (MF-like cells and MSCs) is 
crucial in the constitution of a mSCN in vitro model and can affect the 
responsiveness to paracrine stimuli. 
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Figure 5.32 Comparison between different mSCN models in their responsiveness to Hh paracrine 
signalling:. GLI1 gene expression analysis in 5 different mSCN in vitro model co-cultured in a TW system 
with pancreatic cancer cells (Panc1) known to highly express Shh ligand. In general only the models 
performed in free differentiation media were responsive and the mSCN model 5 showed the highest 
induction. 
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Figure 5.33 Ptch1 protein expression induction by Hh paracrine signalling in different mSCN 
models:. Ptch1 protein expression was used as markers of responsiveness of 5 different mSCN in vitro 
model to Hh paracrine stimuli. In general only the models performed in free differentiation media were 
responsive and the mSCN model 5 showed the highest induction. 
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5.7  Summary of results 
Summarising the results described in this chapter: 
x MSCs showed some responsiveness to Hh paracrine induction 
only after 14 days of paracrine stimulation by TCM. However in 
general NShh, TCM and 2D co-culture did not induce any 
consistent effect on Hh pathway expression. The explanation of 
these results is probably the tendency of the medium used to 
carry out all these assays, to keep MSCs in an inactivated and 
undifferentiated state. 
x The effect of MSCM in keeping MSCs inactivated was confirmed 
by experiments in free differentiation media (PCA, DMEM 0.5 %). 
In these media, MSCs tend to differentiate into myofibroblast-like 
FHOOV DV LQGLFDWHG E\ WKH LQFUHDVH RI Į60$ JHQH DQG SURWHLQ
expression. 
x The expression of the Shh signalling pathway seems to occur 
when the myofibroblast-like population forms. 
x 7KHLQYHVWLJDWLRQRI7*)ȕWUHDWPHQWRQ06&VDFWLYDWLRQVHHPV
to suggest an effect of this growth factor in promoting this 
process.  
x ,QYHVWLJDWLRQRIWKHHIIHFWRI7*)ȕRQ the Hh pathway seems to 
suggest a decreasing effect. However, incongruence between 
gene and protein expression lead to the necessity of further 
investigation. 
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x GLI1 and ACTA2 gene expression correlated after treatment with 
7*)ȕVXJJHVWLQJan involvement of a non-canonical pathway in 
the regulation of GLI1 expression. 
x Shh gene and protein expression significantly increased in a 
mSCN in vitro model obtained by mixing MSCs and MF-like or 
CAF cells in different ratios. An increase in Shh was also 
observed in single populations of MSCs over time together with 
an increase in Į60$DQG3RVWQ. 
x CAFs removed from an in vivo context are not fully activated 
cells and their activation can be induced by growth factors 
present in the FBS in free differentiation medium. 
x Shh gene and protein were highly expressed in mixed 
populations in comparison to the two single populations of CAFs 
(fully activated) and MSCs (undifferentiated), suggesting Shh is a 
marker of the mixed populations. 
x The mSCN in vitro model seems to be the best context in 
comparison to MSC and CAF single populations for a response 
to Hh paracrine stimuli. However, different mSCN models 
respond differently to paracrine stimuli indicating a key role of the 
ratio between the two populations in this response.
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6.1  Results overview 
The investigation of Hh signalling pathway in PDAC performed in this 
study resulted in a number of novel outcomes. The most important of 
them was the demonstration of Shh ligand expression not just at the 
epithelial level but at the stromal level too. This aspect could open up a 
new chemotherapeutic approach in the fight against this type of cancer 
that still has a poor prognosis and weak therapeutic strategies [Hidalgo 
et al 2010].The evidence of Shh expression at the stromal level is 
supported by a number of reports in the literature [Becher et al 2008; 
Quante et al 2011; Siu Wai Tsang et al 2013] but its role in this context 
is still not clear.  
In this study, Shh was observed to be expressed at the gene and 
protein level by a mixed population comprising MSCs from bone 
marrow and MF-OLNHFHOOVDFWLYDWHGĮ60$+ve cells) representative of an 
in vitro mSCN (mesenchymal stem cell niche) model. This result is in 
agreement with the Quante et al work in gastric cancer that showed the 
same increased expression of SHH in a mixed population. Moreover, in 
this study, the role of Shh in the mSCN was further investigated 
demonstrating Shh expression by MF-like cells but only in a mSCN 
context. This observation suggests that Shh may be a marker of the 
mSCN within the tumour microenvironment. Furthermore, stromal 
expression was high in poorly differentiated tumour (PDT) co-locating 
the mesenchymal stem cell niche in the late stage of PDAC and 
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highlighting Shh as an interesting target, particularly at this stage of 
pancreatic tumour progression.  
In the literature, the role of the Hh pathway in PDAC suggests paracrine 
transmission between epithelial cells and stromal-like cells [Yauch et al 
2008, Tian et al 2009]. In order to further investigate this signalling 
transmission CAFs and MSCs (both known to be components of the 
tumour microenvironment) were tested for their responsiveness to Hh 
paracrine signalling using a panel of pancreatic cancer cells. 
Interestingly both CAFs and MSCs showed a variable and small degree 
of paracrine induction of Hh pathway, which suggests the inability of 
these cells to individually respond to Hh paracrine stimuli. Based on this 
evidence and taking into account the expression of Shh in the stromal 
context and its role as a marker of the mSCN, the response to Hh 
paracrine signalling within mSCN was then investigated. Different in 
vitro models of the mSCN were able to respond to tumour paracrine 
stimuli as measured by triggering downstream of Hh pathway 
components to a greater degree than single populations such as CAFs, 
MF-like cells or MSCs alone. 
In this chapter these results will be further discussed as well as their 
utility from a point of view of developing novel chemotherapeutic 
approaches. 
 
 
  
Chapter 6 -Discussion 
  
267 
 
6.2  Shh is over-expressed in primary tumour pancreatic 
tissues at the epithelial and stromal level 
The expression of the Hh pathway in different types of cancer has been 
described in many papers [Tao et al 2011; Bian et al 2007 ;Chen at al 
2009, Yuan et al 2007; Feldman et al 2008; Xu et al 2009]. Hh 
signalling was investigated in particular in pancreatic cancer and 
contrasting data supported both autocrine [Thayer et al 2003] and 
paracrine transmission [Yauch et al 2008; Tian et al 2009] of this 
pathway in this tumour. Moreover, the involvement of the pathway in 
different stages of pancreatic tumour progression has been 
demonstrated [Thayer et al 2003; Morton et al 2007; Bailey et al 2008]. 
Considering the fact that the role of the Hh pathway in cancer in general 
and in particular in PDAC still needs clarification, this study was focused 
on investigating the Hh pathway mechanism of action in pancreatic 
cancer. 
6.2.1  SHH ligand is over express in pancreatic primary tissue in 
comparison to lung tissues 
SHH gene expression was investigated in this study in 14 paired normal 
and tumour human pancreatic tissues (28 in totals) and in 12 normal 
and 35 tumour human lung tissues. This analysis showed an 
over-expression of the Hh ligand in pancreatic tumours, in comparison 
to the normal samples, with few exceptions (only 2 patients) in which 
normal samples showed a higher expression than in tumour samples 
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(Figure 3.1). The overexpression of SHH at gene level in tumour was 
confirmed by investigation of Shh at the protein level (Figure 3.6 and 
3.7). Moreover, investigation of the Hh pathway activity (GLI1 
expression) confirmed this result (Figure 3.3). In pancreatic tissues, 
SHH expression was also compared with the expression of the other 
two Hh ligands (DHH and IHH). IHH was over-expressed in tumour 
samples but the level of expression was much lower than that of SHH. 
Also, neither DHH nor IHH was expressed in several tumour tissues 
leading to the idea that SHH is the main Hh ligand which acts in 
pancreatic cancer (Figure 3.1). In agreement with this hypothesis, 
almost all the literature existing on the role of the Hh pathway in 
pancreatic cancer exclusively focuses on the analysis of Shh ligand 
expression at the gene and protein level with Shh shown to be over-
expressed in pancreatic cancer [Thayer et al 2003; Bailey et al 2008; 
Singh et al 2012]. For these reasons, this study focused on Shh and 
Dhh/Ihh was not further investigated. 
In this study, Hh pathway expression was also investigated in lung 
tumours. Higher expression of SHH was observed in normal samples 
than in tumours. Moreover, the low SHH level of expression in lung 
tumour samples suggested the lack of an important role for this 
pathway in this type of tumour. Finally, the analysis of the Hh pathway 
activity (GLI1 gene expression) in the same human lung normal and 
tumour samples confirmed this conclusion. The expression of SHH and 
GLI1 was also analysed specifically in two different type of lung tumours: 
SCLC (13 samples) and NSCLC (17 samples) (data not shown). This 
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investigation confirmed no overexpression of the Hh pathway in either 
tumour type. However, the number of tumour samples included in this 
analysis was quite low so perhaps a further analysis with more primary 
samples could better clarify the role of the Hh pathway in this type of 
tumour. In agreement with the results shown in this study, a recent 
study in NSCLC showed very low expression of Shh at the gene and 
protein level and no correlation with the clinical outcome [Savani et al 
2012]. On the other hand, other studies were in contrast with this 
conclusion and showed over-expression of Shh at the gene and protein 
level in SCLC and NSCLC tumours at the epithelial level [ Watkins et al 
2003; Gialmanidis et al 2009, Yuan et al 2007]. Thus, the role of the Hh 
pathway in lung tumours is still not clear and a further investigation on it 
could be interesting to clarify the discrepancy found in the literature. 
6.2.2  Shh is over-expressed in pancreatic cancer not only at the 
epithelial level but also at the stromal level.  
The over-expression of SHH at the gene level in pancreatic tumours led 
to the investigation of its expression at the protein level in primary 
human normal and tumour pancreatic tissues . 
19 paired normal and tumour samples plus 1 unpaired tumour samples 
(39 samples in total) were investigated for Shh protein expression, 
initially considering its overall expression in the entire tissues. Then, 
Shh expression specifically at the stromal level and at the epithelial 
level was also analysed to further understand the role of the Hh 
pathway not just at the epithelial but also at the stromal level and to 
Chapter 6 -Discussion 
  
270 
 
correlate it with tumour aggressiveness. Tumour aggressiveness was 
evaluated as level of histological differentiation within tumour samples 
and classified as normal tissues (NT), moderately differentiated tissue 
(MDT), or poorly differentiated tissues (PDT). The Shh and, as 
discussed later, the Ptch1 proteins expression at the stromal and 
epithelial level were quantified by eye and expressed as percentage. 
This method has some limitations due to the fact that is a consequence 
of a subjective valuation and not of computer software, and for this 
reason has to be considered a semi-quantitative system. This approach 
was, however, chosen based on the fact that a quantification of the 
protein investigated in two distinct compartments (stromal and epithelial) 
of the same tumour sample it would have required manual selection of 
the areas to quantify and so it would have been affected by variability 
and loss of accuracy related to a subjective valuation. Generally, the 
IHC quantification of a protein should take into account the relationship 
between the number of cells expressing the protein (stained) with the 
total number of cells (stained and unstained cells). In a context such as 
that of pancreatic cancer with a very high stromal content, a high 
percentage of extracellular matrix between the cells is present. 
Considering this aspect, another and more important reason for use of 
the semi-quantitative approach, is that computer software would have 
not been able to correctly calculate the total stromal area based on the 
number of total stained and unstained stroma cells but it would have 
erroneously included the ECM component, misleading the final 
calculation of the percentage protein expression.  
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To improve the reliability of the data obtained each section was divided 
into 6 squares and the average of the quantification obtained in each 
square calculated. Moreover, the quantification was confirmed by a 
second blinded observer. However, a semi-quantitative approach, by its 
nature, should not be expressed as a percentage and a ranking system 
might be more appropriate in this context. 
This study showed up-regulation of Shh (H-score) in poorly 
differentiated pancreatic tumours highlighting a role of the Hh pathway 
in the advanced stages of PDAC (Figure 3.6 and 3.7). However, this 
result does not necessarily imply that the expression of Shh occurs 
exclusively at the late stage of tumour progression. Statistical analysis 
performed in this study did not show any difference between Shh 
protein expression in NT and MDT. However, normal samples included 
in this study are obtained from patients affected by tumours, and taken 
at the resection margin. For this reason, in some cases, NT samples 
may have unexpected expression of Shh because the sample taken 
contained some tumour cells. This could slightly affect the statistical 
comparison of NT and MDT samples, leaving open the possibility of an 
increased expression of Shh also in less aggressive tumours. Evidence 
from the literature has shown absence of Shh expression in normal 
tissues and its expression in the precursor lesion PanIN of pancreatic 
tumour, as well as in advanced stage primary tumours and metastasis 
[Thayer et al 2003]. 
The highest overall expression of Shh in PDT samples could be 
explained by increasing percentage of stromal Shh expression in more 
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aggressive tumours observed in this study (Figure 3.11). In MDT 
samples the expression of Shh was mainly at the epithelial level (Figure 
3.11 A) whereas PDT showed a much higher stromal Shh expression. 
The Shh over-expression in pancreatic PDT samples could be a 
consequence of expression of Shh at the stromal level exclusively in 
advanced tumours or an outcome of an increasing stromal component 
with pancreatic tumour progression. In line with this last theory, Shh 
expression at the stromal level correlated in this study with vimentin 
staining (used to quantify the stromal component) (Figure 3.9 B), 
indicating that Shh is expressed at the stromal level and its expression 
in PDTs increases as a consequence of the stromal component 
increasing at this stage of pancreatic tumour progression. Considering 
this result, a significant increase of stromal component (vimentin 
staining) along with tumour progression was expected. However, 
statistical analysis of vimentin quantification in NT, MDT and PDT 
(performed with accurate computer programs as average of 6 different 
sections for each sample) did not confirm a significant difference. 
Nevertheless, the analysis by eye of 6 images for each section in the 
three groups considered, strongly suggested a gradual increase of 
stromal component starting from NT, through MDT, to PDT (Figure 3.8 
A). The criteria chosen to distinguish stromal component from epithelial 
component was focused on the cell shape, and the different cell 
organisation. The discrepancies between instrumental quantification 
and observation by eye regarding the vimentin expression are hard to 
explain but could be a consequence of the relatively small number of 
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samples analysed. A number of studies have confirmed the strong 
increase in the desmoplastic effect in pancreatic tumour that often starts 
with pancreatitis and then degenerates further to PDAC [Chu et al 2007; 
Korc et al 2007; Feig et al 2012; Merika et al 2012]. This change is a 
consequence of the interplay between epithelial cancer cells and 
pancreatic stellate cells that in normal tissues are in a quiescent state. 
The progression of cancer triggers different signalling pathways 
(including Hh pathway) which activate PCS (inducing their proliferation) 
and elicit the proliferation of other resident fibroblasts and the 
recruitment of MSCs from bone marrow, leading to an overall increase 
of the tumour stromal component characterised from a gene expression 
signature specific of the tumour profile [Crnogorac-Jurcevic et al 2001; 
Chu et al 2007; Korc et al 2007; Bailey et al 2008; Feig et al 2012].  
The observation of Shh expression at the stromal level in different types 
of cancer has only been previously observed in a small number of 
studies [Quante et al 2011; Becher et al 2008]. In particular, the 
detection of Shh in pancreatic cancer stroma was only recently 
observed in work focused on the inhibition of the PSC proliferation by 
treating them with 10µM of Rhein (a Natural Anthraquinone Derivative). 
This treatment resulted in decreased 6KK *OL Į60$ DQG 7*)ȕ
expression in these cells [Siu Wai Tsang et al 2013] and confirmed the 
expression of the Hh ligand in the tumour stroma observed in this study. 
However, no further investigation has been done yet on Hh autocrine 
signalling at the stromal level.  
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The funding of Shh expression at the stromal level may have important 
implications for cancer therapy. In fact, Shh could be a new target to 
reduce the stromal component, which is known to have important role in 
sustaining tumour progression and also in affecting drug delivery [Olive 
et al 2009; Kucerova et al 2010; Brentnall et al 2012]. 
The investigation of Shh at the epithelial level was also performed in 
this study to clarify Shh epithelial expression and its impact on the 
stromal component and on the Shh expression at the stromal level. An 
interesting correlation was observed in NT, MDT and PDT pancreatic 
tissues between Shh expression in the two components (epithelial and 
stromal) analysed, indicating an increase in Shh stromal staining with 
increased Shh epithelial expression (Figure 3.10). This evidence 
together with the correlation between Shh epithelial expression and 
vimentin staining (stromal component quantification) (Figure 3.9A) 
highlighted a possible role of Shh at the epithelial level in promoting the 
desmoplastic effect typical of PDAC. This observation is supported by 
studies in which in vitro and in vivo experiments showed the induction of 
pancreatic stromal proliferation and activation by a paracrine effect 
triggered by Shh expressed in cancer epithelial cells [Bailey et al 2008; 
Jung et al 2011]. Moreover, the Hh paracrine reactivation in the stromal 
component was also observed to correlate with development of fibrosis 
in kidney and non-alcoholic steatohepatitis [Syn et al 2011; Fabian et al 
2012]. 
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All these results taken together led to further investigating the 
mechanism of the Hh pathway transmission in PDAC and the role of 
Shh expression in the stromal component. 
6.2.3  Hh downstream pathway expression suggests the existence 
of both paracrine and stromal autocrine signal in PDAC. 
In order to clarify the mechanism of the Hh pathway transmission in 
PDAC, Ptch1 (Hh pathway gene target expression) at the gene and 
protein level was investigated in this study as an indicator of the Hh 
pathway activity. 
The overall expression analysis of Ptch1 at the gene and protein (H-
score) level did not show a difference between NT, MDT and PDT 
tissues (Figure 3.12), in contrast with what was observed for Shh gene 
(Figure 3.2) and protein (Figure 3.7) expression and for GLI1 (Figure 
3.3) gene expression which were over-expressed in tumour samples. 
However, higher expression of Ptch1 was observed both in the stromal 
and in the epithelial component of tumour samples in comparison to 
normal samples (Figure 3.15), although the difference was not 
significant. The non significance of statistical analysis could be 
explained, as for Shh analysis, in the origin of normal tissues that 
showed the same tumour-like zones that could have altered the 
outcome. 
In agreement with these observations, evidence from the literature 
showed the over-expression of Ptch1 both in epithelial pancreatic 
cancer cells and in the pancreatic cancer stromal component 
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[Nakamura et al 2007; Tian et al 2009]. In fact, the inhibition of Ptch1 
expression in two different cancer epithelial pancreatic cells (PANC1 
and SUIT2), by using a specific antibody, reduced the Hh pathway 
expression (detected as GLI1 and PTCH1 gene expression) in these 
cells as well as their proliferation [Nakamura et al 2007]. On the other 
hand, transgenic mouse models were responsive to the constitutively 
expression of the oncogene allele SmoM2 (a mutation in the exon 2 of 
the Smo gene sequence) only when it was expressed in the 
mesenchymal compartment of the pancreas but not in the epithelium 
[Tian et al 2009]. 
As for Shh, correlation analysis between Ptch1 protein expression in the 
two tissue compartments (stromal and epithelial) and the amount of 
stroma (vimentin staining) (Figure 3.14) was made in this study. The 
goal of this analysis was to investigate the effect of Hh pathway 
expression at the epithelial level on the desmoplasia (typical of PDAC 
progression) and the investigation of increased Hh pathway activity at 
the stromal level with an increased stromal component, as observed for 
Shh protein. However, this analysis did not show any correlation. The 
fact that Ptch1 at the epithelial level did not correlate with the amount of 
stroma in MDT and PDT samples was not surprising and in agreement 
with the literature. Bailey et al 2008 showed that desmoplasia in PDAC 
progression is a consequence of a paracrine and not autocrine Hh 
signalling transmission. However, the lack of correlation between Ptch1 
at the stromal level and the stroma amount was in contrast with the 
hypothesis of an increase of Hh pathway activity in the stroma over the 
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desmoplastic effect. In order to clarify this discrepancy and better 
understand the type (autocrine/paracrine) of Hh signalling in the PDAC 
context, correlation analysis between Shh and Ptch1 at the epithelial 
and stromal level in all possible combinations (Figure 3.16) was carried 
out. This showed a significant association between Shh expression at 
the epithelial and stromal level with Ptch1 expression in the stromal 
component. These results seems to exclude an autocrine Hh 
transmission signalling in the cancer epithelial cells and support 
paracrine signalling between cancer cells and the tumour 
microenvironment but also a possible autocrine signalling in the stromal 
cells. A number of studies strongly support the hypothesis of Hh 
paracrine transmission in PDAC [Yauch et al 2008; Tian et al 2009; 
Bailey et al 2008; Nakamura et al 2010]; in contrast, the possibility of 
autocrine Hh signalling transmission in the stromal component has not 
previously been demonstrated, highlighting the novelty of these results 
and the need for further investigation of this aspect.  
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6.3  Hh pathway expression in epithelial and stromal 
pancreatic tumour cells 
Based on the Hh pathway analysis in primary pancreatic tissues, a 
need to further understand the mechanism of transmission of the Hh 
pathway in PDAC emerged. A panel of epithelial cancer cells (PANC1, 
BXPC3, P308T and PAN1) and cancer associated fibroblast (CAFs) 
from pancreatic tumours was analysed for basal expression of the Hh 
pathway (Figure 4.1). SHH gene expression was higher in epithelial 
pancreatic cells in comparison to pancreatic CAFs (Figure 4.1) and 
protein expression analysis confirmed its expression in epithelial cells 
especially in the PANC1 pancreatic tumour cell line (Figure 4.2).  
These results confirmed the observations in the literature of over-
expression of the Hh pathway in tumour cells and suggested epithelial 
pancreatic cells as a source of Shh ligand expression [Berman et al 
2003; Thayer et al 2003; Morton et al 2007; Yang et al 2013]. 
Moreover, as observed in primary tissues SHH was much more highly 
expressed than the other two Hh ligands:  DHH and IHH (Figure 4.1).  
IHH was, however, significantly more highly expressed in epithelial 
cancer cells than CAFs. Considering also its higher gene expression in 
primary PDAC in comparison to NT (Figure 3.1) a role of this ligand in 
pancreatic cancer cannot be excluded and could be interesting to 
further investigate to look for a possible synergistic effect between the 
two Hh ligands in the PDAC context. In agreement with this observation, 
in the literature, the Ihh ligand was observed to be reactivated and to be 
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simultaneously over-expressed with Shh in pancreatic cancer [Berman 
et al 2003; Kayed et al 2004].  The analysis of the same pancreatic cells 
for SMO and GLI1 expression showed a significantly higher expression 
of both genes in pancreatic CAFs in comparison to epithelial cancer 
cells. 
The above gene expression analysis of the Hh pathway in epithelial 
cancer cells and in CAFs seems to suggest a role of epithelial cells in 
secreting the Hh ligands and the ability of stromal cells to respond. 
However, correlation analysis between the main genes of the Hh 
pathway and the markers of epithelial (CDH1) and of mesenchymal 
(VIM and HGF) phenotype, performed in this study, left open the 
possibility of downstream pathway expression in epithelial cancer cells. 
In fact, GLI1 and SMO expression correlated with CDH1, an indicator of 
an epithelial phenotype, indicating that autocrine Hh pathway 
transmission signalling could be possible in epithelial pancreatic cancer 
cells. As expected, SHH also correlated with CDH1, again associating 
the ligand secretion to the epithelial cell type. On the other hand the 
SMO and PTCH2 expression correlation with the expression of the 
markers of mesenchymal cells chosen in this study (VIM and HGF) kept 
open the role of the CAFs as the cells in which the Hh pathway can be 
triggered and that are able to express its gene targets. These results, 
taken together, seem in contrast with the autocrine signal at the stromal 
level suggested by the analysis of the Hh gene and protein expression 
in primary tissues. This discrepancy could be explained by the fact that 
in the in vitro stromal context, CAFs do not have the same properties as 
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in the in vivo context. Consistent with this hypothesis is in fact the 
observation, investigated in this study, that CAFs in vitro are not fully 
DFWLYDWHGDQGFDQIXUWKHU LQFUHDVHĮ60$DQG3RVWQH[SUHVVLRQDW WKH
gene and protein level when stimulated by growth factors such as those 
contained in culture medium (Figure 5.22; .23; 5.24).  This aspect will 
be further discussed later on in this chapter. 
The existence of different types of the Hh transmission is in keeping 
with observations in the literature on PDAC, which demonstrate 
autocrine signalling at the epithelial level [Thayer et al 2003; Xu et al 
2009] as well as paracrine transmission between cancer cells and 
tumour microenvironment [Yauch et al 2008, Bailey et al 2008; Tian et 
al 2009]. Since the evidence supporting both mechanisms of 
transmission are strong it seems possible that both occur. However, 
many questions arise from this possibility, such as if there is a 
correlation between tumour stage and type of the Hh transmission, if 
different experimental approaches can influence the type of signalling 
observed, whether different tumours show different types of 
transmission, or if only specific cell types are able to receive the Hh 
stimuli and trigger its downstream signalling activating the expression of 
its gene targets. In this study this last aspect was further investigated. 
6.3.1  Pancreatic CAF or MSCs alone are not able to respond to Hh 
paracrine stimuli in 2D in vitro assays. 
To further characterise the ability of cells to respond to paracrine 
induction of the Hh signalling by epithelial pancreatic tumour cells, 
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MSCs and CAFs were included in this study and investigated for their 
paracrine responsiveness taking into account their different levels of 
activation. This analysis originated from the idea that different levels of 
activation could affect a cell¶V ability to respond to Hh ectopic stimuli 
and also to support tumour growth and progression. 
Studies on Hh pathway paracrine transmission have been carried out 
both in vivo and in vitro. Stromal origin cells from xenograft mice or 
human tumours were shown able to respond to Hh paracrine stimuli by 
triggering Hh pathway downstream signalling and expression of its gene 
targets [Yauch et al 2008; Tian et al 2009; Bailey et al 2008]. However, 
correlation studies between responsiveness to Hh paracrine stimuli and 
the level of cell activation have provided contrasting results.  
Shh was observed to promote stromal cell activation into myofibroblast-
OLNH FHOOV GHWHFWHG DV LQFUHDVH RI Į60$, with their proliferation 
resulting in increased desmoplasia in pancreatic cancer and increased 
fibrosis in renal interstitial fibrogenesis [Bailey et al 2008; Ding et al 
2012]. These observations suggest two important aspects: cell 
DFWLYDWLRQ PHDVXUHG E\ Į60$ H[SUHVVLRQ FDQ EH LQGXFHG E\ WKH +K
pathway and cells not completely differentiated and activated are the 
ones responsive to Hh paracrine stimuli. In agreement with this last 
statement, in normal prostate development Shh triggers the Hh pathway 
in mesenchymal multipotent cells by paracrine induction [Lamm et al 
2002] and also in normal adult gut, by the same mechanism, seems to 
affect the localisation and formation of myofibroblast cells 
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(characterised by a reduction of desmin expression and a parallel 
increase in Į60$H[SUession) [Zacharias et al 2011].  
In contrast, in prostate cancer only tumour with an already-activated 
m\RILEUREODVW H[SUHVVLQJĮ60$ and vimentin) component, defined as 
reactive tumour, had the relevant phenotype (defined with a nine gene 
target signature) to respond to Hh paracrine induction from epithelial 
tumour cells. This could suggest that cells need to be completely 
differentiated and activated to be responsive to Hh stimuli [Shaw et al 
2009]. Moreover, in line with this last observation, a comparison 
between CAFs (considered fully activated and differentiated cells)  and 
NAFs (Normal Associated Fibroblasts) from pancreatic tumour showed 
a significantly KLJKHUH[SUHVVLRQRI602LQĮ60$DQGYLPHQWLQSRVLWLYH
CAF cells (myofibroblast signature), and increased Gli1 expression after 
N-Shh stimulation was observed  [Walter et al 2010].  
Taken together this raises the question of a possible correlation 
between the level of cell activation, required for the acquisition of a 
myofibroblast-like phenotype, and the ability of stromal cells to respond 
to paracrine induction. 
In order to then further investigate the role of cell activation on the 
responsiveness to paracrine MSCs (undifferentiated cells) and CAFs 
cells (fully differentiated cells) were included in this study. 
MSCs came from human bone marrow and, as said, were chosen for 
their property of being able to be activated (DFTXLVLWLRQ RI Į60$
expression vimentin, desmin, Collagen Type 1) [De Wever et al 2008] 
and for their ability to support tumour progression and express, in 
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response to the interplay with tumour cells, a panel of genes correlated 
with an aggressive and invasive phenotype [ thrombospondin-1 (Tsp-1) 
and tenascin-C (Tn-C)] [Tuxhorn et al 2002; Spaeth et al 2009]. On the 
other hand, CAFs, which in the literature are described as highly 
H[SUHVVLQJ Į60$ ZHUH FRQVLGHUHG IXOO\ differentiated fibroblast cells 
expressing FSP and FAP [Spaeth et al 2009]. 
In order to investigate the correlation between cell activation and 
paracrine responsiveness, the experimental design included NShh 
treatment in 2D assays as well as direct and transwell co-culture and 
treatment with TCM. 
NShh treatment of pancreatic CAFs was performed 3 times on the 
same cell lines (P5T). In a first analysis, two similar experiments ( one 
experiment performed including 2 wells repetition and one with no 
repetitions, 3 replicates in total) were performed in the same conditions 
and showed identical results (Figure 4.5): NShh treatment on P5T CAFs 
did not induce Hh pathway paracrine signalling (detected as GLI1 and 
SMO expression) or cell activation (detected as ACTA2 gene 
expression) in P5T cells (Figure 4.5). Finally, a third experiment was 
performed by using the same NShh doses used in all previous 
experiments but also testing additional time points (D0; D3; D6). This 
experiment was a single assay and the results were shown for two wells 
replicates. Again no induction in P5T CAFs of the Hh pathway and cell 
activation was observed after this treatment at any of the time points 
tested (Figure 4.6). In this experiment, the analysis of only two wells 
replicates for one experiment did not allow a proper statistical analysis. 
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However, figure 4.5 represents the results of 3 replicates under each 
experimental condition where the statistical analysis for the comparison 
of treated and control sample did not show any significance. 
Summarising, the first overall view of the three experiments suggested 
that the NShh treatment did not have a consistent effect in pancreatic 
CAFs.  
A similar experiment to investigate NShh effects on MSCs at different 
time points (Day 3, 6 and 9) did not show any Hh induction or cell 
activation (Figure 5.1) resulting in the same conclusion as for CAFs 
being reached for these cells. This experiment was performed as single 
assay by including 2 well repetitions.  
The effect of TCM on CAFs and MSCs was analysed in this study by 
growing both types of cells for 3 and 14 days in conditioned media 
obtained from a panel of pancreatic cancer epithelial cells (PANC1, 
BXPC3, PAN1, P308T) that showed different levels of Shh expression 
at the gene and protein level.  As a great number of cells was needed to 
perform these experiments, only one well/flask was plated. 2 CAF cell 
lines showed variable changes (decrease and increase) in the Hh target 
gene expression (GLI1 and PTCH1) and in cell activation (ACTA2 
expression) (Figure 4.7). The same experiment was carried out using 
MSCs with different passages (lower and higher) and showed a slightly 
more consistent induction of the Hh pathway and cell activation after 14 
days of cell culture, but still low and variable (Figure 5.3 and 5.4). These 
results led to trying different experimental approaches that allows 
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exposure of the mesenchymal cells to constant secretion of the Hh 
ligand in the 2D transwell and direct co-culture assays. 
Three different trans-well co-culture experiments were performed using 
the same CAFs included in all assays performed in this study (P5T and 
P3T) (Figure 4.8; 4.9; 4.10). These experiments were carried out once 
by carrying out 2 well repetitions under each experimental condition. 
The sequence of these experiments was characterised by a progressive 
analysis that included the use of different pancreatic epithelial cancer 
cells, use of additional time points and analysis of more Hh gene targets. 
No responsiveness of CAFs to Hh paracrine induction from epithelial 
cells and no effect of the Hh pathway on cell activation or, vice versa, 
no effect of cell activation on the responsiveness to Hh paracrine stimuli 
was observed. The same transwell co-cultures were tested using MSCs 
at different passages (and so with different levels of activation). These 
cells also did not show responsiveness to Hh paracrine induction 
(Figure 5.5). Finally, direct co-culture between epithelial cancer cells 
and CAFs excluded the need for cell contact as a reason for lack of 
observation of responsiveness to Hh stimuli (Figure 4.11). The 
conclusions of all these experiments highlighted the fact that both CAFs 
and MSCs in the condition used in this study were not able to respond 
to Hh paracrine stimuli and moreover cell activation did not seem a 
factor that affected this ability.  Thus, no further experiments 
investigating modulation of the Hh pathway were performed using CAFs 
or MSCs. An exception to these observations was found in ACTA2 
expression after transwell co-culture, as well as in GLI1 and ACTA2 
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expression after direct co-culture in CAFs (P5T) with BXPC3 cancer 
cells (Figure 4.10B and 4.11) However, neither GLI1 nor ACTA2 
expression increases for this condition were consistent in the two well 
repetitions performed in each experiment in these co-culture assays. 
This fact influenced the reliability of these results and would have 
affected the significance of a statistical analysis for the comparison of 
the control (CAFs co-cultured with themselves) and the co-cultured 
samples.  
As explained, in all these assays the results of each experiment was 
derived from the average of results for 2 wells plated in parallel during 
the same experiment. In case of TCM assay only one well/flask was 
plated. This could have affected the reliability of the results in which the 
changes observed in the Hh pathway gene expression could have 
reached significance, although very low. It was in fact not possible to 
test the significance of the conclusion reached in these assays, due to 
the low statistical power of the experimental design. Ideally, the data 
would be the result of multiple independent experiments. However, it is 
important to note that, as shown above, the experimental plan used in 
this study followed a strict line of progression in which each experiment 
was repeated, but focusing on those conditions which appeared to 
influence the experimental outcome (time, dose of treatments or cell 
type). The goal of this plan was to move forward the investigation of the 
hypothesis and maximise the experimental conditions tested. 
The above results seem in contrast with studies that support the idea of 
paracrine induction of the Hh pathway in stromal cancer cells in PDAC 
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(constituted by both CAFs and MSCs) [Yauch at al 2008, Bailey et al 
2008]. The treatment of CAFs or MSCs with recombinant rShh has 
been observed to induce the increase of GLI1 and PTCH1 gene 
expression [Chan et al 2012; Li et al 2008; De Wever et al 2008]. Trans-
well co-cultures were also used in other studies focused on the 
characterisation of the cancer stromal cells ability to respond to Hh 
pathway paracrine signal. Both MSCs and CAFs populations were 
shown to increase Gli1 and Ptch1 expression when co-cultured with 
cells over-expressing Shh [Li et al 2008; Domenech et al 2012, Chan et 
al 2012] 
The reason for these discrepancies may be explained by the 
experimental conditions in which NShh treatment and the co-cultures 
were performed. In this study, all in vitro experiments with CAFs and 
MSCs were performed in MSCM with 5% of FBS, demonstrated to be 
able to keep the cells in an inactLYDWHGQRĮ60$H[SUHVVLRQVWDWe. In 
the literature, the induction of the Hh pathway in myofibroblast or MSC 
cells was instead observed only in assays performed in media like 
DMEM 10% of FBS or RPMI  5% FBS [Li et al 2008; De Wever et al 
2008; Domenech et al 2012, Chan et al 2012 ], classified in this project, 
as free differentiation media. These observations, opened the possibility 
that stromal cells, in order to be responsive to Hh paracrine, needed to 
be free to become activated and, moreover, suggested the necessity of 
investigating the effect of MSCM on cell activation as will be explained 
in the next section of this chapter.  
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6.4  A myofibroblast-like cell population originates from 
MSCs and expresses Shh ligand 
Evidence from the literature showed that when quiescent hepatic 
stellate cells Q-HSC (a type of multipotent cell normally present in liver 
and considered very similar to pancreatic stellate cells) are grown in 
DMEM 10% they acquire a mesenchymal phenotype (M-HSC) and 
become activated cells, expressiQJĮ60$FROODJHQDQGPHVHQFK\PH-
associated transcription factors Lhx2 and Msx2. This activation process 
was demonstrated to be Hh pathway dependent [Choi et al 2009].   
MSCM (the media used in all in vitro assays performed in this study) 
was a medium designed to grow mesenchymal stem cells. This medium 
contained 5% of FBS and mesenchymal stem cell growth supplement, 
which contains growth factors, hormones, and proteins necessary for 
the culture of normal human pre-adipocytes. A hypothesis formulated in 
this study was that the growth factors added as supplement in this 
media were able to keep the cells inactivated and undifferentiated. 
In order to investigate this and look for the effect of other media on the 
activation of MSCs, these cells were grown in PCA medium (DMEM 
with 20% FBS) but also in DMEM 0.5% and MSCM 5% with no growth 
factor added (MSCM no GF). These media were chosen for their known 
ability to support the growth of primary cells (PCA) and in order to test 
the effect of low percentage of serum (DMEM 0.5%) as well as the role 
of the GF added during the preparation of the MSCM (MSCM no GF) on 
MSC activation. Different time points were tested in these experiments 
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and the effect on cell activation of the different media was analysed as 
Į60$ JHQH DQG SURWHLQ H[SUHVVLRQ DQG FRPSDUHG ZLWK Į60$
expression in MSCs grown in MSCM 5% (the media used in all previous 
experiments). In agreement with the literature, MSCs grown in DMEM 
at both percentages of FBS (Figure 5.7) showed incUHDVHG Į60$
expression after 3 days of culture. However, MSCs grown in MSCM no 
*)VKRZHGD OHYHORIĮ60$H[SUHVVLRQFRPSDUDEOH WR FHOOVJURZQ LQ
MSCM with GF added and significantly lower than the other two media 
(DMEM 0.5% and PCA). These results suggested that the GF were not 
WKHUHDVRQIRU06&0¶VDELOLW\WRNHHSFHOOVLQDFWLYDWHG%DVHGRQWKHVH
results DMEM media used in this study were considered and named 
³IUHH-GLIIHUHQWLDWLRQPHGLD´ )'0 WREHGLVWLQJXLVKHGIURP06&0DQG
MSCM no GF considered insteaG ³SUHYHQWLQJ GLIIHUHQWLDWLRQ PHGLD
3'0´ 
7KHLQYHVWLJDWLRQRIWKHĮ60$WUHQGRYHUWLPHLQ06&VFXOWXUHGIRU
days in PCA media showed an initial rapid differentiation of these cells 
LQWR Į60$+ve cells, and then development into a mixed population in 
ZKLFKĮ60$+ve DQGĮ60$-ve cells are both present. These observations 
confirmed findings in the literature [Quante et al 2011].  
The role of the Hh pathway in the induction of cell activation in Q-HSC 
[Choi et al 2009], the observation of Shh expression during liver fibrosis 
in a mesenchymal stem cell niche (mSCN) constitute from MSCs and 
MF-like cells [Lin et al 2008] and the strong increase of SHH gene 
expression in the mixed population in comparison to the single 
SRSXODWLRQV Į60$-ve DQGĮ60$+ve) [Quante et al 2011], led to further 
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investigation of Hh pathway expression in FDM. MSCs grown in DMEM 
0.5% and PCA free-differentiation media showed an increase in Shh 
and Ptch1 protein expression. Some discrepancies between SHH gene 
and Shh protein expression was observed in these assays (Figure 5.8). 
The explanation could reside in the generally low expression of SHH at 
the gene level that made detection of its expression difficult at times. On 
the other hand, each q-RT-PCR performed for SHH was repeated twice 
at very high concentration of cDNA in order to reduce as much as 
possible the error in its detection.  
The same was not true for Ptch1 that quite often showed inconsistency 
between the gene and protein levels (Figure 5.8). The reason for this 
discrepancy could be the negative feedback exerted by Ptch1 on Hh 
gene targets including PTCH1 and GLI1 (a fundamental mechanism 
that prevents Hh overexpression) [Goodrich et al1999]. It is possible in 
fact that the increase of Ptch1 protein due to the increase of the Hh 
pathway in activated cells triggers the inhibition of the Hh gene targets 
(GLI1 and PTCH1) and that this change took longer to be reflected at 
the protein level. However, in this case, GLI1 gene expression should 
also have reduced, but regulation of Gli1 expression via the non-
canonical pathway could hide this decrease [Nolan-Stevaux et al 2008]. 
To complicate this aspect further, there is also evidence that the 
inhibition of the Hh gene targets by Ptch1 can be triggered by a non-
canonical mechanism that does not involve Hh pathway molecules like 
SUFU and SMO [Rahnama et al 2006]. Finally, It is possible that post-
translational regulation of gene expression due to different binding of 
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regulatRU\IDFWRUVWRWKH¶- DQG¶-UTR of Ptch1 mRNA could affect and 
enhance the rates of translation resulting in higher protein expression 
[Wilkie et al 2003].  
In this study, due to this divergence, protein expression of Ptch1 was 
considered the reliable result to be used for evaluation of Hh pathway 
activity. The match between Shh and Ptch1 protein expression in the 
assays focused on the Hh pathway expression in activated MSCs 
(Figure 5.9) strongly supported the results obtained and the reliability of 
protein expression analysis for both these Hh molecules (Shh and 
Ptch1).  
The culture of MSCs in PCA media for 14 days resulted in higher 
expression of the Hh pathway (Shh and Ptch1 protein expression) after 
3 days and a reduction of both on day 7 and day 14 (Figure 5.8). 
&RQVLGHULQJDOVRWKHSHDNRIH[SUHVVLRQRIĮ60$REVHUYHGDIWHUGD\V
in PCA media, it seemed that Shh could be expressed by Į60$+ve cells. 
However, correlation analysis between SHH and ACTA2 gene 
expression did not showed significance (data not shown). 
On the other hand, in the assays performed by growing MSCs in 
different media and in PCA media for 14 days, GLI1 expression showed 
a different trend from Shh and Ptch1 and a very similar trend was found 
instead between GLI1 and ACTA2 gene expression. This result could 
be interpreted as regulation of GLI1 by a non-canonical pathway that 
interacts with the Hh pathway in the regulation of cell activation.  
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Summarising, the results discussed so far suggest the tendency of 
MSCM to maintain cells in an undifferentiated state and the expression 
of Shh and Ptch1 seem to be affected by this condition. A possible 
H[SUHVVLRQRIWKH+KSDWKZD\LQĮ60$+ve cells was further investigated 
in this study as well as the correlation between GLI1 and ACTA2 and 
the possible pathway that could interact with the Hh pathway in the 
regulation of Gli1. 
6.4.1  TGF-ȕ WUHDWPHQW RI 06&V WULJJHUs an increase in Į60$
expression and is likely to be responsible for GLI1 gene 
expression regulation 
7KH UROH RI 7*)ȕ LQ WKH LQFUHDVH RI Į60$ H[SUHVVLRQ DV D
consequence of cell activation and EMT has been demonstrated. 7*)ȕ
was observed to be expressed by epithelial cancer cells but also at the 
stromal level [Hu et al 2003; Bardeesy et al 2006]. Moreover, 
KHWHURJHQHLW\ LQ 7*)ȕ H[SUHVVLRQ LQ VWURPDO FHOOV VHHPV WR DIIHFW
tumour progression [Franco et al 2011]. 
Cross-UHDFWLRQ EHWZHHQ 7*)ȕ DQG +K VLJQDOOLQJ KDV DOVR EHHQ
GHPRQVWUDWHG DQG VHHPV WR DFW DW GLIIHUHQW OHYHOV 7*)ȕ LV DEOH WR
induce the expression of the Hh ligand in NSCLC and in alcoholic liver 
disease [Jung et al 2008; Maitah et al 2011]. Moreover TGFȕ ZDV
observed to be able to regulate Gli1 and Gli2 expression [Dennler et al 
2007; Nolan-Stevaux et al 2008]. It has also been demonstrated that 
Shh is able to mediate Į60$LQGXFWLRQE\7*)ȕLQ36&directly linking 
these pathways [Siu Wai Tsang et al 2013]. Interestingly it has also 
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EHHQ REVHUYHG WKDW 7*)ȕ WUHDWPHQW RI 06&V HQKDQFHV WKH
responsiveness to Shh paracrine signalling but only in the presence of 
epithelial cancer cells [Domenech et al 2012]. In contrast with this 
LQWHUGHSHQGHQFH EHWZHHQ 7*)ȕ VLJnalling and the Hh pathway, 
60$'DF\WRSODVPLFSURWHLQWKDWDFWLQWKH7*)ȕVLJQDOOLQJLVDEOHWR
trigger, by a non-canonical Hh-independent pathway, the Gli2 
transcription factor, which in turn induced expression of Gli1 [Dennler et 
al 2007]. 
ConsideriQJWKHQWKDWWKHOLWHUDWXUHVKRZVWKHDELOLW\RI7*)ȕWRLQGXFH
H[SUHVVLRQ RI Į60$ DQG *OL [Hu et al 2003; Bardeesy et al 2006; 
Dennler et al 2007; Nolan-Stevaux et al 2008], the correlation between 
WKHVH WZRPROHFXOHVPD\EHGULYHQE\7*)ȕ ,QRUGHU WR confirm this 
K\SRWKHVLVWKHHIIHFWRI7*)ȕRQ06&VDFWLYDWLRQZDVLQYHVWLJDWHGLQD
range of different media after 3 days of treatment and, additionally, in 
PCA media after 14 days of culture. 
Consistent with the tendency for MSCM to keep cells in an inactivated 
VWDWH7*)ȕ WUHDWPHQWRI06&V LQGXFHGDQ LQFUHDVH LQFHOODFWLYDWLRQ
based on gene and protein expression, only in free-differentiation media 
(DMEM 0.5% and PCA media) (Figure 5.11). Culture and treatment of 
MSCs in PCA media for 14 days confirmed at the gene level the same 
induction of ACTA2 gene expression after 3 -7 and 14 days. However, it 
WRRN PRUH WLPH  GD\V WR EH DEOH WR REVHUYH WKH VDPH Į60$
LQGXFWLRQDW WKHSURWHLQ OHYHO)LJXUH7KH,)VWDLQLQJRIĮ60$LQ
7*)ȕ WUHDWHGVDPSOHVJrown in FDM, showed a more homogeneous 
Į60$+ve population than in untreated samples, suggesting that the role 
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of this growth factor was to push the activation of MSCs into a single 
activated MF-like population (Figure 5.10). 
2QFH WKH HIIHFW RI 7*)ȕ RQ FHOO activation had been shown, its 
interaction with the Hh pathway was investigated. Again, this interaction 
was investigated in MSCs under the same culture conditions (cells 
grown and treated for 3 days in different media and in PCA media for 14 
days). Considering the evidence from the literature an increasing effect 
RI7*)ȕRQ6KKDQGDVDFRQVHTXHQFHRQ3WFKZDVH[SHFWHG [Jung 
et al 2008; Maitah et al @ 6XUSULVLQJO\ LQ ERWK DVVD\V 7*)ȕ
treatment induced a decrease in SHH and PTCH1 gene expression 
(Figure 5.12 and 5.13). Protein expression analysis in MSCs grown in 
PCA media for 3, 7 and 14 days confirmed this observation. However, 
protein expression analysis of Shh in different media indicated an 
increase in Shh after treatment in media with lower concentrations of 
FBS (DMEM 0.5%; MSCM 5% and MSCM no GF 5%). It could then be 
possible that percentage of FBS, if too high, could hide (as in PCA 
media) the effect of the treatment. The mismatch between gene and 
protein expression, as explained, could be due to differences in timing 
of expression at the protein and gene levels. However, these 
observations need further investigation to reach a conclusion.  
A more consistent observation was that there were often parallel 
changes in GLI1 and ACTA2 gene expression, and correlation analysis 
between these two molecules after TGF-ȕ WUHDWPHQW ZDV VLJQLILFDQW
This aspect strongly supports the hypothesis of regulation of GLI1 by 
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WKH 7*)ȕ QRQ-canonical pathway as demonstrated in the literature 
[Nolan-Stevaux et al 2008]. 
Gli1 expression at the stromal level, then, should not be considered 
exclusively the result of the Hh pathway paracrine induction but also a 
result of a non-canonical pathway and a possible marker of acquisition 
of a myofibroblast (MF)-like cell phenotype.  
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6.5  The mesenchymal stem cell niche 
The role of a mesenchymal stem cell niche made up of MSCs and MF 
cells (niche cells) has recently been investigated in a number of studies 
in order to understand the nature and composition of the tumour stromal 
components and better clarify their role in tumour progression and 
metastasis [Lin et al 2008; Quante et al 2011; Malanchi et al 2012; 
Lonardo et al 2012]. It has been demonstrated that MSCs are recruited 
from the cancer cells into the tumour microenvironment where they 
differentiate into MF-like cells [Ishii et al 2003; Spaeth et al 2009, 
Paunescu et al 2011]. However, investigation of the formation of the 
mesenchymal stem cell niche in contexts such as the desmoplastic 
reaction may provide a better understanding of these processes Based 
on the mesenchymal stem cell niche concept, MF cells (also called 
niche cells) derive from the differentiation of MSCs. The role of these 
cells is to maintain the survival and induce the proliferation of MSCs 
and vice versa [Lin et al 2008; Quante et al 2011]. MF-like cells derived 
from MSCs were demonstrated to be more aggressive than the other 
tumour stromal cells having a stronger impact on the promotion of 
tumour growth and progression [Quante et al 2011]. 
 Hence,  in view of evidence from the literature [Choi et al 2009; Siu Wai 
Tsang et al 2013] and the results observed so far, the expression of 
Shh ligand and probably also of the downstream Hh pathway could be a 
SURSHUW\ RI Į60$+ve myofibroblast-like cells. However, the expression 
of Shh was demonstrated to increase strongly only in a mixed 
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population consisting of MSCs and MF-like cells [Quante et al 2011]. In 
agreement with this observation, in this study 6KK DQG Į60$
expression in MF-like cells or CAFs was not correlated suggesting that 
Shh expression even if expressed by MF-like cells is a consequence of 
the presence of a mixed population (stem cell niche) in pancreatic 
tumour stroma. 
6.5.1  A mesenchymal stem cell niche (mSCN) model can be 
reproduced in vitro and results in up regulation of the Shh ligand  
In order to investigate the role of Shh in the mesenchymal stem cell 
niche and its eventual expression only in a mixed population, different in 
vitro models of the mesenchymal stem cell niche were tested in this 
study. 
MSCs were shown in the literature [Ishii et al 2003; Direkze et al 2004; 
Spaeth et al 2009; Quante et al 2011; Barcellos-de-Souza et al 2013], 
and confirmed in this study, to be able to differentiate into MFs/CAFs, 
DQG 7*)ȕ ZDV LGHQWLILHG DV D JURZWK IDFWRU DEOH WR VWLPXODWH WKLV
activation [Hu et al 2003; Bardeesy et al 2006; Domenech et al 2012]. 
,Q WKLV VWXG\ WUHDWPHQWRI06&V IRURQHZHHNZLWK7*)ȕ (10ng/ml in 
MSCM no GF) resulted in maximal up-regulation of ACTA2 in 
comparison to the untreated cells (Figure 5.11 A). For this reason, this 
condition was used to obtain an MF-like cell population. MSCs at low 
passage were grown in MSCM (demonstrated in this study to maintain 
cells in an inactivated state) in order to ensure the use of more stem-
like undifferentiated cells. The mSCN in vitro models initially tested 
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used these two populations of cells at a number of ratios (1/1; 3/1 and 
1/3). 
The mixed and the unmixed populations were characterised for their 
expression of 4 genes (SHH, ACTA2, POSTN, NES) and, additionally in 
VRPHH[SHULPHQWV IRU WKHLUH[SUHVVLRQRISURWHLQV Į60$6KKDQG
Postn) chosen as mSCN PDUNHUV7KHFKRLFHRIĮ60$DQG1HVWLQDV
markers of MF cells and MSCs is supported by the literature [Ishii et al 
2003; Direkze et al 2004; Becker et al. 2008 Spaeth et al 2009, 
Mendez-Ferrer et al 2010 Paunescu et al 2011; Quante et al 
2011;Barcellos-de-Souza et al @Į60$H[SUHVVLRQ is in fact a well 
known indicator of MSC differentiation into CAFs [Shaw et al 2009; 
Gravina et al 2013] Moreover, MSC in vitro culture showed the 
H[SUHVVLRQ RI QHVWLQ DV ZHOO DV D 3'*)5Į+-CD51+ subpopulation of 
MSC in the bone marrow stem cell niche [Moradi et al 2011; Pinho et al 
2013]. Finally, the role of Shh and Postn expression as markers of a 
MSC and MF-like cell mixed population have recently been described 
[Lin et al 2008; Quante et al 2011; Malanchi et al 2012].  
In order to investigate the effect of MSCs and MF-like cell mixing on the 
4 mSCN markers, the actual gene expression values ( POSTN, NES, 
SHH, ACTA2), obtained from the analysis of the q-RT-PCR results, 
were compared to the calculated values. These latter were 
mathematically calculated taking into account the contribution 
(respecting the cell proportions used) of the mSCN marker expression 
in the single populations that constitute the mSCN models (i.e in the 1 
MSCs/1 MF-like cells model the calculated value was the average of 
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the 2-¨&W gene expression measures in the two single niche populations). 
Moreover, the trend of the mSCN markers was investigated over time in 
all cell populations. This analysis was used to understand the behaviour 
of the mSCN in culture and to compare the trend over time of the 
mSCN markers between the unmixed single populations and the in vitro 
mSCN models. 
The graphs representing the comparison between the actual and 
calculated values and the mSCN PDUNHUV¶ H[SUHVVLRQ LQ WKH VLQJOH
populations (Figures 5.16; 5.17; 5.19; 5.20; 5.21; 5.22) were the result 
of one experiment. However, as explained before, the same hypothesis 
was tested several times (3 times in this type of experiment) but slightly 
varying at every step those conditions which did not show interesting 
changes in the gene or protein expression of the mSCN markers 
chosen. So, for example, in a first experiment 1/1 MSCs/MF-like mSCN-
model was compared for the actual value of Shh, Postn, Nestin and 
Į60$ DW   DQG  GD\V RI FXOWXUH LQ )'0 '0(0  WR WKH
calculated values as well as the over time trend of the mixed population 
was compared to that in the unmixed cells (Figure 5.16; 5.17). In a 
second experiment the same evaluation was performed for 0, 3, 12 and 
21 days using 3/1 and 1/3 ratios (Figure 5.19; 5.20). In a third 
experiment the mSCN-model was obtained by mixing MSCs with 
primary pancreatic CAFs instead of MF-like cells at 1/1 ratios at 2, 12 or 
21 days of culture in FDM (Figure 5.21; 5.22). This experimental design 
was carried out to guarantee at the same time the repetition of the 
hypothesis tested by adding new steps of investigation every time. 
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However, a limit of this experimental design is that it makes statistical 
analysis difficult. 
In these experiments, the actual SHH expression value detected in the 
mSCN in vitro models was higher in comparison to the calculated value. 
This result was observed in all three assays tested (Figure 5.16; 5.19; 
5.21) and it supports the idea that the mixing of two niche populations 
affects the Hh ligand expression and, moreover, suggests its role as 
marker of the mSCN. Interestingly the SHH gene expression increased 
after the 1 MSC: 1 MFs (Figure 5.16) and  1 MSC:3 MF cell mixing 
(Figure 5.19),  but not in the 3 MSC:1 MF (Figure 5.19) model indicating 
that different ratios of MSCs and MF-like cells can affect the mSCN in 
vitro models and the expression of the Hh ligand. In comparison to the 
models obtained by mixing MSCs and MF-OLNH FHOOV 7*)ȕ Wreated 
MSCs) the mSCN model obtained by mixing 1 CAF: 1 MSC showed a 
lower increase in SHH expression and only after 2 days of culture. This 
result can be explained by the fact that MF-like cells were directly 
derived from MSCs. Since CAFs or MF that originate from bone marrow 
MSCs are more aggressive cells, they are able to better sustain tumour 
growth in comparison to CAFs with other origins [Mishra et al 2008; 
Spaeth et al 2009; Quante et al 2011]. Moreover, they probably better 
mimic the in vivo mSCN that is formed in the bone marrow as a 
consequence of the MSC activation in response to infections or tumour 
progression [Lin et al 2008; Quante et al 2011]. The Shh protein 
expression analysis confirmed the conclusion described for the SHH 
gene expression analysis in these experiments. In general, a good 
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match was observed but in the 1 MSC: 1 MF-like cell model the effect of 
mixing took a longer time (on day 12) to be visible at the protein level. 
Considering these results, the expression of Shh at the stromal level in 
primary pancreatic tumours observed in Chapter 3 could indicate the 
presence of a bone-marrow derived stem cell niche and suggest a new 
role of Hh pathway in determining the composition of pancreatic cancer 
stroma. 
The observation that in these experiments Shh gene and protein 
expression in the mSCN-models analysed was not maintained at higher 
levels compared to MSCs alone at all time points (Figure 5.16; 5.19; 
5.21) is interesting. An explanation of this result could be found in the 
analysis of the MF-OLNHSRSXODWLRQĮ60$JHQHDQGSURWHLQH[SUHVVLRQ
LQ WKH VDPH H[SHULPHQWV 7KH DQDO\VLV RI Į60$ JHQH DQG SURWHLQ
expression showed a quite consistent increase in this cell population 
not just in the mixed population but also in MSCs alone and in MF-like 
cells supposed to be already fully activated (Figure 5.17; 5.18; 5.20; 
5.22; 5.24). The increase in Į60$+ve cells in MSCs is consistent with 
their property of being able to become an MF-like population when 
grown in FDM. Therefore, probably only the results for MSCs in the first 
three experiments at 2 days of culture are relevant. At this time point, 
WKHQXPEHURIĮ60$+ve cells was probably still low enough for them to 
be considered a single population and a relevant control. In agreement 
with this conclusion, increased SHH gene expression in the mixed 
population was observed in comparison to this control (Figure 5.16; 
5.19; 5.21).  
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Taking this argument further, MSCs grown in DMEM 10% for a longer 
time than 2 days could be considered as another possible in vitro 
mSCN model. This is in agreement with published data showing that 
MSCs in culture are able to differentiate into MF-like cells (identified by 
expression of a red fluorescence protein RFP under the control of the 
Į60$ SURPRWHU SURGXFLQJ D Pixed population [Quante et al 2011]. 
Moreover, this mixed population could survive for 80 passages or more 
in comparison to single FACS-sorted MF cells that became senescent 
after a few passages (Figure 6.1). 
 
Another aspect to consider is that WKH H[SUHVVLRQ RI Į60$ LQ 0)-like 
cells was observed in these experiments to increase over time, 
VXJJHVWLQJ WKDW WKH DFWLYDWLRQ REWDLQHG DIWHU 7*)ȕ WUHDWPHQW ZDV QRW
maintained (as shown from the drop down on day 2 of figure 5.16) when 
the treatment were interrupted at the start of each assay. This 
observation suggested a new view of cell activation as a transient stage 
Figure 6.1 MSCs in culture are able to differentiate into MF-like cells. 
Picture taken from Quante, M, et al.  Cancer cell 19, 257±272, February 15, 
2011. Copyright licence obtained from Elsevier. 
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that can be reversed in vitro and that needs constant growth factor 
induction to be maintained. In agreement with this aspect, in work 
focused on the analysis of MSC responsiveness to Hh paracrine 
signalling, it has been shown that the 7*)ȕ-LQGXFHGĮ60$ expression 
persists in vitro no longer than 72h from the suspension of the treatment 
[Domenech et al 2012]. 
7KHYDULDELOLW\RIĮ60$LQ0F-like cells led to use of CAF primary cells, 
believed to be fully activated cells, in the third experiment (Figure 5.19; 
6XUSULVLQJO\WKHOHYHORIĮ60$DWWKHJHQHDQGSURWHLQOHYHODOVR
increased in these cells over time, suggesting the reversibility of cell 
activation and opening a new view of CAF in vitro cells as not fully 
activated cells. Since Į60$H[SUHVVLRQ is considered to be, an indicator 
of cell aggressiveness [Speath et al 2009], based on the results in this 
study, in vitro CAFs, probably lose their activation and their 
aggressiveness, becoming phenotypically similar to normal associated 
fibroblasts NAF. 
Postn gene and protein is believed to be expressed in MF-like cells 
[Erkan et al. 2007] especially when part of a niche with stem cells 
[Malanchi et al 2012]. So in this study an increase in Postn was 
expected in a mixed population and a lower but detectable level of 
expression in MF-like cells or CAFs cells single population. The POSTN 
expression in the mSCN models constituted from MSCs and MF-like 
cells was not affected by the cell mixing (comparison actual vs 
calculated values) either in the 1MSC:1MF model (Figure 5.17) or in the 
3MSC:1MF (Figure 5.20) models. An interesting POSTN expression 
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increase was instead observed after the mixing in the 1 MSC: 3 MF 
model (Figure 5.20) suggesting an impact of the cell ratio on its 
expression, as well as on Shh expression. However, the difference 
between POSTN expression in these mSCN models and in the MF-like 
cells was not large (Figure 5.17 A and D; Figure 5.20 A and D) 
suggesting a similar expression of this marker in single and in mixed 
populations. At a first glance, these results seem in contrast with the 
starting assumption of increased expression of Postn in MF-like cells 
when part of a mesenchymal stem cell niche. This aspect can be 
explained by the experimental conditions used in these assays. The 
MF-like cells used cannot be considered a single population due to the 
LQWHUUXSWLRQRIWKH7*)ȕWUHDWPHQW7KLVZRXOGDOVRH[SODLQWKHabsence 
of a difference in the POSTN expression between actual and calculated 
values in the mSCN models obtained by mixing MSCs and MF-like cells. 
In these models, the calculated value was in fact the result of the 
combination of POSTN expression in already impure single populations 
and for this reason probably higher than in hypothetical single 
populations.  
In agreement with these considerations, POSTN expression in the 
mSCN model, obtained by 1/1 mixing CAFs (single population) and 
MSCs, markedly increased after 12 and 21 days in the actual gene 
expression in comparison to the calculated expression value suggesting 
a clear effect of the cell mixing on its expression (Figure 5.22). 
Moreover, its expression was much higher in this mSCN model than in 
CAFs alone (Figure 5.22 A and D) supporting the idea of POSTN as 
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marker of MF-like cells in the niche context. The analysis of Postn 
protein expression increased over time in all population tested (MSCs, 
CAFs, MF-like cells and mSCN models). These results, in addition to 
WKH YHU\ VLPLODU WUHQG REVHUYHG EHWZHHQ Į60$ DQG 3RVWQ JHQH DQG
protein expression, suggest that Postn is mainly a marker of cell 
activation that reflects the proportion of activated cells but is expressed 
at highest levels in a mSCN FRQWH[W ,QDJUHHPHQW LQGXFWLRQRIĮ60$
by Postn expression via positive feed-back has been observed in the 
tumour microenvironment context [Erkan et al. 2007]. 
Finally Nestin expression remained constant in all cell populations 
tested, although it has been described as a marker of MSCs [Mendez-
Ferrer et al 2010; Moradi et al 2011; Quante et al 2011; Pinho et al 
2013]; this suggests Nestin is a poor marker for detection of MSCs in 
the context analysed in this study. 
In summary, a number of in vitro mSCN models were tested; the 
comparison to a single population was most reliable during the first 
days of culture (day 0 and day 2) when MSCs could still be considered 
as undifferentiated. The variability of SHH expression depending on the 
ratio of MSCs to MF-like cells in the mSCN models strongly reinforced 
the hypothesis of its expression being dependent on the presence of a 
mixed population, and demonstrates the need to strictly follow the same 
experimental protocol when using these mSCN in vitro PRGHOVĮ60$
and Postn had been demonstrated to be good markers of activated 
cells (MF-like population). In particular Postn expression seems to 
increase in the mixed population.  
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In contrast with the conclusion of Shh as marker of a mixed population, 
evidence from literature showed and supported the expression of Shh in 
MSCs and MF like cells single populations. The investigation of Hh 
signalling in liver fibrosis demonstrated in fact the existence of a bone 
marrow stem cell niche constituted from bone marrow MSCs and 
hepatic stellate cells HSC (an activated stroma cell type expressing 
Į60$VLPLODUWR0)-like cells) in which both type of cells endogenously 
express Shh ligand. Moreover, in vitro culture of MSCs showed the 
expression of Shh ligand and its knock-down by using an shRNA 
DIIHFWHG WKH ,)1Ȗ-induced proliferation in MSCs [Lin et al 2008; 
Donnelly et al 2013]. Such evidence strongly supports the existence of 
the stem cell niche in inflammatory condition like desmoplasia, fibrosis 
and cancer but also contrast the idea of Shh expression exclusively in 
the mixed population. However, interestingly, these results were 
achieved by growing the MSCs in DMEM 10%, a condition that was 
here demonstrated to induce the differentiation of MSCs into MF-like 
cells. The expression of Shh observed in these contexts could be then 
associated with a mixed population suggesting the reliability of the 
results found in this study. On the other hand, as explained above,  Shh 
expression was observed in hepatic and pancreatic stellate (activated 
FHOOV H[SUHVVLQJ Į60$ VLQJOH SRSXODWLRQV >/LQ et al 2008; Siu Wai 
Tsang et al 2013] .  
All these aspects taken together reveal the necessity for further 
investigation to confirm the conclusion of Shh as exclusive marker of a 
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of MSC cells with GFP (green fluorescence protein) or RFP (red 
fluorescent protein) whose expression should be linked to the activity of 
Į60$SURPRWHUDVGRQHE\4XDQWHet al, in order to isolate the MF-like 
cell population. At the same time, identification of a marker that would 
allow MSCs to be isolated in the same way is required. By then mixing 
these populations, the effect on Shh expression could be ascertained 
and, in addition, using different ratios, the importance of each 
population in the induction of Shh expression could be evaluated. 
However, this experimental design also has some limitations. Firstly, 
finding a cell-surface marker for MSCs is still a challenge. If such a 
marker were available, the stress to which cell lines are exposed during 
the transfection (e.g. due to cytotoxicity of the transfection reagents) 
can alter the expression of certain genes [Jacobsen et al 2009]. 
Moreover, the cell sorting process requires good recovery of the cells 
and the purity of the sorted cells after a single sorting cannot be 
guaranteed (http://www.facs.ethz.ch/docs/lit). Lastly, sorting of cells to 
obtain a pure population may result in loss of subpopulations of cells 
which are poorly transfected.  
For this reason, an alternative method able to maintain the cells in the 
best culture conditions and so to better mimic the in vivo conditions was 
used. The new assay was based on: 1) the fact that in the previous 
experiments, as explained, the single populations (MSC and MF-like 
cell) used were impure and 2) on the following assumptions:  
x MSCs grown in FDM could be considered a mSCN model 
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x MSCs, to be maintained as single population, need to be kept in 
MSCM over time: MSC S.P. (mesenchymal stem cells single 
population)  
x CAFs, to be fully activated, need to be grown in FDM that 
contains growth factors able to induce and maintain their 
activation mimicking their real in vivo phenotype 
6KKĮ60$DQG3RVWQH[SUHVVLRQ LQ WKH mSCN in vitro model (MSCs 
grown in DMEM) was compared after 2, 14 and 21 days of culture to 
the single populations (MSCs grown in MSCM and CAFs grown in 
FDM). Shh at the gene and protein level in the mSCN model (MSC 
grown in FDM) used in this assay was much higher after 14 and 21 
days of culture than that in the MSC S.P. (MSCs grown in MSCM) or 
the CAF single population (Figure 5.25). Moreover, consistent with this 
observDWLRQ WKH LQFUHDVH LQĮ60$DQG3RVWQDW WKHJHQHDQGSURWHLQ
level over time observed in CAFs, did not match with Shh, which 
remained low and constant (Figure 5.25 ; 5.26; 5.27). Furthermore, only 
DVPDOO LQFUHDVH LQĮ60$DQG3RVWQZDVREVHUYHG LQ06&63. over 
time confirming their stem cell phenotype and the preservation of this 
phenotype in MSCM over time (Figure 5.26 and 5.27). 
This strongly supports the role of Shh as a marker of the stem cell niche 
as previously suggested [Quante et al 2011].  
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6.5.2  The mSCN is the best tumour stromal context able to 
respond to Hh paracrine stimuli 
Another important hypothesis formulated in this study arose from the 
failure of MSCs and CAFs, grown in MSCM, to respond to Hh paracrine 
stimuli as observed in chapter 4 and 5. It was in fact postulated that this 
failure was a consequence of the inability of MSCs to differentiate and 
to form a mixed population (mSCN model). Based on this idea, the 
mSCN should be the best context in the pancreatic tumour 
microenvironment able to respond to Hh paracrine stimuli. The 
confirmation of this idea would provide a new view of Hh signalling in 
pancreatic cancer which would have important consequences for 
pancreatic cancer therapy. 
MSCs grown in FDM were shown to provide a model of the mSCN 
(sections 6.5.1; 6.5.2). The increase in MF-like cells over time was 
demonstrated, as well as an increase in Shh gene and protein 
expression as a mixed population formed. Furthermore, the trend in 
Į60$ JHQH DQG SURWHLQ H[SUHVVLRQ E\  GD\V VKRZHG QRW RQOy the 
formation of a new MF-like population, but also that the behaviour of 
these cells was comparable to that observed in the literature in a very 
similar in vitro model (rapid increase of the MF-like cells after 3 days of 
culture and then stabilisation of a mixed population) [Quante et al 2011].  
Co-culture of this mSCN model with epithelial pancreatic cancer cells or 
treatment with NShh in media with different percentages of FBS 
showed induction of the Hh pathway (tested as GLI1 gene and Ptch1 
protein expression), which was higher in the mSCN model than in MSC 
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S.P. (figure 5.30; 5.31). The analysis of Ptch1 protein expression, in 
both these assays, by IF quantification (Figure 5.30C and 31C)  showed  
significance (p<0.05) for the increase of Ptch1 expression in the SCN 
model co-cultured with PANC1 pancreatic cancer cells in comparison to 
the control (SCN model co-cultured with SCN model). This result 
confirmed the changes observed at gene level (GLI1 expression) and 
those showed by IF images (Ptch1 protein staining) (Figure 5.30 B).  
The IF quantification was performed by using a semi-quantitative 
ranking system. This choice was dictated by the detection limitations 
when working with fluorescent labelled cells. Computer-aided image 
analysis can only measure and analyse those features, in this case 
cells that have been optically labelled (membrane and cytoplasm) and 
thus made visible to the camera. Unstained cell cytoplasm and nuclei or 
negatives cannot be identified for measurement. In all cases, cell nuclei 
are counterstained with DAPI and are visible, which makes all the cells 
present accurately countable. It is not however possible to use a 
computer-aided image analysis to measure the areas of all these cells. 
Any attempt to do so would skew the data in favour of positive staining 
cells, no matter their proportion, in relation to unstained cells. The 
decision to carry out manual quantification improved the accuracy and 
reproducibility, by taking into account the total number of cells present 
on the basis of nuclear counterstaining.  
This approach, however, as it is the result of a subjective evaluation 
does not give perfectly reproducible quantitative information and can be 
affected by analysis variability. For this reason it has been defined as 
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semi-quantitative. In order to reinforce the reliability of this quantification, 
the study was performed blinded under the conditions investigated. 
In contrast with the Hh pathway induction (GLI1 gene and Ptch1 protein 
expression) observed in the SCN model after co-culture with pancreatic 
epithelial cancer cells (PANC1) and after NShh treatment described 
above (Figure 5.3 and 5.31), an increase in GLI1 gene expression, 
although to a smaller degree in MSC S.P. (cells grown in MSCM), was 
observed under the same experimental conditions. This could be due to 
the fact that even if MSCM keeps the cells in an inactivated state, a 
certain level of differentiation does occur.  
An important aspect to analyse in this investigation was therefore the 
stability of the MSCs grown in FDM as mSCN model or, in other words, 
the characterisation of these cells as a source of MF-like single 
population or as a reliable mSCN model. The ability of MF-like cells 
&$)V H[SUHVVLQJ Į60$ WR UHVSRQG WR 6KK SDUDFULQH LQGXFWLRQ from 
cancer cells has been described [Chan et al 2012; Hwang et al 2012; 
Wilkinson et al 2013], suggesting the need to compare the 
responsiveness to Shh paracrine induction of MF-like cells with a 
mSCN model. CAFs grown in MSCM (i.e. inactivated cells) were unable 
to respond to Hh ectopic stimuli (chapter 4). However, it is still 
necessary to investigate whether fully activated CAFs (i.e. grown in 
FDM: MF-like cells) are able to better respond to Shh paracrine 
induction and compare this capability with the responsiveness of a 
mSCN in vitro model. In order to test these options different mSCN 
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models and CAFs grown in FDM (data not showed) were compared for 
their responsiveness to Hh paracrine stimuli. 
6.5.2.1  Shh paracrine responsiveness comparison between different 
mesenchymal mSCN in vitro models 
The paracrine induction of the Hh pathway in five mesenchymal mSCN 
models was compared with the MSCs S.P. All models previously used 
in the study were included (MSC S.P. mixed with MF-like cells obtained 
E\ WUHDWLQJ WKHP ZLWK 7*)ȕ IRU  ZHek; MSCs simply grown in FDM) 
with a new model that considered MSCs as a source of MF-like cells 
(MSCs were in FDM for 1 week and mixed them with MSC S.P. grown 
at low passages in MSCM). Responsiveness to Hh paracrine stimuli 
was assessed using co-culture with pancreatic cancer cells carried out 
either in FDM or in MSCM. The highest induction of the Hh pathway 
was observed in the assays performed in FDM and in the mSCN model 
obtained by mixing MSCs grown for 1 week in FDM and mixed 1/1 with 
MSC S.P. This confirms the previous observation that different ratios of 
MF-like cells and MSCs affect SHH expression (Figure 5.19): the 
proportion of MF-like cells is fundamental for the constitution of the 
mSCN in vitro model and for the responsiveness to paracrine stimuli, 
with higher ratios of this cell type proportionally increasing the 
responsiveness. Finally CAF activated cells (grown in FDM and 
H[SUHVVLQJ Į60$ ZHUH WHVWHG IRU WKHLU UHVSRQVLYHQHVV WR GLIIHUHQW
concentrations of NShh by analysing GLI1 gene expression. No 
induction was observed in any of the conditions tested (data not 
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VKRZHG0RUHRYHU06&VFRQVWDQWO\WUHDWHGZLWK7*)ȕZKLFKUHVXOWV
in differentiation into an MF-like single population, confirmed the 
inability of fully activated cells to undergo paracrine induction, via co-
culture with pancreatic epithelial cells or NShh treatment. However, Hh 
pathway activation was tested in these experiments only at the gene 
level, and for this reason further investigation will be required to confirm 
these observations at the protein level. 
These results further support the idea that cells in the mSCN are better 
able to respond to Hh paracrine signalling than single populations 
(MSCs and activated CAFs) and they represent a finding that suggests 
the mSCN as an important component of the tumour microenvironment. 
However, further investigations are necessary to definitely ascertain this 
conclusion. 
6.5.2.2  Next step in the paracrine induction of Hh signalling in a in vitro 
mSCN model 
In order to definitely ascertain the mSCN as the context able to respond 
to Shh paracrine induction there is again a need for two pure single 
populations (MFs and MSCs) that can be mixed at different ratios to test 
the influence of the MF population on responsiveness to paracrine 
induction. Paracrine induction could be assessed using the assays 
already described in this thesis (Chapter 4 and 5) but in addition it will 
be important to extend the work to 3D in vitro assays that better mimic 
the in vivo interaction between epithelial and stromal-like cells. 
Moreover, a further step that would need to be performed is the 
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modulation of the Hh pathway (Shh silencing in epithelial cancer cells) 
to definitely address the induction observed in the mSCN models as a 
consequence of the Hh pathway paracrine stimuli and not of other non-
canonical pathways.  
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6.6  Applicability of the data presented in this thesis for 
development of novel therapeutic approaches 
A number of studies have been carried out to investigate the effect of 
the Hh pathway inhibition on cancer [Taipale et al. 2000; Chen et al. 
2002; Williams et al. 2003; Feldmann et al. 2008; Lipinsky et al. 2008; 
Lo Russo et al. 2011] So far there are over 50 compounds that are able 
to inhibit Hh signalling acting at different levels of the pathway. [Yang et 
al 2010]. More than one has shown an effect on xenograft tumour 
reduction and decreased proliferation of tumour cells in vitro confirming 
the validity of the Hh pathway inhibition as a chemo-preventive method 
in prostate cancer [Lautharticle 2 et al 2007]. 
Based on the data in this thesis and recent literature regarding the 
paracrine transmission of the Hh signalling in cancer, further inhibitors 
need to be tested in order to check their efficiency in tumour types with 
paracrine Hh signalling. In fact, in the presence of this kind of 
transmission there is the need for an inhibitor able to block the pathway 
at the stromal level. This inhibition should then reduce the amount of 
drug necessary to block tumour growth and therefore toxicity associated 
with chemotherapeutic treatment. In agreement with this last theory, 
treatment with IPI-296, that is known to inhibit SMO, was found to be 
able to reduce the stromal component in PDA (Pancreatic Ductal 
Adenocarcinoma) mouse models and to allow a more efficient 
gemcitabine drug effect with an overall effect on tumour  mass 
reduction [Olive et al 2009]. In this study, Shh expression at the stromal 
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level was observed in the advanced tumour stage (PDT) of pancreatic 
cancer and was suggested as a marker of the presence of a 
mesenchymal stem cell niche in the cancer stroma. Targeting Shh in 
the stromal context could affect not just the survival of the 
myofibroblast-like cell population but also the equilibrium of the 
mesenchymal stem cell  niche (constitute from MF-like cell and MSCs) 
that makes an important contribution to tumour growth and survival 
(Quante et al 2011). Moreover, once the function of Shh in the 
pancreatic tumour microenvironment has been confirmed it will provide 
a valuable therapeutic target whether it is a marker of the mSCN or 
expressed by MF cells. Another issue to consider is the presence of a 
cancer stem cell niche (to be distinguished from the mesenchymal stem 
cell niche). In this context, the use of inhibitors of Shh downstream 
targets as a chemotherapeutic approach may not be successful. It is in 
fact known that cancer stem cells are able to resist to chemotherapeutic 
agents making the treatment with drug ineffective. To overcome the 
cancer stem cell resistance to chemotherapeutic treatment a triple drug 
treatment has been suggested [Lonardo et al 2012]. In this study the Hh 
pathway was shown to be expressed by pancreatic stellate cells which 
in turn, through the nodal/activin pathway promote the survival of 
cancer stem cells (CSC). By targeting the PSC (using CUR199691 Hh 
pathway inhibitor), the interplay between CSC and PSC ( using the 
nodal/activin inhibitor SB431542) and the tumour cells (using 
gemcitabine), a reduction in the stromal component of pancreatic 
cancer was observed [Lonardo et al 2012]. It is important not to confuse 
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the mesenchymal stem cell niche (MF-like cells and MSCs) with the 
cancer stem cell niche that consists of cancer stem cells and 
myofibroblast-like cells. However, a common cell population between 
these two niches is the MF-like cells. Interestingly, this population is 
known to be important for the survival of both niches [Quante et al 2011; 
Lonardo et al 2012]. For this reason, another interesting hypothesis is 
that targeting Shh and causing the disruption of the stem cell niche, and 
so the MF-like population, could indirectly affect the cancer stem cell 
niche balance.  
Treatment of orthotopically transfected mice with 5E1 (a Shh antibody) 
showed the depletion of the stromal component in PDAC [Bailey et al 
2008]. This result was interpreted as a consequence of Shh inhibition at 
the epithelial level; however, this does not exclude the possibility that it 
could be a consequence of its inhibition in the stromal component in 
agreement with the theory outlined above. Shh could then become a 
very interesting target that could enable a much more powerful 
chemotherapeutic approach especially in the late stage of tumour 
development. 
In order to investigate this aspect, different in vivo mouse models could 
be used. Transgenic mice expressing fluorescent stromal cells could be 
used. Targeting these mice with Shh inhibitors (e.g. 5E1 or robtokinine) 
it would be possible to use luminescent images to assess its effect on 
depletion of the stromal component. The combination between 
gemcitabine and Shh inhibitors treatment would also be tested to 
assess its effect on tumour size.   
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Genetically engineered mouse models could also be used for this 
purpose. In particular KPC mice seem to reproduce a PDAC model very 
similar to the human one. These mice, obtained by constitutive 
expression of mutant KRas and P53, seems to reproduce the 
desmoplastic reaction typical of pancreatic tumours [Olive et al 2009]. 
Using this model, having ascertained the expression of Shh at the 
stromal level by IHC, the effect of Shh could be investigated. The 
combination of Shh inhibitors and gemcitabine would also be tested in 
these mice. The effect of double treatment in comparison to 
gemcitabine alone would be firstly investigated, then, the effect of Shh 
inhibition on the survival of the mesenchymal and cancer stem cell 
niches would be investigated. For this purpose the engineered mice will 
be sacrificed and analysed for the presence of the stromal component 
in the pancreatic tumour and for the presence of mSCN PDUNHUVĮ60$
Postn, Shh) and CSC markers by IHC. Treated mice would be 
compared to the untreated ones.  
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6.7  Conclusions 
x Shh, a ligand of the Hh signalling pathway is expressed at the 
stromal and epithelial level in human PDAC. 
x The expression of Shh at the stromal level appears mainly in 
more aggressive tumours (PDT). 
x There is a role for Shh as a marker of the mesenchymal stem 
cell niche consisting of both human bone marrow MSCs and MF-
like stromal cells that are hypothesised to co-exist in the stroma 
of advanced pancreatic cancer. 
x Shh gene and protein expression depends on the ratio of the two 
populations used to establish each mSCN model.  
x Į60$ DQG 3RVWQ DUH JRRG PDUNHUV RI 0)-like cells and initial 
data on Shh expression in the mSCN models tested, suggest 
that the population able to express this ligand is the MF-like cells. 
x MSCs and CAFs when grown alone in medium able to prevent 
their activation (MSCM) are unable to respond to Hh paracrine 
stimuli from epithelial pancreatic cancer cells but are responsive 
in the context of the mSCN. 
The following diagram summarise the conclusions of this study, the new 
hypothesis generated and ideas for future investigations.
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Figure 6.2 Schematic diagram that depicts the conclusions, hypothesis and future aims (red writing) defined in this 
project.. Shh expression increases in the late stage of pancreatic tumour (PDAC) progression in the tumour cells. Epithelial cancer 
FHOOVDOVRSURGXFH7*)ȕZKLFKLQWXUQLQGXFHWKHH[SDQVLRQRIQLFKHFHOOVUHFUXLWHGIURPWKHERQHPDUURZ%07KH mesenchymal 
stem cell niche express Shh which expression is then visible at stroma level in the late stage of PDAC. -mSCN is able to respond to 
Hh paracrine signalling from epithelial cancer cells. It is not clear yet the effect of Hh pathway activation in the mSCN: MF cells 
proliferation or MSCs differentiation into MF cells?. MF cells in the mesenchymal niche context are strongly activated and so they 
H[SUHVVĮ60$DQG3RVWQ7KHmSCN help the survival and proliferation of MF cells which in turn sustain the survival of cancer 
stem cells (CSC), as well present in the tumour microenvironment, forming the cancer stem cell niche. MF cells also sustain the 
tumour growth and the tumour metastasis. Targeting Shh expression in the-mSCN in the tumour microenvironment should 
destabilised the activation and the survival of MF like cells and as consequence blocking the tumour growth and progression. 
--- 
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6.8  Future work  
This work provides a first analysis of a possible new paradigm 
underlying the development of stroma in pancreatic cancer and 
suggests a possible new role for the Hh pathway in PDAC. The 
conclusions reached in this study suggest a new therapeutic approach 
but need further confirmation.  
The further steps required to move the project forwards are as follows: 
x The presence of stem cell niche in the stromal context was 
hypothesised and suggested by the detection of Shh protein 
expression (believed to be a marker of mSCN). However, 
confirmation of the existence of a mSCN in the tumour stroma of 
patients and of the role of Shh as a marker of the mSCN is still 
necessary. IHC co-staining for markers of MSCs and MF-like 
FHOOV Į60$ RU 3RVWQ FRXOG EH XVHG WR GHPRQVWUDte their co-
existence in the cancer stroma. Moreover, comparison between 
normal tissues and tissues taken at different stages in tumour 
progression will also help to confirm the presence of stem cell 
niche in the advanced phase of pancreatic cancer. Co-staining of 
6KKDQGĮ60$FRXOGDOVRFRQILUPLWVH[SUHVVLRQLQWKHVWHPFHOO
niche and which of the two populations is able to express it. 
x Shh was observed to be expressed in the stem cell niche but it is 
still not clear if it can be considered a marker of the niche or is 
simply expressed by MF-like cells. In both cases the discovery of 
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its expression in cancer stromal-like cells is novel and the data 
suggest it is a mSCN marker. 
To further confirm this aspect in vitro, the isolation of the two 
niche populations (MSCs and MF-like cells) will clarify this aspect. 
To perform this isolation an RFP-Į60$ RU 3RVWQ WDUJHWHG FHOO
population (as used by Quante et al 2011) could help to isolate 
the MF-like population by fluorescent activated cell sorting 
(FACS) and assess if these cells are able to express Shh. The 
unsorted cells should be MSCs that, to confirm their nature, 
should be characterised for their expression of mesenchymal 
stem cell markers and their ability to differentiate into adipocytes, 
condrocytes and osteocytes. Mixing the two isolated populations 
at different ratios and comparing them for Shh expression to 
single populations, will clarify the exclusivity of Shh expression in 
mixed populations as well as the relative importance of the two 
niche populations on Shh expression. 
Another way to investigate the role of Shh as a marker of stem 
cell niche and to discover which cell type in the niche is able to 
express it could be to mix the two niche populations (obtained by 
growing MSC in MSCM for as few passages as possible and by 
WUHDWLQJ06&VZLWK7*)ȕ LQ)'0IROORZHGE\FR-staining them 
IRU 6KK DQG Į60$3RVWQ H[SUHVVLRQ 7KH 6KK H[SUHVVLRQ LQ
these mSCN models would be compared to single populations in 
order to definitely ascertain the correlation of Shh with mixed 
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population as indicated in this work and in the literature [Lin et al 
2008; Quante et al 2011]. 
x The role of Shh in the mSCN is another aspect that needs to be 
clarified. A way to investigate it could be by silencing its 
expression (by using the already optimised siRNA) in cells 
demonstrated to express it and then plating the two niche 
populations in two different compartments of a 2D transwell 
system. In this way it would be possible to investigate the effect 
of Shh knock-down on cell survival, proliferation (Ki67 gene and 
protein expression) and differentiation (gene and protein 
H[SUHVVLRQRIĮ60$ LQERWKFHOOSRSXODWLRQV7KHHIIHFWRI6KK
silencing on the survival of the mSCN could also be investigated 
by co-culturing the MSCs and MF-like cells in a 3D model, in 
order to better mimic the in vivo interaction between these two 
populations. Moreover, the investigation of the effect of Shh 
inhibitors (like robtokinin or 5E1 antibody) on the mSCN survival 
would add further to understanding of its role in this mixed 
population and the applicability of its inhibition as 
chemotherapeutic approach. 
x Another area of investigation is the role of Shh expression in the 
in vivo stromal context. More precisely, the investigation of the 
Shh knock-down on in vivo tumour cell survival and tumour 
growth. A new technique that seems very approachable and 
efficient to investigate this aspect is the hollow-fibre assay. [Mi et 
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al 2009]. This method consists of the insertion of luminescent 
labelled human cell populations in a sealed hollow fibre tube 
under the mouse skin. Each hollow fibre has pores that allow the 
passage of protein and molecules but not of cells. The 
advantage of this method in comparison to xenograft and 
transgenic mice, is the necessity of a much lower number of 
animals, considering that more than one hollow fibre can be 
implanted in the same mouse. In this way the experimental 
variability of data will be also reduced and the human 
mesenchymal cells would be preserved and not replaced by 
mouse stromal cells as commonly happens in xenograft mice. 
Moreover, lower costs and shorter study times will be achieved 
using this method [Mi et al 2009]. 
As a first step, the investigation of the mSCN on tumour growth 
would be performed by inserting in each hollow fibre the best 
mSCN in vitro model, obtained in this study, mixed with 
luminescent pancreatic cancer cells. In this way the effect of the 
mSCN on tumour cell proliferation and tumour growth will be 
clarified by bioluminescence images of the hollow-fibre. Epithelial 
cancer cell mSCN co-cultures would be compared with epithelial 
cells cultured alone and co-transplanted in the same mouse. 
Then a co-culture model using mSCN cells transfected with a 
shRNA targeting Shh would be used. The comparison between 
the effect of transfected and un-transfected mSCN cells on 
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cancer cell growth would help to understand the effect of Shh 
stromal expression on tumour growth.  
By using the same type of analysis the effect of Shh inhibitors on 
the depletion of the stroma component could also be investigated. 
In order to achieve this goal, the luminescent mSCN model 
would be co-inserted in the hollow-fibre with epithelial cancer 
cells stably transfected with shRNA targeting Shh. In the same 
mouse two other hollow fibres would be transplanted: containing 
epithelial shRNA negative cancer cell-mSCN co-cultures (with no 
target: shNeg) or un-transfected cancer cell-mSCN co-cultures. 
By treating the mouse with 5E1 or robotnikinin (Shh inhibitors) it 
would be possible to assess by using bioluminescence images if 
the expected mSCN depletion in the stroma is a consequence of 
the inhibition of Shh in cancer cells that block the mesenchymal 
mSCN recruitment (as showed in Bailey et al 2008) or a 
consequence of Shh inhibition at the stromal level. This latter 
option would be confirmed if the 3 hollow fibres with transfected, 
un-transfected or shNeg transfected cancer cells show the same 
depletion of the mSCN population after the treatment with the 
Shh inhibitor. 
x  Further investigations also need to be performed on stem cell 
niche responsiveness to Hh paracrine signal from epithelial 
cancer cells. To investigate this aspect, siShh transfected and 
un-transfected epithelial pancreatic cancer cells would be co-
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cultured in 2D and 3D assay with the mSCN in vitro model. The 
effect of Shh silencing on Hh pathway expression (Gli1 and 
Ptch1 gene and protein expression) in the niche cells would be 
analysed.  
Moreover, considering that Hh pathway canonical activation 
requires localisation of the SMO and Gli transcription factors in 
the cilium [Zeng et al 2010  Qin et al 2011], the mSCN model 
should be analysed for the presence of the cilium by 
investigating the protein expression of two known cilium markers: 
Ȗ-tubulin and Į-acetylated tubulin (Grzelak et al 2014). This 
analysis would also determine if the observed Gli1 paracrine 
activation in the mSCN is a consequence of an Hh canonical 
pathway activation. Both cell populations of the mSCN model 
would then be treated with NShh and/or co-cultured with 
pancreatic cancer cells. At the end of the treatment/co-culture 
the mSCN FHOOVZRXOGEHDQDO\VHGE\,)IRUWKHH[SUHVVLRQRIȖ-
WXEXOLQ DQG Į-acetylated tubulin that constitute the basal 
components of the axoneme and of the cilium respectively 
(Grzelak et al 2014). Moreover, analysis of gene and protein 
expression of IFT122 and PKA in the mSCN would further 
confirm whether the machinery implicated in the Hh signalling 
transduction via SMO and in the localisation of Gli2 and Gli3 
transcriptor factors is activated [Zeng et al 2010; Qin et al 2011] 
The comparison between treated/ co-cultured mSCN models and 
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untreated / normal cultured mSCN models for these proteins 
would further confirm the niche model as a context able to 
respond to Hh paracrine signalling. Co-staining of the cilium 
markers and the MF-OLNH FHOO PDUNHU Į60$FRXOG DOVR DGGUHVV
which cell type in the mSCN model directly responds to the 
paracrine stimuli. Furthermore, the comparison between single 
MSC and MF-like populations and the mSCN model in the same 
experimental design could assess if the mSCN is a better context 
for responsiveness to Hh paracrine signal. 
x 7KH LQWHUDFWLRQ EHWZHHQ WKH 6KK DQG 7*)ȕ SDWKZD\V LQ WKH
mSCN context, observed in this study, also needs further 
clarification In vitro treatment of the mSCN ZLWK7*)ȕwould be 
repeated and the effect on Shh, Gli1 and Ptch1 further 
investigated not just in 2D but in 3D assays as well in order to 
better mimic the in vivo interaction between the cells. Moreover, 
LQ RUGHU WR LQYHVWLJDWH LI WKH DFWLYDWLRQ  RI *OL IURP 7*)ȕ LV D
consequence of canonical activation of Hh or a non-canonical 
pathway the presence of the cilium and the SMO localisation 
would be investigated by IF analysis as described above, before 
DQGDIWHUWKH7*)ȕWUHDWPHQW)XUWKHULQYHVWLJDWLRQFRXOGEHDOVR
GRQHE\FKHFNLQJWKHH[SUHVVLRQRI7*)ȕLQWKHmSCN and the 
effect of its knock-down by siRNA on cell differentiation and Shh 
expression. 
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x Another final important aspect to evaluate is the effect of Hh 
paracrine induction on mSCN proliferation. Treated and untreated NShh 
mSCN models would be compared for their viability and their level of 
proliferation using an MTT assay (a colorimetric assay that allows 
measurement of cell proliferation and survival of viable cells) [Mosmann 
et al 1983] or for their expression of Ki67 (a proliferation marker). 
6.9  Final Conclusions 
Hh pathway is overexpressed in pancreatic tumours. The desmoplastic 
effect, typical of this cancer, is characterised by the recruitment into the 
stromal component of a mesenchymal stem cell niche from the bone 
marrow. The recruitment probably happens in the advanced stages of 
tumour progression. The mSCN is known to support pancreatic tumour 
growth and could be the stromal context capable of responding to Hh 
paracrine stimuli from epithelial cancer cells. Shh seems to be a marker 
of this niche and its inhibition could result depletion of the stromal mass 
and, as consequence, to an increase in the effectiveness of 
chemotherapeutic agents (such as gemcitabine) in reducing tumour 
volume and progression. 
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QWin Standard V3 (Leica microsystems, UK) 
 
H Score macro 
Configure   ( Image Store 2560 x 1920, Grey Images 24, Binaries 8 ) 
Display   ( Colour0 (on), frames (on,off), planes (off,off,off,off,off,off), lut 
0, x 0, y 0, z 1, Reduction off ) 
Image Setup DC Twain  [PAUSE]  ( Camera 1, AutoExposure Off, Gain 
0.00, ExposureTime 75.81 msec, Brightness 0, Lamp 45.00 ) 
Acquire   ( into Colour0 )  
Detection 
PauseText   ( "Detect high levels of staining." ) 
Colour Detect  [PAUSE]  ( RGB: 58-153, 32-102, 0-64, from Colour0 
into Binary1 ) 
PauseText   ( "Detect medium levels of staining." ) 
Colour Detect  [PAUSE]  ( RGB: 124-171, 84-118, 58-120, from Colour0 
into Binary2 ) 
PauseText   ( "Detect low levels of staining." ) 
Colour Detect  [PAUSE]  ( HSI: 0-26, 0-89, 0-192, from Colour0 into 
Binary3 ) 
PauseText   ( "A Colour Detection is used to detect total staining." ) 
Colour Detect  [PAUSE]  ( HSI+: 7-178, 4-237, 33-202, from Colour0 
into Binary0 ) 
Binary Edit  [PAUSE]  ( Erase from Binary0 to Binary0, nib Rect, width 
1 ) 
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Measure high area 
MFLDIMAGE = 1 
Measure field   ( plane MFLDIMAGE, into FLDRESULTS(1), statistic 
into not found ) 
Selected parameters:     Area 
HIGH.AREA = FLDRESULTS(1) 
Measure total area 
MFLDIMAGE = 0 
Measure field   ( plane MFLDIMAGE, into FLDRESULTS(1), statistics 
into not found ) 
Selected parameters:     Area 
TOTAL.AREA = FLDRESULTS(1) 
Measure medium area 
MFLDIMAGE = 2 
Measure field   ( plane MFLDIMAGE, into FLDRESULTS(1), statistics 
into not found ) 
Selected parameters:     Area 
MEDIUM.AREA = FLDRESULTS(1) 
Measure low area 
MFLDIMAGE = 3 
Measure field   ( plane MFLDIMAGE, into FLDRESULTS(1), statistics 
into not found ) 
Selected parameters:     Area 
LOW.AREA = FLDRESULTS(1) 
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Report final results  
Results layout = %high staining area, %moderate staining area, %low 
staining area, h-score 
Setup Output Window   ( "Percentage area measurements and H-
Score", Move to x 36, y 783, w 683, h 161 ) 
Display   ( 100*(HIGH.AREA/TOTAL.AREA), 1 digit after '.', tab follows ) 
Display   ( 100*(MEDIUM.AREA/TOTAL.AREA), 1 digit after '.', tab 
follows ) 
Display   ( 100 * (LOW.AREA/TOTAL.AREA), 2 digits after '.', tab 
follows ) 
Display   
( ((100*(HIGH.AREA/TOTAL.AREA))*3)+((100*(MEDIUM.AREA/TOTAL
AREA))*2)+(100*(LOW.AREA/TOTAL.AREA)), 2 digits after '.', tab 
follows ) 
Display Line  
Pause   ( No dialog ) 
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DAB count macro 
 
Configure   ( Image Store 2560 x 1920, Grey Images 24, Binaries 8 ) 
Display   ( Colour0 (on), frames (on,off), planes (off,off,off,off,off,off), lut 
0, x 0, y 0, z 1, Reduction off ) 
Image Setup DC Twain  [PAUSE]  ( Camera 1, AutoExposure Off, Gain 
0.00, ExposureTime 61.16 msec, Brightness 0, Lamp 45.00 ) 
Acquire   ( into Colour1 ) 
Grey LUT   ( Normal from Colour1 to Colour1 ) 
PauseText   ( "A Colour Detection is used to detect positive staining." ) 
Colour Detect  [PAUSE]  ( HSI: 0-255, 0-255, 0-115, from Colour1 into 
Binary1 ) 
Binary Edit  [PAUSE]  ( Erase from Binary1 to Binary1, nib Fill, width 1 ) 
PauseText   ( "detect total area stained" ) 
Colour Detect   ( RGB: 0-188, 0-188, 0-191, from Colour1 into Binary0 ) 
Colour Detect  [PAUSE]  ( RGB: 0-164, 0-164, 0-164, from Colour1 into 
Binary0 ) 
Binary Edit  [PAUSE]  ( Erase from Binary0 to Binary0, nib Fill, width 1 ) 
Binary Identify   ( BinMode from Binary0 to Binary0 ) 
MFLDIMAGE = 1 
Measure field   ( plane MFLDIMAGE, into FLDRESULTS(1), statistics 
into not found ) 
Selected parameters:     Area 
POS.AREA = FLDRESULTS(1) 
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Measure total area 
MFLDIMAGE = 0 
Measure field   ( plane MFLDIMAGE, into FLDRESULTS(1), statistics 
into not found ) 
Selected parameters:     Area 
TOTAL.AREA = FLDRESULTS(1) 
Measure degree of positivity by taking integrated optical density of the 
intensity component where the positve stain is detected 
This IOD is later normalized to the total tissue area detected 
Grey Calibrate   ( Optical Density ) 
MGREYIMAGE = 1 
MGREYMASK = 1 
Measure Grey   ( plane MGREYIMAGE, mask MGREYMASK, 
histogram into GREYHIST(256), stats into GREYSTATS(5) ) 
Selected parameters:  Sum Blu, Mean Blu, StdD Blu,  Med Blu, Mode 
Blu Display Grey Results  
Field Data Window ( 51, 526, 921, 153 ) 
Histogram Results Window ( 51, 548, 409, 192 ) 
Histogram Window ( 460, 548, 460, 192 ) 
Setup Results Window ( Close Grey Field Data ) 
Setup Results Window ( Close Grey Histogram Data ) 
Setup Results Window ( Move Grey Histogram to x 1002, y 670, w 238, 
h 286 ) 
Report final results 
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Setup Output Window   ( "Immunochemistry Measurement Results", 
Move to x 30, y 789, w 527, h 161 ) 
Display   ( TOTAL.AREA, 1 digit after '.', tab follows ) 
Display   ( POS.AREA, 1 digit after '.', tab follows ) 
Display   ( 100 * (POS.AREA / TOTAL.AREA), 2 digits after '.', tab 
follows ) 
Display   ( GREYSTATS(1) / TOTAL.AREA, 2 digits after '.', tab follows ) 
Display Line  
PauseText   ( "The final results are calculated and reported." ) 
Pause   ( No dialog). 
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